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ANXIETY IN PARKINSON’S DISEASE:  RELATION TO COGNITION AND 
POTENTIAL OF NON-PHARMACOLOGICAL INTERVENTIONS 
GRETCHEN O. REYNOLDS 
Boston University Graduate School of Arts and Sciences, 2017 
Major Professor:  Alice Cronin-Golomb, Professor of Psychological and Brain Sciences 
ABSTRACT 
 In addition to the classic motor symptoms, Parkinson’s disease (PD) causes a 
variety of non-motor symptoms that compromise quality of life and daily functioning.  
Anxiety, in particular, is prevalent and debilitating, but under-studied and under-treated.  
There is urgent need to understand the relation of anxiety to other non-motor symptoms, 
and to develop evidence-based treatments.  Cognitive-behavioral therapy (CBT) and 
aerobic and resistance exercise are promising non-pharmacological treatment strategies 
for anxiety in PD, with potential to simultaneously reduce additional PD symptoms. 
 Study 1 assessed a large sample of non-demented individuals with mild to 
moderate PD (N=77) and examined the relation between self-reported anxiety (Beck 
Anxiety Inventory [BAI]) and cognition with a focus on executive function and attention 
(Trail Making, Verbal Fluency, Digit Span). The majority of participants reported 
subclinical symptoms of anxiety (BAI ≤18).  Higher anxiety correlated with poorer set-
shifting, as well as with more advanced disease stage and severity.   
Study 2 implemented a single-case experimental design to evaluate the utility and 
feasibility of a 12-week cognitive-behavioral intervention for individuals with PD who 
 	
 
vii 
also met criteria for a DSM-5 anxiety disorder (N=9).  Weekly therapy sessions were 
conducted in-person (N=5) or via secure videoconferencing (N=4).  At post-treatment, 
five participants reported significant reductions in anxiety and two additional participants 
reported significant reductions in comorbid depression.  Most improvements were 
maintained at 6-week follow-up.  Effects of CBT on secondary outcome measures (e.g., 
cognition, motor symptoms, sleep) varied widely across participants.  Adherence and 
retention were high, as was satisfaction with treatment.  
 Study 3 reviewed the effects of aerobic and resistance exercise on disturbances of 
mood, cognition, and sleep in PD and healthy adults.  The literature supports aerobic and 
resistance exercise as feasible and promising adjunct treatments for mood, cognition, and 
sleep in PD, contingent upon additional exercise research that systematically targets non-
motor symptom outcomes. 
 Together these studies show that even subclinical anxiety is associated with 
cognitive disturbance in mild-moderate PD, and provide preliminary evidence for the 
effectiveness of CBT (in-person and internet-delivered), as well as aerobic and resistance 
exercise, as encouraging and viable treatments for anxiety in this disorder. 
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CHAPTER 1:  GENERAL INTRODUCTION 
 
 Parkinson’s disease (PD) affects approximately 1.8% of the population over age 
65, as well as younger individuals, with the prevalence projected to double by 2040 
(Kowal, Dall, Chakrabarti, Storm, & Jain, 2013; Mayeux, 2003; Prediger, Matheus, 
Schwarzbold, Lima, & Vital, 2012).  The national economic burden of PD in 2010 was 
estimated to be over $20.7 billion in the United States alone (Kowal et al., 2013).  In light 
of the substantial human, economic, and societal costs, it is imperative to better 
characterize and understand the many symptoms of PD that emerge throughout the course 
of the disorder, in order to develop treatments to alleviate current symptoms or to 
potentially delay disease progression. 
Traditionally conceptualized as a classic movement disorder, PD is characterized 
by dopaminergic neuronal death in the substantia nigra and subsequent basal ganglia 
dysfunction.  The disease is diagnosed upon observation of the cardinal motor signs:  
reduced movement and/or speed of movement (akinesia or bradykinesia), rigidity, 
tremor, and disorders of gait, balance, and posture (Grimbergen, Langston, Roos, & 
Bloem, 2009; Jankovic, 2008; Kim, Allen, Canning, & Fung, 2013; Rodriguez-Oroz et 
al., 2009).  In addition to the motor symptoms, various non-motor symptoms (NMS) also 
appear during the course of the disease, but they remain poorly understood and grossly 
undertreated.  Prevalent NMS include neuropsychiatric symptoms (e.g., anxiety, 
depression, apathy, and hallucinations), sleep disruption, cognitive impairments, sensory 
symptoms (e.g., hyposmia, vision difficulties, and pain), and autonomic and 
 	
 
2 
gastrointestinal dysfunction, as well as fatigue (Chaudhuri, Healy, & Schapira, 2006; 
Rodriguez-Oroz et al., 2009).  The NMS often emerge in the early stages of PD or in the 
prodromal period before the emergence of motor symptoms, and significantly contribute 
to a reduced quality of life, often to an even greater extent than the motor symptoms 
(Chaudhuri et al., 2006; Hanna & Cronin-Golomb, 2012; Martinez-Martin, Rodriguez-
Blazquez, Kurtis, Chaudhuri, & Group, 2011; Prakash, Nadkarni, Lye, Yong, & Tan, 
2016).  Although research is increasingly beginning to examine the NMS (Cronin-
Golomb, 2013), they continue to be under-diagnosed and inadequately treated in this 
population (Chaudhuri & Odin, 2010; Seppi et al., 2011; Shulman, Taback, Rabinstein, & 
Weiner, 2002).  Accordingly, there is a critical need to better characterize and treat these 
symptoms, particularly those for which there are efficacious, evidence-based treatments 
within the general (non-PD) population. With better recognition and diagnosis of NMS, 
we can hope to adapt extant interventions for use in PD and also to develop novel 
treatments to improve NMS in this population, with the goal of optimizing quality of life 
and daily functioning across all stages of the disease. 
 
Anxiety in PD:  Prevalence and Manifestation 
 Of the NMS, anxiety is especially common and disabling.  Anxiety disorders 
occur at higher rates in PD than in age- and sex-matched control adults (Nuti et al., 2004) 
as well as control adults matched for having a chronic disorder affecting movement 
(osteoarthritis) (M. A. Menza, Robertson-Hoffman, & Bonapace, 1993).  In a sample of 
127 adults with idiopathic PD, current and lifetime prevalence rates of at least one 
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anxiety disorder diagnosis were 43% and 49%, respectively (Pontone et al., 2009), 
although prevalence estimates for anxiety in PD vary widely across studies.  In 
considering persons with PD and clinically significant anxiety disorders or those who 
score above clinical cutoffs on anxiety rating scales, current prevalence rates range from 
12.8% to 43.0% (Broen, Narayen, Kuijf, Dissanayaka, & Leentjens, 2016; N. N. 
Dissanayaka et al., 2010; N. N. Dissanayaka et al., 2014; Pontone et al., 2011; Richard, 
Schiffer, & Kurlan, 1996; Walsh & Bennett, 2001), with anxiety symptoms occurring in 
20% to over 50% of individuals with PD (Chen & Marsh, 2014; Marinus, Leentjens, 
Visser, Stiggelbout, & van Hilten, 2002; Shulman et al., 2002).   
With regard to types of anxiety, the most common anxiety disorders reported in 
PD are panic disorder, generalized anxiety disorder (GAD), social phobia, and anxiety 
disorder, not otherwise specified (NOS) (N. N. Dissanayaka et al., 2010; N. N. 
Dissanayaka et al., 2014).  At the same time, additional clinical subtypes of anxiety have 
been described in PD, e.g., anxious-depression (R. G. Brown et al., 2011).  To further 
complicate the classification and diagnosis of anxiety in PD, some individuals with PD 
report situational anxiety related to motor symptoms, such as fear of falling or avoidance 
of crowded areas due to freezing of gait (Pontone et al., 2009).  There is a need to better 
elucidate the unique characteristics and subtypes of anxiety in PD in order to improve 
symptom recognition and diagnostic accuracy and also to inform treatment development. 
 In addition to its high prevalence, anxiety is particularly problematic in PD 
because of its co-occurrence with various other NMS.  Anxiety is frequently comorbid 
with additional psychiatric symptoms, especially depression, as well as with fatigue, 
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sleep disruption, and sensory symptoms.  Comorbidity of these NMS is associated with 
increased disease severity as indexed by the Unified Parkinson’s Disease Rating Scale 
(UPDRS), Hoehn & Yahr motor stage (H&Y), and the Schwab & England ADL scale 
(Jiang et al., 2015; M. A. Menza et al., 1993; Shulman, Taback, Bean, & Weiner, 2001).  
Moreover, NMS may reduce quality of life to a greater degree than the motor symptoms 
(Qin et al., 2009) and also increase caregiver burden (Schrag, Hovris, Morley, Quinn, & 
Jahanshahi, 2006).  Anxiety, in particular, correlates with greater disability (Witjas et al., 
2002) and uniquely contributes to a poorer quality of life in PD, independent of 
depression (Havlikova et al., 2011), and more so than depression, cognitive status, or 
motor stage (Hanna & Cronin-Golomb, 2012).  Unfortunately, despite such adverse 
effects, anxiety in PD continues to be understudied, under-diagnosed, and under-treated, 
with many trials continuing to focus on depression and only including anxiety as a 
secondary outcome, if at all (Leentjens, Dujardin, Marsh, Martinez-Martin, et al., 2011; 
Shulman et al., 2002; Weintraub & Burn, 2011).  Better recognizing and describing 
anxiety across all stages of the disease may lead to the development of novel 
interventions to directly target anxiety in PD and improve quality of life. 
 
Brain Bases of Anxiety in PD 
 Although the increased prevalence of anxiety in PD may be related, in part, to the 
psychosocial stress and/or stigma that may occur in response to diagnosis, it is also clear 
that it is endemic to the disease.  A variety of neurobiological mechanisms may 
contribute to the development and maintenance of anxiety in this population.  Since the 
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1960s, PD has been well-characterized by dopaminergic loss in the striatum and 
associated disruption of the basal ganglia and motor circuits (Rodriguez-Oroz et al., 
2009).  Distinctive inclusion aggregates, either globular Lewy bodies and/or spindle-like 
Lewy neurites, develop in vulnerable neurons as the disease progresses (Braak, 
Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004; Obeso, Rodriguez-Oroz, Rodriguez, 
Arbizu, & Gimenez-Amaya, 2002).  Braak and colleagues divided the neuropathological 
progression in PD into six stages, with pathology first emerging in the medulla 
oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus (stages 1-2), 
then progressing to the substantia nigra and midbrain (stages 3-4), and ultimately 
compromising the neocortex (stages 5-6) (Braak et al., 2004).  Across these stages, 
neuronal deterioration significantly affects both somatomotor and limbic systems (Braak 
et al., 2003), including the amygdala and its nuclei, which may contribute to changes in 
emotional, cognitive, and autonomic functioning in PD, given the amygdala’s projections 
to limbic areas (e.g. hippocampus and entorhinal region), prefrontal cortex, and centers 
that regulate endocrine functions (Braak et al., 1994).   
 Both animal and human studies suggest an association between dopaminergic 
depletion and anxiety in PD.  Tadaiesky and colleagues (Tadaiesky et al., 2008) reported 
an increase in anxiety among rats following induced degeneration of dopaminergic 
neurons in the striatum and subsequent dopaminergic loss in prefrontal regions.  In 
humans, striatal dopamine transporter (DAT) imaging has revealed an inverse association 
between anxiety in PD and DAT availability in the left anterior putamen (Weintraub et 
al., 2005), although the study only included individuals with relatively mild affective 
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symptoms.  A second DAT study reported a positive correlation between social anxiety 
symptoms and DAT density in the bilateral putamen and left caudate (Moriyama et al., 
2011).  This second study was limited by the relatively small sample size (11 PD adults 
with social anxiety disorder (SAD) vs. 21 PD adults without SAD), as well as the 
relatively young mean age of the sample (51.2 years) and the failure to measure or 
control for depressive symptoms.  A study of 34 newly diagnosed, untreated adults with 
PD revealed significantly lower DAT availability in the bilateral caudate and left 
putamen when comparing PD participants with (n=9) and without (n=25) anxiety, using a 
cut-off score of 7 on the anxiety subscale of the Hospital Anxiety Depression Scale (Erro 
et al., 2012).  In the overall PD group, increased anxiety correlated with reduced DAT 
availability in the right caudate.  Taken together, these studies implicate dopaminergic 
dysfunction in the striatum in the development of anxiety in PD, and suggest the need for 
research to clarify the potential lateralization of this association across all stages of PD.  
 In addition to dopaminergic systems, non-dopaminergic dysfunction has also been 
implicated as a potential neurobiological mechanism of anxiety in PD, specifically within 
noradrenergic and serotonergic systems.  First, postmortem studies of individuals with 
PD have revealed the most extensive neuronal loss in the noradrenergic locus coeruleus 
(LC), even in comparison to the substantia nigra (Zarow, Lyness, Mortimer, & Chui, 
2003).  The basal ganglia’s extensive connections with brainstem nuclei, including the 
LC and raphe nuclei, suggest disruption to noradrenergic and serotonergic functioning, 
respectively (Obeso et al., 2002), starting in early disease stages with PD neuropathology 
now thought to begin in the lower brainstem before progressing to the substantia nigra 
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(Braak et al., 2004).  This disruption may contribute to the development of anxiety in PD, 
given that noradrenergic and serotonergic systems and their projections to corticolimbic 
regions are heavily involved in the modulation of anxiety in the general population 
(Millan, 2003; Ressler & Nemeroff, 2000).  Indeed, anxiety was reported to negatively 
correlate with dopamine and noradrenaline transporter binding in the left LC, as well as 
the left ventral striatum, left caudate, and bilateral amygdala and thalamus in a sample of 
20 adults with PD, eight of whom had a history of major depression (Remy, Doder, Lees, 
Turjanski, & Brooks, 2005).  Although the study focused on depression in PD and only 
examined anxiety as a secondary outcome, the authors noted that the inverse association 
between anxiety and LC binding, in particular, implicates noradrenergic dysfunction in 
the neurobiology of anxiety in PD.  Of note, the noradrenergic LC has been associated 
with panic disorder in PD and the general population (Gorman, Kent, Sullivan, & Coplan, 
2000; Walsh & Bennett, 2001), and panic disorder in PD has been correlated with an 
earlier age of motor symptom onset (Pontone et al., 2009), underscoring the need to 
consider non-dopaminergic dysfunction in the brainstem as a potential mechanism of 
anxiety in the early stages of PD.  
In addition to disruption to multiple neurotransmitter systems, PD pathology 
affects various brain regions involved in the modulation of anxiety, namely limbic 
structures, as well as ventral prefrontal and parietal regions.  The olfactory bulb is one of 
the first affected structures, with neuropathology emerging in the presymptomatic stages 
of the disease (Braak et al., 2004).  This finding is important because anxiety, in turn, has 
been associated with olfactory impairment in a study of 96 non-demented adults with PD 
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with a short disease duration on average, suggesting that NMS, including olfactory and 
mood disturbances, may develop early in the disease as a result of brainstem 
neuropathology (Berendse, Roos, Raijmakers, & Doty, 2011).  In addition to early 
involvement of the brainstem and limbic structures, there is evidence of focal cortical 
thinning in orbitofrontal cortex, ventrolateral prefrontal cortex, and occipito-parietal 
regions, as well as subcortical volume loss in the striatum, among non-demented adults 
with early-stage PD, who also reported high levels of state anxiety relative to that seen in 
healthy control participants (Tinaz, Courtney, & Stern, 2011).  Although anxiety did not 
correlate with imaging data, Tinaz and colleagues (2011) posited that the higher anxiety 
levels in the PD group may relate to cortical thinning and subsequent disruption of 
information flow between limbic and neocortical areas involved in emotional processing.  
 In sum, abnormalities in many neurotransmitter systems and brains regions may 
contribute to the development and maintenance of anxiety in PD, suggesting that anxiety 
is not solely a reaction to the motor symptoms of the disease, but rather a symptom 
arising from the pathophysiology of the disease.  For further review of potential 
neurobiological mechanisms of anxiety in PD, refer to (Prediger et al., 2012).   
 
Current Treatment of Anxiety in PD:  Pharmacological Strategies 
 Despite the high prevalence and detrimental impact of anxiety in PD, there are 
very few relevant treatment studies (Chen & Marsh, 2014; Djamshidian & Friedman, 
2014; Seppi et al., 2011; Weintraub & Burn, 2011).   In regard to pharmacological 
interventions for anxiety in PD, there is a concerning lack of recommended treatments or 
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consistent prescribing patterns by neurologists (Palanci, Marsh, & Pontone, 2011; 
Pontone et al., 2013; Prediger et al., 2012).  Among 250 adults with PD, over half of the 
patients with anxiety disorders without comorbid depression were untreated with 
medications (Pontone et al., 2013), highlighting its under-recognition and under-
treatment.   
Anxiolytic medications with potential application in PD include benzodiazepines, 
buspirone, selective serotonin reuptake inhibitors (SSRIs), noradrenaline selective 
reuptake inhibitors (NSRIs), tricyclic antidepressants, and adjustment in dopaminergic 
dose, although the potential of these agents is mitigated in part by concerns about 
variable efficacy and unfavorable side-effect profiles in this population.  For example, 
many of these drugs have the potential for adverse side effects, including sedation, 
cognitive impairment, falls, insomnia, and nausea (Chen & Marsh, 2014; Pena et al., 
2016; Prediger et al., 2012).  It is important to note that there is also the potential for 
harmful drug-drug interactions among older adults who frequently use both prescription 
and nonprescription medications (Qato et al., 2008), and persons with PD, many of whom 
are older, may wish to avoid adding another medication to their regimen if alternative 
treatments for anxiety are available.  Finally, pharmacological treatments designed to 
treat anxiety in the general population are not PD-specific and therefore may not consider 
the underlying neurobiology of the disorder (B. S. Connolly & Fox, 2012).  
Antidepressants, commonly prescribed for the treatment of both depression and anxiety 
in the general population, are generally well-tolerated in PD (Pena et al., 2016), and 
across two studies, have yielded large, but non-significant, secondary effects on anxiety 
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(Troeung, Egan, & Gasson, 2013); the authors noted that the effects likely did not reach 
statistical significance due to the limited sample size and the potential for Type II error. 
Antidepressants, do not, however, work for many individuals with PD (Weintraub & 
Hoops, 2011).  These findings together highlight the need for controlled treatment trials 
with a focus on anxiety in PD, in order to clarify the effects of antidepressants on this 
prevalent, but often under-studied, symptom. 
 
Potential of Cognitive-Behavioral Treatment for Anxiety in PD 
 Given the counter-indications of pharmacologic treatments for anxiety in PD, 
psychosocial and behavioral treatments may present a viable alternative treatment 
strategy for anxiety in PD, with emerging evidence to support the use of cognitive-
behavioral therapy (CBT), in particular.  As in pharmacological studies, anxiety has also 
been largely neglected in psychosocial treatment research in PD, typically appearing as 
only a secondary outcome measure in depression studies (S. Yang, Sajatovic, & Walter, 
2012).  A review of psychosocial interventions in PD found only eight studies published 
between 1997 and 2011 that included depression or anxiety as outcomes, including 
studies of CBT, psychodrama, education, behavior therapy, and multidisciplinary 
rehabilitation (S. Yang et al., 2012).  In this review, CBT was the most frequently studied 
intervention and showed promising effects for depression and anxiety in PD, although the 
studies were generally limited by small sample sizes, and none included individuals with 
PD who met diagnostic criteria for an anxiety disorder (e.g., per DSM-5). 
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 The evidence that does exist so far suggests that CBT may be effective for 
treatment of depression and/or anxiety in PD and warrants significant clinical and 
research attention (Armento et al., 2012; Egan, Laidlaw, & Starkstein, 2015; Pachana et 
al., 2013).  In a pilot study (Dobkin, Allen, & Menza, 2007) followed by a randomized 
controlled trial (Dobkin, Menza, Allen, Gara, et al., 2011), individual CBT improved 
depression in a sample of 80 depressed adults with PD relative to clinical monitoring, and 
also improved anxiety, quality of life, coping, and PD symptoms (motor and non-motor) 
as indexed by the Unified Parkinson’s Disease Rating Scale (total score).  In exploratory 
analyses of UPDRS subscales, significant improvements were observed in mood and 
motor function in the CBT group (Dobkin, Menza, Allen, Gara, et al., 2011). There is 
also preliminary evidence that telephone-administered or internet-based CBT may be 
feasible and effective treatments for depression and anxiety in PD (Calleo et al., 2015; 
Kraepelien, Svenningsson, Lindefors, & Kaldo, 2015; Veazey, Cook, Stanley, Lai, & 
Kunik, 2009).  Group CBT has also yielded promising reductions in depression and 
anxiety in PD with follow-up periods of one to six months, though samples were small 
(Feeney, Egan, & Gasson, 2005; Troeung, Egan, & Gasson, 2014).  Specific to anxiety, a 
single case report of a 60-year-old man with PD reported significant improvement in his 
social anxiety after 12 weeks of group CBT, both at post-treatment and at a 6-month 
follow-up (Heinrichs, Hoffman, & Hofmann, 2001).  In light of these promising findings, 
it would be of value to systematically examine the utility and feasibility of CBT for 
anxiety among adults with PD, particularly in larger samples, with longer follow-up 
periods, and with diagnostic information as an inclusion criterion, as many studies 
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continue to rely on self-report cutoffs to determine anxiety levels.  In addition to 
improvements in anxiety and depression, CBT may also yield benefits for other NMS, 
such as cognition or sleep (Dobkin et al., 2014; H. Yang & Petrini, 2012).  Accordingly, 
CBT for anxiety in PD represents an attractive treatment approach and a viable 
alternative to pharmacological treatment with minimal side effects and with the potential 
to teach lasting skills to individuals to manage anxiety and improve overall quality of life. 
 
Potential of Exercise Interventions for Anxiety and Non-Motor Symptoms in PD 
 In addition to CBT, exercise interventions represent another treatment strategy 
that may improve anxiety and other NMS in PD, particularly for those who do not 
respond to CBT or who do not have access to CBT.  To date, exercise research in PD has 
largely focused on the physical benefits, with evidence that aerobic and resistance 
exercise improve motor symptoms, strength, balance, and gait in PD, as well as quality of 
life (da Silva et al., 2016; Goodwin, Richards, Taylor, Taylor, & Campbell, 2008; 
Lamotte et al., 2015; Lamotte G., 2015; Monteiro et al., 2016).   
Besides the promising effects on physical functioning, aerobic and resistance 
exercise may also improve specific NMS in PD, including mood, cognition, and sleep 
(Lamotte et al., 2015; Murray, Sacheli, Eng, & Stoessl, 2014; Nascimento et al., 2014; 
Reynolds, Otto, Ellis, & Cronin-Golomb, 2016), as will be discussed in detail in Study 3.  
To illustrate, in a small study of 20 participants (10 per group), twelve weeks of twice 
weekly Nordic walking significantly reduced fatigue, depression, and apathy among PD 
participants, relative to a usual-care control group (Cugusi et al., 2015).  With regard to 
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potential cognitive benefits, a recent RCT revealed that two years of structured exercise, 
either progressive resistance training or a program of stretching, balance and 
strengthening yielded improvements in attention and working memory in non-demented 
adults with mild to moderate PD (David et al., 2015).  Aerobic and resistance training 
may also improve sleep in PD (Nascimento et al., 2014; Rodrigues de Paula, Teixeira-
Salmela, Coelho de Morais Faria, Rocha de Brito, & Cardoso, 2006).  Additional 
research with larger sample sizes, objective sleep measures, and more rigorous control 
groups are needed to better understand the potential effects of exercise on sleep, as well 
as cognition and mood, in this population. 
As well as aerobic and resistance training, there is a growing body of evidence on 
the utility of alternative forms of exercise, such as dance, tai chi, and qigong as potential 
treatments for motor and non-motor symptoms in PD.  Dance, especially tango, may 
yield benefits for quality of life, mood, cognition, and sleep in PD, besides motor 
improvements (Hackney & Earhart, 2009; Hashimoto, Takabatake, Miyaguchi, 
Nakanishi, & Naitou, 2015; Lewis, Annett, Davenport, Hall, & Lovatt, 2016; McNeely, 
Duncan, & Earhart, 2015; Rios Romenets, Anang, Fereshtehnejad, Pelletier, & Postuma, 
2015; Sharp & Hewitt, 2014; Sumec, Filip, Sheardova, & Bares, 2015).  Likewise, 
individuals with PD who engaged in 16 weeks of tai chi (three times per week), relative 
to a non-contact control group, showed significant improvement on overall quality of life 
and emotional well-being, as well as a trend toward improvement in working memory 
(Nocera, Amano, Vallabhajosula, & Hass, 2013).  Similarly, in a small pilot study of 7 
participants with PD, six weeks of qigong improved gait and sleep (Wassom, Lyons, 
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Pahwa, & Liu, 2015).  Given these encouraging results, further studies with larger sample 
sizes are warranted to determine the most effective type of alternative exercise in PD and 
to more systematically examine questions of exercise dose and longevity of effects with 
regard to both motor and non-motor symptoms. 
 The potential mechanisms of exercise-induced effects in PD are discussed in 
greater detail in Study 3, but broadly speaking, exercise in humans is thought to increase 
levels of neurotrophic factors such as brain-derived neurotrophic factor (BDNF) 
(Szuhany, Bugatti, & Otto, 2015), which has significant implications for the potential 
mechanisms of action of exercise in neurodegenerative diseases, such as PD, and any 
associated improvements in cognition (Campos et al., 2016).  It has been suggested that 
exercise may exert neuroprotective effects and also improve cognition in PD via 
neurotrophic factors and neuroplasticity (Ahlskog, 2011b).  More specifically, the 
combination of aerobic exercise and goal-based motor skill training in PD may support 
neuroplasticity in critical motor circuits known to be affected in the disease, such as the 
striatopallidal (indirect) pathway in the striatal-thalamic-cortical circuit associated with 
automaticity (Petzinger et al., 2013).  These changes may include normalization of 
corticomotor excitability (Fisher et al., 2008), as well as increased dopamine D2 receptor 
binding potential in the dorsal striatum of adults in the early stages of PD (Fisher et al., 
2013; Petzinger et al., 2013).  In addition to effects on corticomotor excitation and BDNF 
levels, exercise may also induce gray matter volume changes in PD (Hirsch, Iyer, & 
Sanjak, 2016).  For example, twenty individuals with PD who completed six weeks of 
balance training showed improvements in balance and associated gray matter changes in 
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several brain regions (anterior precuneus, inferior parietal, ventral premotor, anterior 
cingulate, and middle temporal gyrus), as well as a time-dependent volume increase in 
the right cerebellum (Sehm et al., 2014).  Further research is needed to elucidate potential 
mechanisms of exercise-induced brain and behavioral changes in PD, with the goal of 
designing tailored exercise interventions to improve the motor and non-motor symptoms 
of the disease, while also supporting overall physical fitness and brain health, across all 
stages of the disease. 
In summary, aerobic and resistance training have the greatest amount of empirical 
support with regard to the positive impact of exercise on the motor symptoms of PD, with 
alternative forms of exercise being explored more recently.  The majority of studies to 
date have focused primarily on the physical benefits of exercise, rather than specifically 
targeting NMS such as mood, cognition, and sleep.  Given the known anxiolytic, 
cognition-, and sleep-enhancing effects of exercise in the general population (Asmundson 
et al., 2013; Kredlow, Capozzoli, Hearon, Calkins, & Otto, 2015; Smith et al., 2010; B. 
M. Wipfli, Rethorst, & Landers, 2008), exercise may be an especially favorable 
adjunctive intervention for individuals with PD to support overall physical health and 
motor functioning, and also to potentially improve distressing NMS, which often emerge 
in the early stages of the disease.  Further, to the extent that exercise may promote 
neuroplasticity in PD, particularly within basal ganglia circuitry and prefrontal regions, it 
may ultimately prevent or at least delay further disease progression. 
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Specific Aims and Hypotheses 
 The three studies presented here were designed to achieve the following goals:  
(1) to examine the relation between anxiety and cognition among adults with PD, (2) to 
determine the utility and feasibility of a transdiagnostic cognitive-behavioral intervention 
to treat anxiety in PD, and (3) to synthesize the literature on aerobic and resistance 
exercise in older adults and in PD and highlight the potential therapeutic effects of 
exercise as an adjunctive treatment for symptoms of mood, cognition, and sleep in PD.   
 
Study One: The Relation of Anxiety and Cognition in PD 
 The increasing research focus on NMS in PD has underscored the high degree of 
comorbidity among these symptoms, even in the early stages of the disease (Naismith & 
Lewis, 2011; Stankovic et al., 2016).  In order to better identify and treat these symptoms 
in clinical practice, a more thorough understanding of the relations among NMS is 
essential.  In particular, mood and dysexecutive symptoms may emerge in early stages of 
the disease, due to disruption in brainstem and frontostriatal systems, respectively 
(Chaudhuri et al., 2006; Foltynie, Brayne, Robbins, & Barker, 2004; Prediger et al., 2012; 
Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007).  Study One examined the 
relation between anxiety and specific aspects of cognition (executive function and 
attention) among a large sample of adults with mild to moderate idiopathic PD.  It was 
hypothesized that anxiety would correlate with cognitive performance in PD, such that 
individuals who perform more poorly on cognitive tests would report higher anxiety than 
those with better cognitive performance.  Poor cognitive performance may indicate more 
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advanced PD pathology, and pre-existing anxiety may interfere with one’s ability to 
perform optimally on cognitive testing.   
 
Study Two: The Utility and Feasibility of Cognitive-Behavioral Treatment for Anxiety in 
Parkinson’s Disease:  A Pilot Study 
 With emerging research in PD on the classification, recognition, and 
pathophysiology of anxiety in PD, we can hope to use this information to develop 
effective, evidence-based treatments to improve affective symptoms in this population.  
Pharmacological treatments for anxiety in PD represent one strategy, although they do 
not work for many adults with PD, and also have the potential for adverse side effects.  
The goal of Study Two was to pilot a transdiagnostic cognitive-behavioral intervention in 
persons with PD who also met criteria for at least one anxiety disorder.  This study 
critically evaluated the utility and feasibility of this intervention using a multiple-baseline 
single-case experimental design, allowing examination of post-treatment changes in 
anxiety and secondary outcome measures (e.g., depression, sleep, cognition, quality of 
life).  Treatment adherence and satisfaction were also evaluated.  It was hypothesized that 
CBT would reduce anxiety at post-treatment and a 6-week follow-up, and also improve 
secondary outcomes, including depressive symptoms and quality of life.  It was also 
hypothesized that CBT would alleviate cognitive symptoms, as well as disease-specific 
motor symptoms-- e.g., freezing of gait or tremor-- because those symptoms may be 
exacerbated by anxiety.  The third prediction was that study participants would report 
satisfaction with treatment, which may further contribute to symptomatic change. 
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Study Three:  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and 
Sleep in PD 
 Research in the general population suggests that CBT may not improve symptoms 
of anxiety or depression for all individuals (Hofmann, Asnaani, Vonk, Sawyer, & Fang, 
2012; Loerinc et al., 2015).  As an alternative intervention for disturbances of mood, as 
well as of cognition and sleep, aerobic and resistance exercise present especially feasible 
and appealing treatment approaches for those with PD.  Robust evidence in the general 
population indicates that exercise yields positive effects on mood (reducing both anxiety 
and depression), cognition, and sleep (Asmundson et al., 2013; Bherer, Erickson, & Liu-
Ambrose, 2013; Kredlow et al., 2015; Smith et al., 2010; Stathopoulou, Powers, Berry, 
Smits, & Otto, 2006).  In PD, aerobic exercise has largely been used to improve physical 
symptoms, but it likely has the potential to also improve NMS; research studies must be 
designed to specifically measure potential changes in mood, cognition, and sleep.  The 
goal of Study Three was to synthesize the research on the effects of aerobic and 
resistance exercise on mood, cognition, and sleep, as shown in healthy older adults and in 
individuals with PD.  The review was intended to provide a rationale for the targeted use 
of exercise interventions to ameliorate symptoms of mood, cognition, and sleep in PD. 
 
Significance 
 This research project proposes to advance the study of anxiety in PD, with the 
goal of better recognizing, classifying, and treating this as well as other NMS (cognition 
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and sleep) in PD.  To date, research on affective symptoms in PD has focused primarily 
on depression, with anxiety often considered only as a secondary or exploratory outcome, 
despite the significant negative effects of anxiety on quality of life (Hanna & Cronin-
Golomb, 2012).  The current project has PD-related anxiety as its primary focus. 
First, the results from Study One expand our knowledge of the relations among 
anxiety and cognition in PD, in order to inform future diagnosis and treatment of these 
symptoms.  Second, the pilot study of CBT for anxiety in PD critically evaluates the 
utility and feasibility of an intensive, but time-limited, intervention.  To the best of our 
knowledge, this is the first study of individual transdiagnostic CBT in PD to focus 
exclusively on anxiety, rather than depression or some combination of the two.  Another 
innovative aspect of Study Two was that CBT was conducted in the clinic or over the 
internet according to participant preference, which has significant implications for the 
dissemination of psychological treatments among older adults with neurologic disorders.  
The hope is that these findings will provide the impetus for further treatment 
development for anxiety and NMS in PD, including the eventual implementation of 
larger, randomized controlled trials to establish evidence-based interventions for anxiety, 
as well as for comorbid symptoms of mood, cognition, and sleep.  Finally, as CBT may 
not be available or feasible for many persons with PD and may not be effective for some, 
the potential of aerobic and resistance exercise is considered as alternative non-
pharmacological treatment with the ability to improve not only mood, but also cognition 
and sleep in PD, with simultaneous benefits for physical functioning and overall health. 
 	
 
20 
In conclusion, these three studies together significantly expand current knowledge 
of anxiety in PD, with regard to both the manifestation and treatment of this symptom.  
This work emphasizes the increasing need for research and clinical focus on NMS in PD, 
especially anxiety, in order to better recognize and diagnose these symptoms and to 
develop disease-specific treatments to optimize quality of life and daily functioning.
 	1This chapter is in press as:  Reynolds, G.O., Hanna, K.K., Neargarder, S., & Cronin-Golomb, A. (in press).  
The relation of anxiety and cognition in Parkinson’s disease.  Neuropsychology.  	
  
CHAPTER 2:  STUDY ONE – THE RELATION OF ANXIETY AND 
COGNITION IN PARKINSON’S DISEASE1 
 
Introduction 
Afflicting approximately 1% of the population over age 60 (Mayeux, 2003; 
Prediger et al., 2012), Parkinson’s disease (PD) is associated with classic motor 
symptoms as well as with a variety of non-motor symptoms, including cognitive 
dysfunction and neuropsychiatric symptoms (Cronin-Golomb, 2013).  Non-motor 
symptoms are often comorbid with one another, with increased comorbidity associated 
with greater disease severity as indexed by motor and functional measures (Shulman et 
al., 2001).  These non-motor symptoms significantly contribute to a poor quality of life in 
individuals with PD (Duncan et al., 2014), often to a greater extent than the motor 
symptoms (Bonnet & Czernecki, 2013; Qin et al., 2009), but they remain understudied 
and under-diagnosed (Shulman et al., 2002).  In particular among the non-motor 
symptoms, anxiety and cognitive dysfunction are highly prevalent in PD, even in the 
early stages of the disease. Emerging research is beginning to more closely consider 
cognitive impairment and affective disorders in this population (Bogdanova & Cronin-
Golomb, 2012, 2013; Pluck & Brown, 2002; Santangelo et al., 2009), but the literature 
remains limited (Poletti, De Rosa, & Bonuccelli, 2012). 
Although the relation between anxiety and cognitive function is not well 
characterized in PD, anxiety has long been associated with impaired cognitive
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performance in non-PD populations, particularly on attentionally demanding tasks 
(Derakshan & Eysenck, 2009).  In older adults, including those with mild cognitive 
impairment, anxiety has been associated with cognitive deficits (Forsell, Palmer, & 
Fratiglioni, 2003) and has also been shown to predict cognitive decline in individuals 
without depression or cognitive impairment (Sinoff & Werner, 2003).  There is some 
evidence that those who develop anxiety disorders later in life (age 55 and above; an age 
group that includes most individuals with PD) may exhibit poorer overall cognition than 
those with early-onset anxiety disorders (DeLuca et al., 2005), suggesting that anxious 
individuals with PD may be at an increased risk for cognitive dysfunction due to their age 
alone.  Specifically, individuals with anxiety disorders exhibited impairments in 
executive function and episodic memory (Airaksinen, Larsson, & Forsell, 2005), and 
older adults with generalized anxiety disorder showed impairments in short-term and 
working memory, information processing speed, inhibition and problem-solving, and 
immediate and delayed memory, compared to control adults (Butters et al., 2011; Caudle 
et al., 2007; Mantella et al., 2007). These findings suggest that anxiety and cognition are 
likely to also be related in PD. 
The lack of research on affective symptoms in PD is concerning, as clinically 
significant anxiety occurs in up to 40% of individuals with PD (Aarsland, Marsh, & 
Schrag, 2009; Walsh & Bennett, 2001), and anxiety disorders occur at higher rates in PD 
than in the overall population (Nuti et al., 2004; Walsh & Bennett, 2001).  Anxiety in PD 
contributes to reduced subjective quality of life (Carod-Artal, Ziomkowski, Mourao 
Mesquita, & Martinez-Martin, 2008; N. N. Dissanayaka et al., 2010; Hanna & Cronin-
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Golomb, 2012; Havlikova et al., 2011; Leentjens, Dujardin, Marsh, Martinez-Martin, et 
al., 2011; McKinlay et al., 2008; Pontone et al., 2009) and greater self-perceived 
disability (Witjas et al., 2002).  Of further concern in PD, anxiety may compromise 
information processing ability and thereby negatively affect gait, potentially leading to 
falls (Ehgoetz Martens, Ellard, & Almeida, 2015).  Anxiety can also co-occur with 
depression in PD (N. N. Dissanayaka et al., 2010; M. A. Menza et al., 1993), and 
clinically significant depressive symptoms occur at rates of 35% in this population 
(Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008).  Consideration of comorbid 
depression is important, given that depression in PD has been associated with cognitive 
decline (Starkstein, Mayberg, Leiguarda, Preziosi, & Robinson, 1992), and with 
executive dysfunction and working memory deficits, even in early disease stages 
(Dirnberger & Jahanshahi, 2013; Uekermann et al., 2003). 
Cognitive dysfunction occurs in the majority of individuals with PD 
(Mamikonyan et al., 2009).  Up to 57% of those with PD are affected by mild cognitive 
impairment within the first 3-5 years after diagnosis (Williams-Gray et al., 2007), and up 
to 14% of individuals with PD over age 65 develop some type of cognitive impairment 
each year (Galvin, 2006).  Cognitive deficits in PD are associated with greater motor 
severity and typically include executive dysfunction, visuospatial and constructional 
deficits, and attention/working memory deficits (Dirnberger & Jahanshahi, 2013; 
Muslimovic, Post, Speelman, & Schmand, 2005; Pfeiffer, Lokkegaard, Zoetmulder, 
Friberg, & Werdelin, 2014).  Visuospatial, attentional, and executive deficits are the most 
typical in PD individuals with mild cognitive impairment (PD-MCI) (Aarsland, Bronnick, 
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& Fladby, 2011).  In a recent study of individuals with mild to moderate PD with neither 
dementia nor mild cognitive impairment, measures of attention and executive function 
(frontal-type tests) were the most sensitive to cognitive compromise (Miller, Neargarder, 
Risi, & Cronin-Golomb, 2013).  Understanding cognitive deficits in the early stages of 
the disease is important because they may predict the progression of cognitive 
dysfunction to dementia (Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 2003; 
Kehagia, Barker, & Robbins, 2010; Levy et al., 2002; Williams-Gray et al., 2009; 
Williams-Gray et al., 2007).  
Regarding potential mechanisms, similar brain regions and neurotransmitter 
systems have been implicated in the development of anxiety and cognitive dysfunction in 
PD and in the overall population, suggesting that the symptoms may be related in PD, at 
least in part, as a result of shared underlying neurocircuitry.  First, disrupted frontostriatal 
circuitry likely contributes to the executive deficits in non-demented individuals with PD, 
including deficits in flexibility, planning, and working memory (Kehagia, Barker, et al., 
2010).  Specifically, these impairments have been associated with prefrontal 
dopaminergic dysregulation (Cools, Barker, Sahakian, & Robbins, 2001; Narayanan, 
Rodnitzky, & Uc, 2013) and basal ganglia dysfunction (Kehagia, Barker, et al., 2010; 
Obeso et al., 2002; Obeso et al., 2000).  At the same time, widespread Lewy-body 
pathology occurs in PD in brain areas associated with anxiety, such as the amygdala, 
which has major projections to the prefrontal cortex (Braak et al., 1994; Braak et al., 
2004; Pontone et al., 2009; Prediger et al., 2012), suggesting potential disruption to 
affective and cognitive functioning.  Emerging work also points to a potential role of 
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dopaminergic degeneration in the ventral tegmental area in the pathophysiology of non-
motor symptoms in PD, namely depression, anxiety, and executive dysfunction 
(Alberico, Cassell, & Narayanan, 2015). 
The sources of mild cognitive deficits in early-stage PD may also include 
structural changes in frontal and temporoparietal regions as well as non-dopaminergic 
dysfunction (Hanna-Pladdy, Jones, Cabanban, Pahwa, & Lyons, 2013).  Noradrenaline 
and serotonin have been implicated in the development of anxiety in PD and the general 
population (Millan, 2003; Prediger et al., 2012; Ressler & Nemeroff, 2000).  Specifically, 
noradrenergic dysfunction has been implicated in deficits in attentional set-shifting, such 
as the task-switching deficits observed in individuals with PD (Kehagia, Cools, Barker, & 
Robbins, 2009; Kehagia, Murray, & Robbins, 2010).  In PD, noradrenergic dysfunction 
has been associated with depression and anxiety (Remy et al., 2005), and also with 
cognitive impairment and dementia (Del Tredici & Braak, 2013).  Likewise, serotonergic 
dysfunction occurs early in PD and may contribute to anxiety, considering the projections 
from the serotonergic raphe nuclei to corticolimbic regions (Prediger et al., 2012).  
Serotonergic neuronal loss has the potential to compromise cognition as well (Halliday, 
Leverenz, Schneider, & Adler, 2014), based on reduced levels of serotonin observed in 
PD in key brain regions, such as the hippocampus and frontal cortex (Scatton, Javoy-
Agid, Rouquier, Dubois, & Agid, 1983).  
  To date, the limited research on affective symptoms and cognitive function in PD 
has investigated the effects of depression and apathy on cognition, with relatively 
minimal attention given to the study of anxiety and cognition in this population (Poletti et 
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al., 2012).  In the present study, we sought to expand our understanding of this relation in 
a relatively large sample of individuals with PD.  We focused on executive functioning 
(set-shifting, phonemic fluency) and attention/working memory, as deficits in these 
domains are usually the cognitive symptoms that are documented in mild to moderate PD 
(Miller et al., 2013).  The main hypothesis was that higher anxiety levels would correlate 
with poorer performance on neuropsychological measures of executive function and 
attention.  
 
Method 
Participants 
Participants included 77 non-demented individuals with PD (39 men, 38 women; 
mean age = 62.9 years, SD 7.4), who were referred from the Parkinson’s Disease Center 
of Boston Medical Center and local PD support groups.  These individuals were 
participants in studies that used partly overlapping measures of cognition, as well as the 
same measures of anxiety.  The study protocols were approved by the Boston University 
Institutional Review Board, with consent obtained according to the Declaration of 
Helsinki.   
Participants with PD met the clinical criteria for mild to moderate idiopathic 
disease, following the United Kingdom Parkinson’s Disease Society Brain Bank 
diagnostic criteria (A. J. Hughes, Daniel, Kilford, & Lees, 1992).  Exclusion criteria 
included coexisting serious chronic illness (including psychiatric or neurological); use of 
psychoactive medications besides antidepressants and anxiolytics, which are commonly 
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prescribed in PD; history of intracranial surgery, traumatic brain injury, alcoholism or 
other drug abuse; and visual acuity poorer than 20/40.   All participants were non-
demented, as indicated by scores of 25 or better on a standard cognitive screening 
measure, the Mini-Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 
1975), and performance on the several cognitive tests described below.  
In the PD group, motor disability was staged using the Hoehn & Yahr scale 
(Hoehn & Yahr, 1967).  There were 15 participants in Stage I (unilateral), 51 in Stage II 
(mild bilateral), and 11 in Stage III (moderate bilateral).  Of the 77 participants, 40 had 
motor symptom onset on the left body side (LPD), 36 on the right side (RPD), and one 
had bilateral onset.  All were tested in their “on” medication state.  Disease and motor 
disability was rated with the Unified Parkinson’s Disease Rating Scale (UPDRS: (Fahn & 
Elton, 1987)).  UPDRS scores were available for 45/77 participants.  UPDRS total score 
(sections 1-3) was used as a measure of overall disease severity, and the motor subscale 
(section 3) was used as a measure of motor symptom severity.  Levodopa equivalent 
dosages (LED) were calculated using a standard formula (Tomlinson et al., 2010); 
medication information was available for 39/77 participants.  Of these 39 participants, 
five were taking anti-anxiety medication, and three were taking antidepressant 
medication. Table 1 provides a summary of participant characteristics. 
 
Procedure and Measures 
 Following the administration of the MMSE, participants completed a series of 
neuropsychological tests and mood questionnaires.  The neuropsychological tests 
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assessed current cognitive functioning primarily in the domains of executive functioning, 
working memory, and attention because these were the tests for which we had been 
collecting data across studies for several years, which permitted us to examine a large 
sample.  Not all participants received all tests.     
Tests of attention and working memory included the Trail Making Test A, and 
Digit Span Forward and Backward.  Tests of executive functioning included the Trail 
Making Test B and Phonemic Fluency; Category Fluency was also administered. 
 We administered the Digit Span subtest from the Wechsler Memory Scale III 
(Wechsler, 1997) to assess attention (Forward and Backward conditions) and working 
memory (Backward condition).  Score for each condition was the total number of correct 
trials.  The Trail-Making Test (TMT) (Tombaugh, 2004) was given to evaluate attention, 
set-shifting, and executive function. The task was to quickly draw lines connecting 
numbers in order (TMT-A; attention), and alternate between numbers and letters in order 
(TMT-B; set-shifting, executive function).  Score for each was time to completion.  To 
isolate set-shifting measured by TMT-B, a derived TMT-difference score was calculated 
(TMT-B – TMT-A), which removes the psychomotor component of the task that is 
captured in TMT-A (O'Rourke et al., 2011).  To further assess executive function, 
participants engaged in the Word Association Test for phonemic fluency (Delis, Kaplan, 
& Kramer, 2001).  They were instructed to name as many unique words beginning with 
the letters F, A, and S (phonemic fluency; FAS) as possible.  The categorical fluency trial 
was also administered, which required participants to name as many unique animals 
(categorical fluency; Animals) as possible.  The time limit for each trial was 60 seconds.  
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Score for phonemic fluency was the total number of correct responses, summed across 
the F, A, and S trials.  Score for categorical fluency was the total number of correct 
responses.   
 To measure anxiety symptoms, participants were administered the Beck Anxiety 
Inventory (BAI) (Beck & Steer, 1993).  The BAI is a 21-item self-report measure of 
anxiety, on which higher scores indicate more anxiety symptoms.  Participants also were 
given the Beck Depression Inventory II (BDI) (Beck, Steer, & Brown, 1996) to assess 
current depressive symptoms.  The BDI is a 21-item self-report measure of depressive 
symptoms, with higher scores indicative of higher levels of depression.   
 
Data Analysis 
 Statistical analyses were conducted with IBM SPSS Statistics, Version 22.  
Correlational analyses were conducted to determine whether neurocognitive functions 
were related to symptoms of anxiety in the PD sample.  The relation between anxiety and 
cognitive performance was examined using correlational analyses.  The skew in the BAI 
score distribution dictated the use of non-parametric analyses (Spearman’s correlations).  
The sample size for each analysis was dependent upon the number of individuals in the 
sample who had been administered those particular cognitive tests.  For the 77 PD 
participants, the sample size for each analysis ranged from 57 to 62.  By test, the sample 
sizes were as follows: TMT-A: 62; TMT-B: 62; FAS: 59; Animals: 57; Digit Span 
Forward: 58; Digit Span Backward: 58.  To account for the number of analyses and 
correlations between outcome variables, we used a conservative alpha level of .01 
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because some of the tests belonged to the same cognitive domain.  Because some 
participants did complete all of the cognitive tests, a conservative alpha level was used to 
minimize Type I error rate. 
 
Results 
Within-Group Levels of Anxiety and Depression 
The mean BAI in the sample was 10.0 (SD 7.7).  Twelve of the 77 PD 
participants reported clinically significant levels of anxiety on the BAI when using a 
highly specific cutoff score of 18 (Higginson, Fields, & Troster, 2001). Four of the 12 
had clinically significant depression scores (BDI-II ≥17).  In this subgroup of 12, mean 
BDI-II was 15.2 (SD 7.9), mean age was 65.8 years (SD 9.8), mean education was 14.4 
years (SD 2.4), mean disease duration was 10.9 years (SD 8.4), and all were in H&Y 
stages 2 or 3.  Of these 12 with clinically significant anxiety, nine completed TMT-A and 
TMT-B, and seven completed Verbal Fluency (FAS and Animals) and Digit Span. 
The mean BDI-II in the sample was 8.2 (SD 6.2).  Clinically significant levels of 
depression were reported by eight of the participants on the BDI-II, using a highly 
specific cutoff score of 17 (Higginson et al., 2001). Four of the eight had clinically 
significant anxiety scores (BAI ≥18). 
Within the PD group, levels of anxiety did not differ for men vs. women (t(75) = 
.09, p=.93) or by side of motor symptom onset (LPD, RPD; t(74) = 1.07, p=.29).  
Depression levels did not differ between men and women with PD (t(75) = 1.71, p=.09) 
or by side of motor symptom onset (LPD, RPD; t(74) = .03, p=.98).  Age at testing did 
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not correlate with anxiety (ρ=-.14, p=.23).  Data were accordingly collapsed across 
gender, side of motor symptom onset, and age for the following analyses.  
 
Within-Group Correlational Analyses 
Anxiety correlated with certain clinical characteristics, as shown in Table 2.  
These included disease stage (H&Y), disease severity (UPDRS total), and depression, 
with higher anxiety associated with more advanced stage, greater severity, and higher 
depression.  Anxiety also correlated with education and disease duration at a trend level, 
with higher anxiety associated with lower education and longer disease duration.  
Anxiety was not associated with medication usage (LED) or motor symptom severity.  
Depression correlated with disease severity (ρ =.47, p=.001) and there was a trend for a 
correlation with motor symptom severity (ρ=.32, p=.03), but not with age, education, 
disease duration, medication usage, or disease stage (all ps>.05; see Table 3).   
Because demographic and mood variables may influence neuropsychological 
performance, we conducted correlational analyses to examine these potential effects in 
our PD sample. Age, education, medication usage (LED), motor symptom severity, and 
overall disease severity (UPDRS total) did not correlate with cognitive performance (all 
ρs≤ |.26|, ps≥.04); UPDRS and LED correlational analyses were conducted with the 
subset of participants for whom those data were available.  Disease stage (H&Y) 
correlated with performance on TMT-B (ρ=.37, p=.003), and there were trends for TMT 
B-A (ρ=.29, p=.02) and category fluency (ρ=-.31, p=.02), but not for other cognitive tests 
(all ρs≤ |.22|, ps ≥.087).  There were trends for disease duration to correlate with TMT-B 
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(ρ=.29, p=.02) and TMT B-A (ρ=.30, p=.02), but not for other cognitive tests (all ρs< 
|.20|, ps ≥.15).   
Anxiety significantly correlated with performance on TMT-B (ρ=.37, p=.003; 
Figure 1), and remained significant after removing the psychomotor component of the 
task (TMT B-A: ρ=.34, p=.007; Table 4).  Anxiety did not correlate with performance on 
the tests of phonemic fluency, categorical fluency, attention, or working memory (Table 
4).  Depression did not correlate with performance on any of the cognitive measures 
(Table 5).  The pattern of findings remained the same after excluding the eight 
participants with clinically significant depression scores, such that there was a trend for 
anxiety to correlate with TMT-B (ρ=.32, p=.016) and TMT B-A (ρ=.33, p=.016), but not 
with other cognitive measures (all ρs≤ |.23|,  ps ≥.11).   
 
Discussion 
We examined the relation between anxiety and cognitive functioning in a large, 
well-characterized sample of non-demented individuals with mild to moderate idiopathic 
PD. Higher anxiety was significantly associated with more advanced disease stage and 
severity, and there was a trend for anxiety to also be associated with lower education and 
longer disease duration.  Anxiety also correlated with depression, and depression was 
associated with greater disease severity, with a trend for an association with motor 
symptoms as indexed by the UPDRS motor subscale.  Regarding cognitive function, 
higher anxiety correlated with poorer set-shifting (TMT-B) among PD participants even 
after removing the psychomotor component of the cognitive task (TMT B-A).  Anxiety 
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level did not correlate with performance on tests of attention, working memory, 
phonemic fluency, or categorical fluency. Depression did not correlate with cognitive 
performance, which is likely related to floor effects as the mean depression score in our 
sample was well within normal limits. 
We had originally predicted an association between anxiety and executive and 
attentional dysfunction in PD.  Our results are consistent with a recent study by Martens 
and colleagues (2016) that reported a correlation between anxiety and TMT B-A in PD, 
but no significant correlations between anxiety and the digit span subtests.  Our findings 
with a relatively large number of measures of executive function and attention (including 
digit span) accord with and expand upon those of the study of Martens and colleagues, 
highlighting the specific association between anxiety and set-shifting in mild to moderate 
PD.  The relation between anxiety and TMT-B is consistent with attentional control 
theory (Eysenck, Derakshan, Santos, & Calvo, 2007), which asserts that anxiety 
decreases attentional control and increases attention to threat, thereby compromising 
cognitive processes including inhibition and shifting.  Consistent with this theory, in a 
sample of community-dwelling older adults, individuals with increased anxiety showed 
poorer processing speed/shifting attention and inhibition abilities (Beaudreau & O'Hara, 
2009), which is in keeping with the association we observed between anxiety and set-
shifting in our PD sample.   
An earlier paper from our lab examined anxiety and cognition as related to side of 
motor symptom onset in PD (Bogdanova & Cronin-Golomb, 2012).  A consistent finding 
was the relation between disease duration and anxiety, which was observed in the 2012 
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sample and at a trend level in the present sample, suggesting that the relation between 
anxiety and cognition may evolve as the disease progresses.  The current study, relative 
to the 2012 study, included a larger sample of individuals with mostly mild anxiety in 
early disease stages, with analyses collapsed across side of motor symptom onset.  We 
also included discussion of depression and motor symptoms when possible and used a 
derived metric to better isolate set-shifting and account for motor slowing.  Of note, the 
present sample was similar to the 2012 sample in age and gender distribution, but current 
participants were milder overall, as indexed by shorter disease duration (6.5 years 
compared to 8.7) and less advanced disease stage (H&Y stages 1-3 compared to stages 2-
3), which underscores the importance of studying anxiety and cognition even in the early 
stages of PD. 
It is important to note that neuropsychological tests vary in their sensitivity to 
cognitive impairment in PD (Miller et al., 2013); hence, it is possible that some of our 
cognitive measures were not sensitive enough to capture the relation between anxiety and 
mild cognitive deficits in our sample of high-functioning, non-demented PD participants 
with mostly quite mild anxiety symptoms.  In a sample of 42 non-demented PD 
participants and 28 control participants, 36% of the PD group showed deficits (defined at 
1.5 SD below the control-group mean) on TMT-B, while only 15% showed deficits on 
Digit Span Forward and Digit Span Backward, suggesting that TMT-B performance may 
be affected to a greater extent than Digit Span in early PD (Miller et al., 2013).  Anxiety 
may impair cognitive performance, especially on complex or attentionally demanding 
tasks (Derakshan & Eysenck, 2009), which may explain the observed association 
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between anxiety and TMT-B, and the lack of association between anxiety and a relatively 
simple task (Digit Span Forward) in our sample.  Although Digit Span Backward is also a 
demanding task, there was greater variability in our sample on TMT-B (SD=45.8) than 
Digit Span Backward (SD=2.8), which may have reduced the power to discern an 
association between anxiety and working memory.  Likewise, although phonemic fluency 
is often impaired in early PD (Miller et al., 2013), in our present sample there was 
considerably less variability in performance of this test (SD=11.5) than for TMT-B.  
Also, the reduced power of non-parametric analyses, the use of which was dictated by the 
data characteristics, may have limited our ability to detect significant correlations 
between anxiety and measures of fluency or attention.    
Our study was subject to limitations.  First, our cognitive assessment was 
restricted to tests of executive function, attention, and categorical fluency.  We drew upon 
neuropsychological data from several years of consecutive participants, and these were 
the tests that were common across that time period.  The advantage of the selection of the 
tests was the large sample size for whom anxiety and cognition in a particular domain 
could be examined.  Future research on anxiety and cognition in PD should include a 
more comprehensive assessment of cognitive function, and in particular, measures of 
complex visuospatial function and reasoning, as deficits in these domains are regularly 
observed in PD (Amick, Miller, Neargarder, & Cronin-Golomb, 2012; Amick, Schendan, 
Ganis, & Cronin-Golomb, 2006; Bogdanova & Cronin-Golomb, 2012).  Second, our 
sample was assessed with only one measure of anxiety, the BAI, which includes several 
somatically-based items, e.g. “wobbliness in legs,” “unsteady,” “hands trembling,” 
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“shaky,” which are similar to PD motor symptoms (e.g., tremor or feelings of 
unsteadiness) (Leentjens et al., 2008; Leentjens, Dujardin, Marsh, Richard, et al., 2011).  
Mitigating this concern, we have found no difference in the ability of the BAI and its less 
somatically-laden counterpart, the State-Trait Anxiety Inventory, to predict quality of life 
in mild to moderate PD (Hanna & Cronin-Golomb, 2012).  Future studies may consider 
inclusion of recently developed PD-specific anxiety scales, such as the Parkinson Anxiety 
Scale (Leentjens et al., 2014).  Third, our sample consisted of non-demented and mainly 
high-functioning individuals with PD who reported mostly mild to moderate levels of 
anxiety.  The relation may be different in individuals with more advanced PD or more 
severe anxiety.  Inclusion of a PD control group (e.g., non-anxious vs. highly anxious PD 
participants) may elucidate the effects of anxiety on cognition when controlling for the 
cognitive dysfunction associated with the disease itself (e.g. executive deficits due to 
frontostriatal disruption).  Finally, information about disease severity (UPDRS) was 
available for the majority, though not all, of our participants with PD (45/77), which 
limits our interpretation of the relation between anxiety, cognition, and motor symptom 
severity. Among the subset with UPDRS scores, motor symptom severity did not 
correlate with anxiety or cognition, nor was there a relation between anxiety and 
cognition, likely due to floor effects, as the BAI mean was quite low (6.6).  We included 
the participants without UPDRS data in order to increase the range of BAI scores and 
examine the relation between anxiety and cognition in a larger PD sample.   
Taken together, our results suggest that anxiety may be related to poorer 
performance on measures of set-shifting even in high-functioning individuals with mild 
 	
 
37 
to moderate PD.  With a better understanding of the manifestation of non-motor 
symptoms in PD subgroups, we can hope to increase recognition of anxiety and cognitive 
dysfunction, particularly in the early stages of the disease, in order to inform subsequent 
treatment options.  This is important because, as we have documented, anxiety may 
deleteriously affect quality of life to a greater extent than do the motor symptoms of PD 
(Hanna & Cronin-Golomb, 2012). With research dedicated to a more comprehensive and 
systematic evaluation of anxiety and cognition in PD at various stages of the disease, we 
can work toward developing treatment approaches to address the often devastating effects 
of mood and cognitive impairments in PD, and ultimately improve daily functioning and 
quality of life for people living with this disorder. 
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Table 1.   Demographic, Clinical, and Neuropsychological Characteristics.   
Means (M) and Standard Deviations (SD), Unless Otherwise Noted	  
Age	 62.9 (7.4)	
Men:Women	 39:38 	
Education	 17.1 (2.6)	
MMSEa 	 28.8 (1.2)	
Disease Duration   	 6.5 (5.4) 	
H&Yb   2 (1-3)  
UPDRS Totalc 27.0 (10.7) 
UPDRS Motor Subscaled 16.4 (7.3) 
LEDe        361 (231) 
BAI 10.0 (7.7) 
BDI-II 8.2 (6.2) 
TMT-A (sec) 33.6 (15.0) 
TMT-B (sec) 79.0 (45.8) 
TMT B–A (sec) 45.4 (38.2) 
FAS (total) 43.9 (11.5) 
Animals (total) 22.4 (5.9) 
Digit Span Forward (total) 11.1 (2.6) 
Digit Span Backward (total) 7.5 (2.8) 
          
aMini-Mental State Examination 
bHoehn & Yahr stage:  Median (range) 
cUnified Parkinson’s Disease Rating Scale (UPDRS) Total (sections 1-3); UPDRS scores 
were available for 45/77 participants.  
dUnified Parkinson’s Disease Rating Scale (UPDRS) Motor Subscale (section 3). 
eLevodopa-equivalent dosages (LED); medication information was available for 39/77 
participants. 
BAI=Beck Anxiety Inventory; BDI-II=Beck Depression Inventory-II; TMT-A=Trail 
Making Test A; TMT-B=Trail Making Test B; FAS=phonemic fluency; 
Animals=categorical fluency.  
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Table 2.  Spearman’s Correlations between Anxiety (BAI) and Participant- and 
Disease-related Variables in PD  
 
VARIABLE         rho   p-value  N                         
  
Age    -.14  .23   77    
Education   -.28  .02   77 
Disease Duration    .29  .01     77 
H&Y    .31**  .007   77 
UPDRS total   .41**  .005   45 
UPDRS motor   .15  .31   45 
LED    .04  .83   39    
Depression   .58**  <.001   77  
 
 
 
 
Table 3.  Spearman’s Correlations between Depression (BDI-II) and Participant- 
and Disease-related Variables in PD  
 
VARIABLE         rho   p-value  N                         
  
Age    -.12  .29   77    
Education   -.22  .053   77 
Disease Duration    .03  .77   77 
H&Y    .22  .061   77 
UPDRS total   .47**  .001   45 
UPDRS motor   .32  .03   45 
LED    -.03  .87   39    
 
** p<0.01 
PD=Parkinson’s Disease; BAI=Beck Anxiety Inventory; H&Y=Hoehn & Yahr; 
LED=Levodopa-equivalent dosage (available for 39/77 participants with PD); 
UPDRS=Unified Parkinson’s Disease Rating Scale (available for 45/77 participants with 
PD)   
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Table 4.  Spearman’s Correlations between Anxiety (BAI) and Neuropsychological 
Performance in PD  
 
     
VARIABLE         rho   p-value  N   
  
TMT-B    .37**  .003   62 
TMT B-A   .34**  .007   62     
FAS    -.14  .28   59 
Animals   -.24  .07   57 
TMT-A    .07  .61   62 
Digit Span Forward  .09  .50   58 
Digit Span Backward  -.19  .16   58 				
Table 5.  Spearman’s Correlations between Depression (BDI-II) and 
Neuropsychological Performance in PD  
 
     
VARIABLE         rho   p-value  N 
TMT-B    .21  .099   62    
TMT B-A   .18  .16   62     
FAS    -.08  .57   59 
Animals   -.25  .062   57 
TMT-A    .12  .34   62 
Digit Span Forward  -.03  .80   58 
Digit Span Backward  -.17  .21   58 
 
** p<0.01 
PD=Parkinson’s Disease; BAI=Beck Anxiety Inventory; FAS=phonemic fluency; 
Animals=categorical fluency. 
 
 
 
 
 
  
 	
 
41 
Figure 1.  
  
 
Figure 1.  The line demonstrates a significant correlation between BAI and TMT-B 
among PD participants (ρ=.37, p=.003). PD = all Parkinson’s disease participants; 
BAI=Beck Anxiety Inventory; TMT-B=Trail Making Test B. 
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CHAPTER 3:  STUDY TWO – THE UTILITY AND FEASIBILITY OF 
COGNITIVE-BEHAVIORAL TREATMENT FOR ANXIETY IN PARKINSON’S 
DISEASE: A PILOT STUDY 
 
Introduction 
 Anxiety is one of the most prevalent and distressing non-motor symptoms of 
Parkinson’s disease (PD); yet it remains under-studied and inadequately treated (Chen & 
Marsh, 2014; N. Dissanayaka et al., 2015).  The prevalence of anxiety disorders in PD is 
estimated to be 31%, with the most common disorders being generalized anxiety disorder 
(14%), social phobia (13.8%), anxiety not otherwise specified (13.3%), specific phobia 
(13%), and panic disorder (6.8%) (Broen, Narayen, Kuijf, Dissanayaka, & Leentjens, 
2016).  There is also emerging evidence of subtypes of anxiety and depression in PD (R. 
G. Brown et al., 2011), as well as anxiety symptoms that are specific to PD, such as 
distress, worry, and embarrassment related to motor symptoms (N. N. Dissanayaka, J. D. 
O'Sullivan, et al., 2016), which has important implications for diagnosis and treatment.  
The neurobiological mechanisms of anxiety in PD likely involve multiple 
neurotransmitter systems, suggesting that anxiety is not solely a reaction to the motor 
symptoms (Prediger et al., 2012).  The high prevalence is concerning because anxiety is 
often comorbid with other non-motor symptoms (M. A. Menza et al., 1993; Naismith & 
Lewis, 2011), and significantly compromises quality of life, even among recently 
diagnosed patients, early in the disease course (Duncan et al., 2014; Hanna & Cronin-
Golomb, 2012).  Together, the prevalence and negative impact highlight the urgent need 
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for clinical research focused on anxiety in PD with the goal of better recognizing and 
treating this symptom across all stages of the disease.  
To date, there has been very little treatment outcome research on anxiety in PD.  
As of July 2013, there were no randomized controlled trials of any kind for the treatment 
of anxiety in PD (Seppi et al., 2011; Troeung et al., 2013), and the limited research on 
affective symptoms in PD has focused more on depression than anxiety (N. N. 
Dissanayaka et al., 2014; S. Yang et al., 2012).  Even more concerning is the fact that 
non-depressed individuals with PD and anxiety disorders are less likely to be treated with 
medication compared to individuals with comorbid anxiety and depression (Pontone et 
al., 2013).  In this study of 250 individuals with PD, 53% of the participants with anxiety 
disorders were not receiving pharmacologic treatment (Pontone et al., 2013).  Selective 
serotonin reuptake inhibitors (SSRIs) are often the standard pharmacologic treatment for 
anxiety in PD, while benzodiazepines may not be recommended due to potential for 
increased falls and cognitive dysfunction (Chen & Marsh, 2014; B. Connolly & Fox, 
2014; N. Dissanayaka et al., 2015).  Across two depression trials, SSRIs (citalopram) and 
tricyclic antidepressants (nortriptyline and desipramine) have yielded secondary 
improvements on anxiety in PD, although concern remains about the potential side 
effects of these drugs, which include bradykinesia, erectile dysfunction, orthostatic 
hypotension, and cardiac arrhythmias (D. Devos et al., 2008; M. Menza et al., 2009; 
Troeung et al., 2013).  Many older adults may wish to avoid adding another medication to 
their regimen to avoid harmful interactions (Mintzer & Burns, 2000; Qato et al., 2008).  It 
is also important to note that psychotropic drugs are not specifically designed for use in 
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PD and may exacerbate PD symptoms and/or interact harmfully with PD medications (B. 
S. Connolly & Fox, 2012).  Overall, there remains a limited evidence base to guide the 
pharmacologic treatment of anxiety in PD (Seppi et al., 2011).   
Non-pharmacological treatments offer an encouraging alternative treatment for 
anxiety in PD, with particular promise for cognitive-behavioral therapy (CBT; (Armento 
et al., 2012; Egan et al., 2015; Pachana et al., 2013)).  Psychosocial interventions for 
depression and anxiety in PD have included CBT, psychodrama, education, behavior 
therapy, and multidisciplinary rehabilitation, with CBT yielding reductions in depression 
and anxiety among depressed PD patients or those who endorsed elevated anxiety 
symptoms on a self-report rating scale (S. Yang et al., 2012).  In single-case and small 
pilot studies, individual and group CBT have shown the potential to alleviate anxiety and 
depression among individuals with PD and psychiatric diagnoses of anxiety and/or 
depression, with interventions delivered in person or by phone (Calleo et al., 2015; N. N. 
W. Dissanayaka et al., 2016; Feeney et al., 2005; Heinrichs et al., 2001; Mohlman et al., 
2010; Veazey et al., 2009).  In a waitlist-controlled trial, group CBT reduced levels of 
depression and anxiety among 18 participants with PD and comorbid diagnoses of 
depression and/or anxiety, with effects maintained at a 6-month follow-up (Troeung et 
al., 2014).  A group mindfulness intervention also showed preliminary efficacy in 
ameliorating anxiety and depression and improving cognition and motor symptoms in PD 
(N. N. Dissanayaka, F. Idu Jion, et al., 2016). 
These promising findings on CBT for anxiety in PD are consistent with the more 
extensive evidence for the efficacy of CBT for depression in this population.  A small, 
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uncontrolled study reported that individual CBT reduced depression among eight 
individuals with PD, with 57% achieving remission at post-treatment (Farabaugh et al., 
2010).  In the first RCT of CBT for depression in PD, Dobkin and colleagues reported 
that ten weeks of CBT alleviated depression and also showed positive effects on 
secondary outcomes of anxiety, quality of life, coping, and PD-specific symptoms 
(UPDRS total score and motor subscale), relative to a clinical monitoring control group 
(Dobkin, Menza, Allen, Gara, et al., 2011).  Results were similar in a smaller, 
uncontrolled trial of phone-delivered CBT for depression in PD (Dobkin, Menza, Allen, 
Tiu, et al., 2011).  Together, these studies suggest that CBT may have similar efficacy 
when used to directly target anxiety in PD and underscore the need for treatment outcome 
research focused on anxiety. 
Finally, it will be important to consider dissemination of non-pharmacological 
treatments for anxiety in PD.  Reported barriers to utilization of psychological treatment 
in PD include lack of local services, reduced physical mobility, and lack of transportation 
(Dobkin et al., 2013).  As described above, telephone-delivered CBT interventions have 
shown promising preliminary effects for reducing anxiety and depression in PD (Dobkin, 
Menza, Allen, Tiu, et al., 2011; Veazey et al., 2009).  Similarly, in a pilot study of nine 
PD participants with elevated anxiety and/or depression scores on the Hospital Anxiety 
and Depression Scale, internet-delivered CBT yielded improvements in depression, but 
not anxiety, at post-treatment (Kraepelien et al., 2015).  The protocol was self-guided and 
based on behavioral activation, with minimal therapist contact (<15 minutes/week) 
(Kraepelien et al., 2015).  To improve participant engagement and satisfaction, the 
 	
 
46 
authors suggested specific modifications for future interventions, including increased 
participant-therapist interaction, caregiver involvement, and more user-friendly 
technology (Kraepelien et al., 2015). 
 The aim of the present study was to examine the utility and feasibility of a 
transdiagnostic cognitive-behavioral treatment for anxiety disorders in PD.  The study 
implemented a manualized CBT protocol that has demonstrated efficacy in the treatment 
of anxiety and depression in non-PD populations (Farchione et al., 2012).  A single-case, 
multiple-baseline experimental design with three baseline conditions was used to 
examine within-subject variability and individual responses to specific intervention 
components, based on weekly measures of anxiety and depression.  It was predicted that 
the intervention would reduce anxiety among PD participants and also yield positive 
effects on secondary outcome measures, including depression, quality of life, cognition, 
sleep, and any motor symptoms that may be exacerbated by anxiety. 
 
Method 
Participants 
 Participants were nine individuals who met the clinical criteria for mild to 
moderate idiopathic PD (Hoehn & Yahr motor stage: range I-II) (Hoehn & Yahr, 1967), 
following the United Kingdom Parkinson’s Disease Society Brain Bank diagnostic 
criteria (A. J. Hughes et al., 1992).  Inclusion criteria were (a) met diagnostic criteria for 
any anxiety disorder as defined in the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5; (Association, 2013)), (b) at least eight years of formal 
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education, (c) psychotropic medication stability (at least 6 weeks prior to the intake and 
during study), (d) high-speed internet access and a webcam if completing therapy 
sessions online.  Exclusion criteria were:  (a) serious or chronic medical or neurological 
illness if not well-managed, other than PD, (b) history of moderate to severe traumatic 
brain injury, (c) current or recent (past 90 days) history of alcohol or substance use 
disorder, with the exception of nicotine, marijuana, and caffeine, (d) current suicidal or 
homicidal ideation or intent, (e) dementia (MMSE <25), (f) corrected binocular visual 
acuity poorer than 20/50, (g) average “off” time >50% of the day (periods of time when 
PD medication wears off, resulting in worsening of symptoms), (h) current DSM-5 
diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or 
substance/medication-induced disorder, or a principal diagnosis of specific phobia, (i) 
recent experience with an adequate trial of cognitive-behavioral therapy (CBT), defined 
as 8 sessions within the past 5 years, (j) concurrent psychosocial treatment (i.e. therapy) 
focused on anxiety or depression.  One participant (P8) had a history of deep brain 
stimulation (DBS).  Demographic information is reported in Table 6. 
Research Design 
 This study implemented a single-case, multiple baseline across subjects 
experimental design (Barlow, Nock, & Hersen, 2009; Hayes, Barlow, & Nelson-Gray, 
1999) to evaluate symptom change during treatment.  Single-case experimental designs 
(SCEDs) have high internal validity (Barlow & Hersen, 1973) and allow for flexibility to 
adapt treatment to meet the unique needs of each individual participant (Nock, Michel, & 
Photos, 2007).  The multiple baseline design is especially well-suited to examine the 
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utility and feasibility of a novel intervention, given its ability to establish functional 
relationships between individual symptomatic changes and specific treatment modules 
(Barlow et al., 2009; Hayes et al., 1999).  Participants were randomized to one of three 
baseline conditions (two, four, or six weeks) with three participants per condition, in 
accordance with sample size recommendations (Barlow et al., 2009).  Primary outcome 
measures of anxiety and depression were assessed weekly to track symptom change. 
Procedures 
 Participants were recruited through local neurology clinics, the Fox Trial Finder, 
local flyers, and word-of-mouth. After phone screening, eligible individuals were 
scheduled for the intake.  See Figure 2 for participant flow.  All participants gave written 
informed consent, and all procedures were approved by Boston University’s Internal 
Review Board.  Participants completed four primary assessments of approximately 3-5 
hours and twelve weekly hour-long sessions of cognitive-behavioral treatment.  During 
the first assessment, participants were screened for visual acuity and dementia (per the 
Modified Mini Mental State Examination (mMMSE; (Stern, Sano, Paulsen, & Mayeux, 
1987))).  The mMMSE scores were converted to the traditional MMSE scale for 
screening purposes, and all participants scored 25.75 or greater.  All assessments and 
therapy sessions were conducted at the Center for Anxiety and Related Disorders 
(CARD) at Boston University.  At the approximate halfway point of the study, the 
protocol was amended to give participants the option to complete therapy sessions via a 
secure videoconferencing platform (WebExTM), in an effort to reduce burden of travel 
and improve recruitment rates.  For participants who elected the online option, the four 
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primary assessments were conducted in the participants’ homes.  Participants incurred no 
charge for the 12 therapy sessions, and received financial compensation after each of the 
four primary assessments.   
The lead investigator of the study (GOR) conducted all assessments and therapy 
sessions (with the exception of in-person UPDRS assessments described below).  She 
was a Master’s level doctoral student at the time of data collection with training in ADIS 
administration and UP delivery from senior clinicians and advanced graduate students at 
CARD and UPDRS training from neurologists and physical therapists at Boston Medical 
Center and at BU’s College of Health and Rehabilitation Sciences: Sargent College. 
 Four Primary Assessments (intake/pre-baseline, post-baseline/pre-treatment, 
post-treatment, 6-week follow-up):  These assessments lasted 3-5 hours each and 
consisted of a semi-structured diagnostic interview, self-report questionnaires, and brief 
neuropsychological measures.  If the participant met diagnostic criteria for at least one 
DSM-5 anxiety disorder, he/she was then randomized to a two-, four-, or six-week 
baseline phase.  To reduce participant burden and fatigue, self-report questionnaires for 
secondary outcome measures were available online via Qualtrics, a secure online 
platform used regularly in clinical research.   
 Baseline Phase (2, 4, or 6 weeks):  Participants completed brief weekly self-
report measures of anxiety and depression online via Qualtrics.  Questionnaires were 
reviewed weekly by the examiner to assess stability in scores and to monitor for issues of 
risk.  Once stability in weekly scores was observed during the baseline phase, participants 
completed the second primary assessment.  The baseline phase was extended for four 
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participants (P2, P5, P8, P9).  P2 and P5 showed variability in anxiety scores during the 
first 4 weeks of the baseline, requiring extension of the baseline phase by three weeks 
(P2) and one week (P5).  P8 was randomized to the 4-week baseline condition, but her 
phase was extended by three weeks due to PD-symptom variability (increased OFF time) 
and scheduling conflicts.  For these three participants (P2, P5, P8), the last 4 weeks of the 
baseline are used for comparison to the intervention phase.  P9 (randomized to the 6-
week baseline, which was extended by one week) showed variability during the first 4 
baseline weeks and failed to complete the one of the anxiety measures during week 3.  
The last 6 weeks of the baseline condition are used for her analyses, with the exception of 
the Overall Anxiety Severity and Impairment Scale (OASIS), for which only 6 datapoints 
were collected across the 7 weeks, all of which were utilized as a baseline. 
 Intervention Phase (12 weeks): Participants engaged in twelve 50-60 minute 
weekly sessions of cognitive-behavioral therapy (CBT).  The CBT followed the Unified 
Protocol for Transdiagnostic Treatment of Emotional Disorders (UP; (Barlow et al., 
2011)).  The UP comprises five core treatment modules to target emotional processing:  
present-focused awareness, cognitive flexibility, emotional avoidance and emotion-
driven behaviors, awareness and tolerance of physical sensations, and interoceptive and 
situational emotion exposures, as well as modules on motivation, psychoeducation, and 
relapse prevention.  Weekly homework was assigned and reviewed each session, and 
progress was tracked by charting weekly anxiety and depression scores in session.  See 
Table 7 for an outline of weekly session content.  Psychoeducation about anxiety and PD 
was incorporated as needed.  At the halfway point in treatment, a 20-30 minute 
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informational session was conducted with a partner or family member of the participant, 
if the participant and the partner both agreed to this option.  Seven of the nine participants 
chose this option (all except P2 and P8).  During this brief session, the therapist met 
individually with the partner or family member (either in person, via WebExTM, or by 
phone) and introduced psychoeducation about emotions and cognitive 
appraisal/reappraisal to facilitate increased practicing of these skills by the participant.  
All sessions were supervised by a licensed clinical psychologist.  All sessions were 
audiotaped (or videotaped via WebExTM), and just over 10% (12 of 108 session tapes) 
were randomly chosen for review by a certified UP trainer to ensure adherence to the 
treatment protocol and provide feedback to the therapist, based on a checklist of 
predetermined goals.  Overall adherence ratings for all sessions were 85% or greater, 
with modal adherence of 100%.  All qualitative ratings ranged from good to excellent. 
Measures 
Diagnostic interview:  Diagnostic information was obtained with the Anxiety 
Disorders Interview Schedule (ADIS-5; (T. A. Brown & Barlow, 2013)), a semi-
structured diagnostic interview for DSM-5 anxiety disorders, with additional sections for 
depression, trauma, and substance use.  Each diagnosis was assigned a clinical severity 
rating on a scale from 0 (no symptoms) to 8 (severe symptoms) with ratings of four or 
greater indicative of clinically significant symptoms.  To participate in the study, 
participants must have received a severity rating of at least 4 for at least one anxiety 
disorder during the intake.  Only diagnoses with ratings ≥4 were assessed at subsequent 
assessments.   
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Primary outcome measures: The following measures of anxiety and depression 
were administered at all assessments and weekly during the baseline and intervention 
phases:  Beck Anxiety Inventory (BAI; (Beck & Steer, 1993)), Overall Anxiety Severity 
and Impairment Scale (OASIS; (Norman, Cissell, Means-Christensen, & Stein, 2006)), 
State-Trait Anxiety Inventory (STAI; (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 
1983)), Beck Depression Inventory (BDI-II; (Beck et al., 1996)), Overall Depression 
Severity and Impairment Scale (ODSIS; (Bentley, Gallagher, Carl, & Barlow, 2014)), 
Geriatric Depression Scale (GDS; (Yesavage et al., 1982)).  
Secondary outcome measures:  The following measures were administered at 
the four primary assessments.  Mood and anxiety scales included the Anxiety Sensitivity 
Index (ASI; (Reiss, Peterson, Gursky, & McNally, 1986)), Apathy Scale (AS; (Starkstein, 
Mayberg, Preziosi, et al., 1992)), Pain Catastrophizing Scale (PCS; (Sullivan, Bishop, & 
Pivik, 1995)), Panic Disorder Severity Scale (PDSS; (Shear, Clark, & Feske, 1998)), 
Penn State Worry Questionnaire (PSWQ; (Meyer, Miller, Metzger, & Borkovec, 1990)), 
Social Interaction Anxiety Scale (SIAS; (Mattick & Clarke, 1998)), and Social Phobia 
Inventory (SPIN; (Connor et al., 2000)).   
PD-specific rating scales included the Freezing of Gait Questionnaire (FOG; 
(Giladi et al., 2000)), Parkinson’s Disease Quality of Life Questionnaire (PDQ-39; (Peto, 
Jenkinson, Fitzpatrick, & Greenhall, 1995)), Parkinson’s Disease Sleep Scale 
(Trenkwalder, Kohnen, et al., 2011), Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS; (Goetz, Tilley, Shaftman, Stebbins, Fahn, Martinez-Martin, Poewe, Sampaio, 
Stern, Dodel, Dubois, Holloway, Jankovic, Kulisevsky, Lang, Lees, Leurgans, LeWitt, 
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Nyenhuis, Olanow, Rascol, Schrag, Teresi, van Hilten, & LaPelle, 2008)). To maximize 
reliability and minimize potential examiner bias, an independent evaluator (IE) 
administered UPDRS assessments for the five participants who were assessed at CARD.  
The IE was blind to study hypotheses, well trained in human subjects research, and well 
trained in UPDRS assessment by collaborators at Sargent College and Boston Medical 
Center.  For participants assessed in their homes (and treated via WebExTM), UPDRS 
assessments were administered by the lead examiner (GOR), who had also been trained 
in UPDRS assessment with collaborators at Sargent College and Boston Medical Center. 
Additional scales included the Falls Self-Efficacy Scale (FES; (Tinetti, Richman, 
& Powell, 1990)), Short-Form McGill Pain Questionnaire (McGill-SF; (Melzack, 1987)), 
and the Telepresence in Videoconference Scale (administered at mid- and post-treatment 
only (Bouchard & Robillard, 2000, 2006)).   
Brief neuropsychological tests of executive function and attention included Digit 
Span (forward and backward), Trail Making Test A & B, Verbal Fluency (letter and 
categorical) (Delis et al., 2001; Lezak, Howieson, & Loring, 2004; Wechsler, 1997).  
Two brief measures of treatment satisfaction (Client Satisfaction Questionnaire (CSQ-8 
(Larsen, Attkisson, Hargreaves, & Nguyen, 1979); Post-treatment feedback form, see 
Appendix A) were administered at post-treatment. 
Data Analysis  
 As is standard in SCEDs, visual inspection was the primary analytic strategy 
(Barlow et al., 2009; Hayes et al., 1999; Kazdin, 2003).  The relative change in slope 
between assessment points was used to determine the effects of specific treatment 
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components on observed symptom changes.  Observed changes in the slope or level of 
the dependent variables (weekly measures of anxiety and depression) during phase shifts 
(transitions from baseline to intervention/follow-up), compared to either previous within-
subject or simultaneous between-subject baseline phases, were used to determine if the 
observed changes in symptoms were functionally related to the study phase (treatment).   
 To complement visual inspection, reliable change (RC) scores were computed for 
primary and secondary outcome measures per the method described in Au et al. (under 
review).  For each participant, change scores were calculated for baseline (last baseline 
score – first baseline score), pre-post treatment (post-treatment score – last baseline 
score), and pre-follow-up (6-week follow-up score – last baseline score).  A standard 
error of the difference (Sdiff) was then calculated for each measure per the following 
equation:  Sdiff  = sqrt[2(SE)2], where SE = SD X sqrt(1 – rxx), and where SE=standard 
error of measurement; sqrt=square root; SD=standard deviation of the measure (from 
published norms or larger samples either in PD or clinical populations); rxx=reliability 
coefficient from published data.  Due to the small sample size of the present study, SDs 
and internal consistency coefficients were taken from published studies with larger 
samples (Antony, Coons, McCabe, Ashbaugh, & Swinson, 2006; Bentley et al., 2014; 
Campbell-Sills et al., 2009; Delbaere et al., 2010; Donnell & McNally, 1990; Giladi et 
al., 2009; Goetz, Tilley, Shaftman, Stebbins, Fahn, Martinez-Martin, Poewe, Sampaio, 
Stern, Dodel, Dubois, Holloway, Jankovic, Kulisevsky, Lang, Lees, Leurgans, LeWitt, 
Nyenhuis, Olanow, Rascol, Schrag, Teresi, van Hilten, LaPelle, et al., 2008; Hawker, 
Mian, Kendzerska, & French, 2011; Heimberg, Mueller, Holt, Hope, & Liebowitz, 1992; 
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Jenkinson, Fitzpatrick, Peto, Greenhall, & Hyman, 1997; Kabacoff, Segal, Hersen, & 
Van Hasselt, 1997; Leentjens, Dujardin, Marsh, Richard, et al., 2011; O. Moore, Peretz, 
& Giladi, 2007; Rector, Szacun-Shimizu, & Leybman, 2007; Shear et al., 2001; Stanley, 
Novy, Bourland, Beck, & Averill, 2001; Starkstein, Mayberg, Preziosi, et al., 1992; 
Sullivan, 2009; Sullivan et al., 1995; Trenkwalder, Kohnen, et al., 2011; Williams et al., 
2012; Wright, Asmundson, & McCreary, 2001; Yardley et al., 2005).  95% confidence 
intervals (CIs) around change scores were then computed for each measure by 
multiplying Sdiff by 1.96. 
RC scores were used to determine if observed changes during the baseline and 
treatment phases were greater than would be expected due to chance alone.  For 
secondary outcome measures, RC scores were computed for quality of life (PDQ-39), 
motor symptom severity (MDS-UPDRS: Part III), disorder-specific questionnaires (e.g. 
GAD=PSWQ; Panic disorder=ASI, PDSS; SOC=SIAS, SPIN), and any other 
questionnaires for which the participant endorsed clinically significant scores at the 
intake.  The following scores were used to determine clinical significance: AS≥14 
(Starkstein, Mayberg, Preziosi, et al., 1992), ASI>23 (Maller & Reiss, 1992), FES>23 
(Delbaere et al., 2010), FOG >6 (O. Moore et al., 2007), McGill-SF >14 (Wright et al., 
2001), PCS≥30 (Sullivan, 2009), PDSS≥8 (Shear et al., 2001), PDSS-2>10.5 (Kovács et 
al., 2016), PSWQ>50 (Therrien & Hunsley, 2012), SIAS≥34 (E. J. Brown et al., 1997), 
SPIN≥19 (Connor et al., 2000).  For measures with no identified cutoffs (FOG, McGill-
SF), a conservative approach was adopted such that scores that fell above the published 
mean at the intake were analyzed for pre-post and pre-follow-up changes.  For the 
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neuropsychological measures, change was explored using the 20% method (Raymond, 
Hinton-Bayre, Radel, Ray, & Marsh, 2006), chosen due to lack of a matched control 
group and our focus on idiographic analysis.  A change score of 20% or greater relative 
to the intake score was considered clinically significant.  Exploratory, qualitative 
analyses were used to examine treatment satisfaction and acceptability of the 
intervention. 
 
Results 
Figures 3-8 plot the scores on the weekly measures of anxiety and depression 
across all nine participants, with each figure containing one participant from each 
baseline condition.  Tables 9-10 report individual change scores and 95% CIs for primary 
outcome measures of anxiety and depression during baseline, intervention, and follow-up 
phases.  
Functional Analysis of Baseline Data 
 Weekly anxiety scores remained relatively consistent regardless of baseline 
length.  The one exception was observed variability on the STAI-S during the baseline 
for P7, P8, P9, which precludes analysis of pre-post or pre-follow-up changes on this 
specific index, as any variability during those comparisons may have been related to 
external factors, similar to patterns observed during baseline.  Likewise, depression 
scores remained relatively stable across all participants during the baseline phase, except 
for variability on the BDI-II for P4 and P7.  Neither of these participants met diagnostic 
criteria for a depressive disorder during the study, suggesting that their scores on the 
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BDI-II during baseline reflect normal within-subject variability; though this variability 
does preclude conclusions about potential effects of the intervention on subclinical 
depressive symptoms for these two participants.  For those who demonstrated a 
significant change in the level or slope of weekly anxiety and depression scores (P1, P2, 
P4, P5, P6, P7, P9), the change did not occur until the intervention and/or follow-up 
phases regardless of baseline condition (see graphs for P1 (2-week baseline), P2 (4-week 
baseline), and P9 (6-week baseline)).  These findings suggest that the changes in anxiety 
or depression among the seven responders were functionally related to the intervention, 
and not to external factors or simply the passage of time. 
Functional Analyses of Primary Outcome Measures 
Anxiety 
 From the start to the end of the baseline, anxiety scores were largely consistent or 
trended slightly upward (e.g., P1) across all nine participants, with the exception of 
significant decreases in STAI-S for P7, P8, and P9.  Occasional sharp changes in anxiety 
during baseline were observed for some participants (e.g., P9 (BAI, STAI-S increases in 
weeks 2-3), and P2 (BAI decrease in week 3)), but the scores quickly stabilized.  During 
the intervention, visual inspection showed a reduction (change in level or slope) in at 
least one anxiety measure for seven of the nine participants (all except P3 and P8).  
Statistically significant reductions in anxiety were observed for seven of the nine 
participants (P1, P2, P4, P5, P6, P7, P8) at either post-treatment or follow-up (Table 2).  
The statistically significant change in STAI-S for P9 at follow-up cannot be solely 
attributed to the intervention due to similar variability reported during her baseline phase 
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on that same measure; however, her post-treatment and follow-up scores on this measure 
do not overlap with any of the scores during the baseline, suggesting some positive effect 
of the intervention.  Seven of the nine participants also reported improved symptoms on 
the diagnostic interview (Table 8), such that they no longer met criteria for at least one 
anxiety disorder at post-treatment and/or follow-up (e.g., P1, P2, P4, P6, P9; P5 and P7 
for GAD only), while others reported improvements in symptoms (e.g., P5, P7, P8 for 
panic disorder at post-treatment only).  
Isolated spikes in anxiety were observed for some participants during treatment 
(e.g., week 11 for P1, weeks 10-12 for P2, weeks 5-7 and 12 for P4, week 9 for P7, weeks 
4 and 9 for P9), which were related to specific external factors (e.g., family stressors, 
physical pain, the holidays, winter weather, missed sessions, illness) or treatment 
components (e.g., exposures).  For example, P2 showed a rapid response to treatment, 
which corresponded with sessions on motivation and psychoeducation during weeks 2 
and 3.  For P5, BAI levels rose at the start of treatment (sessions 1-5), which coincided 
with external stressors for her (the departure of her husband on a month-long trip).  Her 
husband returned by session 6, and of note, her BAI scores continued to trend steadily 
downward for the remainder of treatment (sessions 6-12) even after his return.  For P8, an 
initial increase in the slope on BAI and STAI-S (weeks 1-5) coincided with increased 
OFF periods related to DBS reprogramming, and there was a subsequent decline in 
anxiety for the remainder of treatment (weeks 5-12).  Throughout treatment, P8 reported 
several medically-warranted adjustments in dopaminergic dose and changes to DBS 
settings, several of which significantly worsened her motor symptoms (e.g., increased 
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dyskinesias).  These changes likely affected her anxiety ratings, but these changes were 
consistent from weeks 1-10 of the intervention phase, and the downward trend in anxiety 
scores began in week 5.   
Depression 
Depression scores remained stable or trended slightly upward for seven of the 
nine participants during baseline (P1, P2, P3, P5, P6, P8, P9), other than occasional, 
isolated changes (e.g., P6 (sharp drop during week 4) and P9 (increase during weeks 3-
5)).  However, two participants (P4, P7) showed significant decreases in depression 
scores (BDI-II) during baseline, which limits interpretation of any changes observed on 
this measure at post-treatment and follow-up for these participants.   
Visual inspection showed a change in level and/or slope on at least one primary 
depressive measure during treatment or follow-up for seven participants (P1, P2, P5, P6, 
P7, P8, P9), and all seven showed statistically significant reductions in depressive 
symptoms at post-treatment and/or follow-up, relative to the baseline.  Sharp increases in 
depressive symptoms during treatment (e.g., weeks 5-6 for P4, week 10 for P7, weeks 5-6 
for P8, week 4 for P9) were observed to correspond with treatment components (e.g., 
exposures), external stressors, or poor responses to DBS/PD-medication adjustments for 
P8 only (e.g., increased OFF time and severe dyskinesias, which reportedly contributed to 
her increased depression).  P4 reported a decline in depressive symptoms on the BDI-II 
during treatment that was significant at post-treatment and follow-up, but this change 
cannot be fully accounted for by the intervention due to the downward trend observed on 
this measure during baseline.  However, P4 showed a gradual decline in GDS scores 
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during treatment that reached statistical significance at follow-up, relative to the stable 
GDS scores observed during baseline.  Two of the participants (P3, P8) met diagnostic 
criteria for a comorbid depressive disorder at the intake.  P3 reported no changes at post-
treatment or follow-up on the clinical interview and continued to meet diagnostic criteria 
for dysthymia (CSR≥4).  P8 met criteria for major depression at post-treatment and 
follow-up, but reported a slight improvement in depressive symptoms at follow-up.   
Secondary Outcome Measures – Disorder-Specific Questionnaires 
Four (P1, P2, P4, P7) of the nine participants reported significant and consistent 
improvements on disorder-specific questionnaires at post-treatment and follow-up (Table 
11).  One additional participant (P8) reported significant improvement on one disorder-
specific questionnaire (PDSS) at follow-up only, as well as non-significant improvement 
on one measure of social phobia (SPIN) at post-treatment and also at follow-up, though 
to a lesser extent.  Two participants (P5, P6) reported non-significant improvements on 
most disorder-specific questionnaires at post-treatment and follow-up, with the one 
exception being no changes in worry (PSWQ) for P5.  On a measure of social phobia 
(SPIN), P6’s score dropped to 16 at post-treatment and follow-up, which is below the 
clinical cutoff of 19.  Two of the nine participants (P3, P9) did not report any significant 
changes on disorder-specific questionnaires; P3’s PSWQ scores fell just below the 
clinical cutoff of 50 at all assessment points.   
Other notable improvements were observed for three participants (P2, P5, P7) 
who endorsed elevated symptoms on additional intake questionnaires that did not 
correspond with their principal anxiety diagnoses.  At post-treatment and follow-up, P2 
 	
 
61 
reported a significant reduction on a measure of social phobia (SPIN) on which he scored 
at the clinical cutoff at the intake.  P5 reported significantly reduced symptoms of social 
anxiety on the SIAS at follow-up, but not post-treatment, relative to her intake score, 
which fell just above the cutoff.  At post-treatment, but not follow-up, P7 reported 
significantly reduced symptoms of panic disorder (PDSS) after scoring above the clinical 
cutoff on this measure at the intake.  
Secondary Outcome Measures – Quality of Life, Motor Symptoms, Freezing of Gait, 
Fear of Falling, Apathy, Sleep, Pain, & Cognition 
One participant (P4) reported significantly improved quality of life at post-
treatment and follow-up.  There were no significant changes in quality of life among the 
other eight participants, but two participants (P1, P9) reported modest (non-significant) 
improvements at post-treatment and follow-up.  There were no consistent effects of the 
intervention on motor symptoms.  At post-treatment, P8’s demonstrated improved motor 
symptoms, but this finding is difficult to interpret given her adjustments during treatment 
to DBS programming and PD-related medications.  Two other participants demonstrated 
minimal (non-significant) improvements in motor symptoms at post-treatment and 
follow-up (P5, P6), while two other participants showed worse motor symptoms at either 
post-treatment (P7) or follow-up (P2).  Three participants endorsed elevated freezing of 
gait at the intake (P3, P7, P8), and one (P8) reported significantly worse freezing of gait 
at the follow-up.  Otherwise, there were no changes in freezing among these participants 
at post-treatment or follow-up.  Two participants endorsed elevated fear of falling at the 
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intake (P1, P4) and both reported significantly reduced fear of falling at post-treatment 
and follow-up. 
Six participants endorsed elevated apathy at the intake.  Two of the six (P4, P9) 
reported significantly reduced apathy at post-treatment and/or follow-up, while one 
participant (P3) reported significantly worse apathy at post-treatment and follow-up.  
Seven participants reported elevated sleep disruption at the intake, and only one reported 
significant improvement at post-treatment and follow-up (P4).  Two participants (P1, P8) 
reported significantly worse sleep at follow-up only.  There were no significant changes 
in sleep for the other four participants.  Two participants (P7, P8) endorsed elevated pain 
at the intake, and there were no significant changes in their pain levels at post-treatment 
or follow-up.  See Tables 11 and 12 for change scores for secondary outcome measures. 
Regarding cognition, six of the nine participants (P3, P4, P5, P6, P7, P9) 
improved on TMT-A at either post-treatment or follow-up, but those who showed 
improvement at post-treatment (P3, P4, P7, P9) did not maintain the gains at follow-up 
(Table 13).  On TMT-B, three participants (P1, P8, P9) significantly improved at post-
treatment and/or follow-up, while five participants (P2, P3, P5, P6, P7) significantly 
declined at post-treatment and/or follow-up.  Three participants (P1, P6, P9) improved on 
lexical fluency at post-treatment and/or follow-up with no changes among the other six 
participants.  For categorical fluency, three participants improved (P6, P8, P9) and two 
declined (P1, P5) at post-treatment and/or follow-up.  One participant (P3) significantly 
improved on Digit Forward at post-treatment, but there were no changes on this measure 
for the remaining eight participants at post-treatment or follow-up.  On Digit Backward, 
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four participants (P1, P2, P3, P6) significantly improved at post-treatment and/or follow-
up, and two participants declined, either at post-treatment (P4) or follow-up (P8). 
Treatment Satisfaction and Telepresence Ratings 
 All participants rated the intervention as either “very acceptable” (4/5) or 
“extremely acceptable” (5/5) (mean= 4.6/5), and all participants were either “very 
satisfied” (4/5) or “extremely satisfied” (5/5) (mean=4.6/5).  Mean score on CSQ-8 was 
30.9 (range=29-32) out of a possible 32.  Across the four internet participants, mean 
telepresence scores were 80.72% at mid-treatment and 80.75% at post-treatment (0-100% 
scale), indicating >80% overall agreement that videoconference sessions seemed natural, 
that participants felt present with the therapist in session, and that participants were 
absorbed in the sessions as they occurred. 
 
Discussion 
To our knowledge, this trial of individual CBT for anxiety in PD is the first to 
implement a multiple-baseline, single-case experimental design using a 12-week, 
transdiagnostic CBT protocol, delivered both in-person and via the secure 
videoconferencing.  A recently published article reported that six sessions of manualized 
CBT reduced anxiety and caregiver burden in 12 PD participants and their caregivers (N. 
N. W. Dissanayaka et al., 2016); the CBT protocol emphasized behavioral elements and 
implemented a dyadic approach, with treatment delivered to patients and caregivers 
simultaneously.  Results from the present study add to these findings by indicating that 
twelve sessions of individual CBT yielded clinically significant reductions in anxiety at 
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either post-treatment or a 6-week follow-up, relative to the baseline phase, for seven of 
the nine PD participants, all of whom met diagnostic criteria for a DSM-5 anxiety 
disorder at baseline.  All seven responders also reported improvements in anxiety on the 
diagnostic interview, and no longer met diagnostic criteria for at least one of their 
principal anxiety diagnoses at post-treatment and/or follow-up.  Two participants (P5, P7) 
with co-principal anxiety diagnoses at baseline no longer met diagnostic criteria for GAD 
at post-treatment or follow-up but continued to meet diagnostic criteria for panic disorder 
and agoraphobia (P5) and social anxiety disorder (P7).  An eighth participant reported 
improvements in anxiety at the follow-up only, and the ninth participant showed no 
response to the intervention.  Seven of the nine participants also reported reduced 
depressive symptoms at post-treatment and/or follow-up.  Levels of acceptability and 
satisfaction with treatment were high across all participants, regardless of treatment 
modality (e.g., in-person or internet-delivered sessions).   
The effects of the intervention on secondary outcomes were highly variable.  
There were minimal and/or inconsistent effects on quality of life, motor symptoms, 
freezing of gait, apathy, sleep, pain, and most aspects of cognition (set-shifting, verbal 
fluency, attention, working memory).  Six participants showed improved psychomotor 
speed at post-treatment or follow-up, but post-treatment gains were not maintained at 
follow-up.  Of the two participants who endorsed fear of falling at the intake, both 
reported reduced fear at post-treatment and follow-up. 
Consistent with our hypotheses, the intervention yielded significant reductions in 
anxiety and depression for the majority of participants.  The intervention was also highly 
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feasible with minimal dropout rates.  However, we also predicted that the intervention 
would positively affect additional secondary outcomes, including quality of life, 
cognition, sleep, and any motor symptoms that may be worsened by anxiety.  These latter 
hypotheses were not supported, other than improved psychomotor speed, and reduced 
fear of falling.  Maintenance of psychomotor speed gains was unclear, but the fear of 
falling finding warrants further exploration.  Both participants with elevated fear of 
falling at the intake improved at post-treatment and follow-up, suggesting that the 
positive effects of the intervention on anxiety generalized to their fear of falling.   
The lack of significant effects on quality of life, cognition, sleep, and motor 
symptoms may be related to ceiling effects, as most study participants were high-
functioning and highly educated individuals in mild to moderate disease stages, leaving 
little room for improvement on secondary outcomes.  It is also possible that secondary 
outcome measures were not sensitive enough to capture any subtle changes in this high-
functioning participant group.  In addition, some secondary outcome measures may be 
directed linked to neuropathological changes and therefore, may require more targeted 
interventions.  Sleep disruption, for example, is very common and heterogeneous in PD, 
related to nighttime motor symptoms, nocturia, depression, medication effects, 
dysfunction in various neurotransmitter systems (Suzuki, Miyamoto, Miyamoto, 
Iwanami, & Hirata, 2011), and even increasedα-synuclein pathology in brainstem and 
limbic regions (Kalaitzakis, Gentleman, & Pearce, 2013). 
Strengths of the study included the use of a rigorous single-case experimental 
design, stringent inclusion criteria including presence of at least one DSM-5 anxiety 
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disorder, use of an efficacious transdiagnostic CBT protocol, assessment of therapist 
adherence to protocol, and the flexibility for participants to choose in-person or internet-
delivered therapy sessions.  The promising effects of this intervention on anxiety and 
depression warrant further investigation.  First, future work will need to examine 
predictors of treatment response.  One important consideration will be comorbid apathy, 
which is distinct from depression and present in approximately 40% of individuals with 
PD (den Brok et al., 2015).  Of note, the one individual who showed no response to the 
intervention reported frequent amotivation and elevated apathy at the intake and pre-
treatment assessments (AS=19, 26), and reported worse apathy at post-treatment and 
follow-up.  Given that CBT relies so heavily on homework compliance and out-of-
session practice, it is likely that his apathy acted as a significant barrier to treatment 
response.  Future studies may benefit from incorporating additional sessions on 
motivation for individuals with comorbid apathy.  The second participant who showed a 
minimal treatment response had a history of DBS and much more frequent OFF periods, 
compared to the other participants.  Research that examines the relation between anxiety 
and motor symptoms will be helpful in informing future treatments for individuals with 
anxiety, history of DBS, and motor fluctuations. 
Most importantly, this study highlights the utility and feasibility of in-person and 
internet-delivered CBT, as results did not differ by treatment modality.  The protocol was 
modified to allow for internet-delivered sessions due to slow and difficult recruitment, as 
has been reported in previous treatment trials for depression and anxiety in PD (Troeung 
et al., 2014).  Indeed, Dobkin and colleagues have described several barriers to seeking 
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mental healthcare in PD, including dismissal of mood symptoms, cost, lack of PD-
specific local options, lack of referral, mobility issues, embarrassment, and transportation 
difficulties (Dobkin et al., 2013); their study also found a high interest in telehealth 
among PD respondents, which underscores the important findings from this study.  The 
incorporation of a telehealth option facilitated access for individuals who otherwise 
would not have been able to participate.  Moreover, the four telehealth participants 
reported high treatment satisfaction, and all showed a significant response to treatment.   
Limitations of the study included limited generalizability and lack of independent 
evaluators for the clinician-administered diagnostic interviews.  Single-case experimental 
designs emphasize internal validity and allow for the flexibility to tailor a novel 
intervention to the individual, which was well-suited for this pilot study.  To build upon 
this work, controlled studies with larger samples are needed, with the eventual goal of a 
large RCT.  Future modifications to the CBT protocol that may be particularly helpful in 
this population are 1) additional modules on motivation or increased caregiver 
involvement (Kraepelien et al., 2015), especially for individuals with high baseline 
apathy, 2) monitoring of homework compliance, 3) shorter treatment course for 
individuals who show a rapid response to treatment, 4) supplemental modules or 
adaptation of weekly handouts to optimize organization for any individuals with 
executive dysfunction at baseline.  Specific CBT modules, such as psychoeducation and 
motivation, may also be helpful as a brief adjunctive treatment for individuals with 
situational anxiety related to psychosocial stressors, for example.  Future work should 
also consider the potential of CBT to be combined with pharmacotherapies (Cuijpers et 
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al., 2014) or exercise (Merom et al., 2008) to maximize treatment response in PD.  There 
is also the possibility of simultaneously treating anxiety, freezing of gait, and cognitive 
set-shifting in PD, given the recently observed association between these symptoms 
(Martens et al., 2016).  Intervention trials that recruit individuals with elevated anxiety 
and FOG will better elucidate potential treatment effects on these symptoms, as the 
majority of participants in the present study did not report elevated FOG. 
Taken together, additional treatment studies are critically needed with a focus on 
anxiety in PD, both for in-person and internet-delivered interventions, in order to 
replicate the current findings and eventually implement an RCT to evaluate 
generalizability.  This study demonstrated the utility and feasibility of transdiagnostic 
CBT for anxiety in PD, when delivered in person or via secure videoconferencing.  The 
intervention also reduced mild to moderate depressive symptoms among the majority of 
participants.  Exploratory examinations of treatment effects on additional secondary 
outcomes were much more mixed and require further study.  We hope the findings will 
provide the impetus for larger treatment trials with a focus on anxiety in this population, 
with the goal of establishing evidence-based psychological treatment options for 
individuals with PD and increasing dissemination of these treatments to assist individuals 
in accessing mental healthcare and developing long-term skills to manage anxiety across 
all stages of the disease. 
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Table 6. 
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?
?
CSR = Clinical Severity Rating; GAD = generalized anxiety disorder; SOC = social 
anxiety disorder; LSA=limited-symptom panic attack; DYS=persistent depressive 
disorder (dysthymia); PD=panic disorder. MDD=major depressive disorder. 
Tx=Treatment. 
 
Only clinically significant anxiety/depression diagnoses (CSR ≥4) are reported, and only 
these diagnoses were reassessed at subsequent assessments. 
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Table 7.  Content Outline for CBT Sessions (Barlow et al., 2011). 
 
Session Major Topic  Content/Goals 
1 Introduction Establish rapport, review presenting 
complaints, introduce treatment program 
(format, procedures, monitoring forms) 
2 Motivation Discuss motivation to maximize treatment 
engagement, set specific treatment goals 
3 Psychoeducation Discuss functional nature of emotions, 
introduce three-component model of emotions 
and emotion-driven behaviors, discuss 
triggers and consequences of emotions and 
emotional reactions, discuss learned 
experiences 
4 Emotional 
Awareness (Part 1) 
Introduce and practice nonjudgmental, 
present-focused awareness 
5 Emotional 
Awareness (Part 2) 
Continue to practice emotional awareness 
techniques using a musical mood induction 
6 Cognitive 
Appraisal & 
Reappraisal 
Discuss relationship between thoughts and 
emotions, introduce automatic appraisals, 
discuss common thinking traps, practice 
cognitive reappraisal 
7 Emotion 
Avoidance & 
Emotion-Driven 
Behaviors 
Introduce and discuss emotion avoidance and 
emotion avoidance strategies, discuss 
emotion-driven behaviors, develop alternative 
action tendencies 
8 Awareness & 
Tolerance of 
Physical 
Sensations 
Identify physical sensations associated with 
emotions, discuss role of physical sensations 
in emotional response, conduct symptom 
exercises to elicit uncomfortable physical 
sensations  
9 Emotion Exposure Discuss purpose of exposures, develop 
emotional and situational avoidance 
hierarchy, design emotion exposures 
10 Emotion Exposure Conduct emotion exposure 
11 Emotion Exposure Conduct emotion exposure 
12 Relapse 
Prevention/Review 
Review skills and treatment progress, identify 
and troubleshoot triggers, encourage skill 
generalization, set new goals and discuss 
ways to maintain treatment gains 
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Table 8.  Clinical Severity Ratings for Anxiety and Depressive Disorder Diagnoses. 
 Intake Pre-Tx Post-Tx 6-Week 
Follow-Up 
 DX CSR DX CSR DX CSR DX CSR 
P1  GAD 4 GAD 4 GAD 1 GAD 1 
P2  PD 4 PD 4 PD 1 PD 0 
P3  GAD 5 GAD 5 GAD 5 GAD 5 
 DYS 5 DYS 5 DYS 5 DYS 5 
P4  OTHER 
SPEC 
ANX 
(LSA) 
6 OTHER 
SPEC 
ANX 
(LSA) 
6 OTHER 
SPEC 
ANX 
(LSA) 
2 OTHER 
SPEC 
ANX 
(LSA) 
2 
 SOC  5 SOC 4 SOC 2 SOC  2 
P5  PD 5 PD 5 PD 4 PD 4 
 AG 6 AG 6 AG 5 AG 5 
 GAD 4 GAD 4 GAD 3 GAD 3 
P6  SOC 4 SOC 4 SOC 4 SOC 3 
P7  SOC 5 SOC 5 SOC 4 SOC 4 
 GAD 5 GAD 5 GAD 3 GAD 3 
P8  PD 6 PD 6 PD 5 PD 6 
 AG 6 AG 6 AG 6 AG 6 
 SOC 6 SOC 6 SOC 6 SOC 6 
 GAD 6 GAD 6 GAD 6 GAD 6 
 MDD 5 MDD 6 MDD 5 MDD 4 
P9  GAD 4 GAD 4 GAD 2 GAD 2 
P=Participant; CSR=Clinical Severity Rating; SOC=social anxiety disorder; 
GAD=generalized anxiety disorder; OTHER SPEC ANX=other specified anxiety 
disorder; LSA=limited-symptom panic attacks; DYS=persistent depressive disorder 
(dysthymia); PD=panic disorder. MDD=major depressive disorder.   
*Only clinically significant diagnoses (CSR>=4) reported at the intake are listed, and 
only those diagnoses were reassessed at the subsequent timepoints.
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Table 9a.  Anxiety Change Scores (CS) with 95% CIs.  
 
 BAI 
95% CI = CS±8.93 
OASIS 
95% CI = 
CS±4.46 
P1 
 BL 
 Pre-Post 
 Pre-FU 
 
3 (-5.93, 11.93) 
-9 (-17.93, -0.07)* 
-10 (-18.93, -1.07)* 
 
1 (-3.46, 5.46) 
-6 (-10.46, -1.54)* 
-6 (-10.46, -1.54)* 
P2 
 BL 
 Pre-Post 
 Pre-FU 
 
4 (-4.93, 12.93) 
-9 (-17.93, -0.07)* 
-10 (-18.93, -1.07)* 
 
2 (-2.46, 6.46) 
-5 (-9.46, -0.54)* 
-5 (-9.46, -0.54)* 
P3 
 BL 
 Pre-Post 
 Pre-FU 
 
1 (-7.93, 9.93) 
0 (-8.93, 8.93) 
-1 (-9.93, 7.93) 
 
2 (-2.46, 6.46) 
1 (-3.46, 5.46) 
3 (-1.46, 7.46) 
P4# 
 BL 
 Pre-Post 
 Pre-FU 
 
-4 (-12.93, 4.93) 
-10 (-18.93, -1.07)* 
-7 (-15.93, 1.93) 
 
-4 (-8.46, 0.46) 
-8 (-12.46, -3.54)* 
-7 (-11.46, -2.54)* 
P5 
 BL 
 Pre-Post 
 Pre-FU 
 
3 (-5.93, 11.93) 
-5 (-13.93, 3.93) 
-8 (-16.93, 0.93) 
 
-2 (-6.46, 2.46) 
0 (-4.46, 4.46) 
-4 (-8.46, 0.46) 
P6 
 BL 
 Pre-Post 
 Pre-FU 
 
-4 (-12.93, 4.93) 
-5 (-13.93, 3.93) 
-3 (-11.93, 5.93) 
 
1 (-3.46, 5.46) 
-4 (-8.46, 0.46) 
-5 (-9.46, -0.54)* 
P7^ 
 BL 
 Pre-Post 
 Pre-FU 
 
5 (-3.93, 13.93) 
-4 (-12.93, 4.93) 
-8 (-16.93, 0.93) 
 
1 (-3.46, 5.46) 
-6 (-10.46, -1.54)* 
-4 (-8.46, 0.46) 
P8 
 BL 
 Pre-Post 
 Pre-FU 
 
4 (-4.93, 12.93) 
0 (-8.93, 8.93) 
-9 (-17.93, -0.07)* 
 
3 (-1.46, 7.46) 
-4 (-8.46, 0.46) 
-5 (-9.46, -0.54)* 
P9 
 BL 
 Pre-Post 
 Pre-FU 
 
-18 (-26.93, -9.07)* 
-1 (-9.93, 7.93) 
0 (-8.93, 8.93) 
 
-2 (-6.46, 2.46) 
-2 (-6.46, 2.46) 
-3 (-7.46, 1.46) 
*Improvement significant at p<.05 
BL=last baseline score – first baseline score 
Pre-post=post-treatment score – last baseline score 
Pre-FU=6-week follow-up score – last baseline score 
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Table 9b.  Anxiety Change Scores (CS) with 95% CIs.  
 
 STAI-S 
95% CI = CS±10.47 
STAI-T 
95% CI = CS±11.70 
P1 
 BL 
 Pre-Post 
 Pre-FU 
 
2 (-8.47, 12.47) 
-30 (-40.47, -19.53)* 
-30 (-40.47, -19.53)* 
 
2 (-9.70, 13.70) 
-13 (-24.70, -1.30)* 
-23 (-34.70, -11.30)* 
P2 
 BL 
 Pre-Post 
 Pre-FU 
 
6 (-4.47, 16.47) 
-19 (-29.47, -8.53)* 
-18 (-28.47, -7.53)* 
 
6 (-5.70, 17.70) 
-21 (-32.70, -9.30)* 
-21 (-32.70, -9.30)* 
P3 
 BL 
 Pre-Post 
 Pre-FU 
 
1 (-9.47, 11.47) 
-5 (-15.47, 5.47) 
3 (-7.47, 13.47) 
 
-5 (-16.70, 6.70) 
0 (-11.70, 11.70) 
3 (-8.70, 14.70) 
P4# 
 BL 
 Pre-Post 
 Pre-FU 
 
9 (-1.47, 19.47) 
-5 (-15.47, 5.47) 
1 (-9.47, 11.47) 
 
0 (-11.70, 11.70) 
1 (-10.70, 12.70) 
1 (-10.70, 12.70) 
P5 
 BL 
 Pre-Post 
 Pre-FU 
 
-5 (-15.47, 5.47) 
-22 (-32.47, -11.53)* 
-28 (-38.47, -17.53)* 
 
-1 (-12.70, 10.70) 
-16 (-27.70, -4.30)* 
-20 (-31.70, -8.30)* 
P6 
 BL 
 Pre-Post 
 Pre-FU 
 
-3 (-13.47, 7.47) 
-1 (-11.47, 9.47) 
-2 (-12.47, 8.47) 
 
-2 (-13.70, 9.70) 
-2 (-13.70, 9.70) 
-2 (-13.70, 9.70) 
P7^ 
 BL 
 Pre-Post 
 Pre-FU 
 
-18 (-28.47, -7.53)* 
0 (-10.47, 10.47) 
-2 (-12.47, 8.47) 
 
2 (-9.70, 13.70) 
-6 (-17.70, 5.70) 
-16 (-27.70, -4.30)* 
P8 
 BL 
 Pre-Post 
 Pre-FU 
 
-14 (-24.47, -3.53)* 
4 (-6.47, 14.47) 
-9 (-19.47, 1.47) 
 
1 (-10.70, 12.70) 
-5 (-16.70, 6.70) 
-5 (-16.70, 6.70) 
P9 
 BL 
 Pre-Post 
 Pre-FU 
 
-20 (-30.47, -9.53)* 
-7 (-17.47, 3.47) 
-18 (-28.47, -7.53)* 
 
-6 (-17.70, 5.70) 
-4 (-15.70, 7.70) 
-10 (-21.70, 1.70) 
*Improvement significant at p<.05 
BL=last baseline score – first baseline score 
Pre-post=post-treatment score – last baseline score 
Pre-FU=6-week follow-up score – last baseline score 	
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#P4 slightly increased his parkinsonian medications to address motor symptoms during 
the middle of treatment.  	^At the follow-up, P7 reported retrospectively that she increased her psychotropic 
medication dose from 20mg to 30mg for “about a week” during the middle of treatment 
in response to increased frustration about an ongoing physical pain issue (unrelated to 
anxiety).  She was unable to provide the exact dates when she adjusted the dose, but 
likely in the 1-2 weeks prior to session 9.  She denied noticing any effect of the increased 
dose and as a result returned to the original 20mg dose shortly after making the change.  
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Table 10.  Depression Change Scores (CS) with 95% CIs. 	
 BDI-II** 
95% CI = CS±6.49 
95% CI = CS±4.56 
ODSIS 
95% CI = CS±3.42 
GDS** 
95% CI = CS±5.33 
95% CI = CS±4.08 
P1 
BL 
Pre-Post 
Pre-FU 
 
1 (-3.56, 5.56) 
-5 (-9.56, -0.44)* 
-5 (-9.56, -0.44)* 
 
2 (-1.42, 5.42) 
1 (-2.42, 4.42) 
-2 (-5.42, 1.42) 
 
3 (-1.08, 7.08) 
-5 (-9.08, -0.92)* 
-9 (-13.08, -4.92)* 
P2 
BL 
Pre-Post 
Pre-FU 
 
1 (-3.56, 5.56) 
-6 (-10.56, -1.44)* 
-5 (-9.56, -0.44)* 
 
1 (-2.42, 4.42) 
-4 (-7.42, -0.58)* 
-4 (-7.42, -0.58)* 
 
-1 (-5.08, 3.08) 
-3 (-7.08, 1.08) 
-2 (-6.08, 2.08) 
P3 
BL 
Pre-Post 
Pre-FU 
 
0 (-6.49, 6.49) 
0 (-6.49, 6.49) 
1 (-5.49, 7.49) 
 
3 (-0.42, 6.42) 
-1 (-4.42, 2.42) 
-3 (-6.42, 0.42) 
 
-1 (-6.33, 4.33) 
2 (-3.33, 7.33) 
2 (-3.33, 7.33) 
P4 
BL 
Pre-Post 
Pre-FU 
 
-8 (-12.56, -3.44)* 
-10 (-14.56, -5.44)* 
-13 (-17.56, -8.44)* 
 
-3 (-6.42, 0.42) 
-2 (-5.42, 1.42) 
-2 (-5.42, 1.42) 
 
2 (-2.08, 6.08) 
-4 (-8.08, 0.08) 
-5 (-9.08, -0.92)* 
P5 
BL 
Pre-Post 
Pre-FU 
 
0 (-4.56, 4.56) 
-5 (-9.56, -0.44)* 
-4 (-8.56, 0.56) 
 
0 (-3.42, 3.42) 
0 (-3.42, 3.42) 
0 (-3.42, 3.42) 
 
-1 (-5.08, 3.08) 
-3 (-7.08, 1.08) 
-3 (-7.08, 1.08) 
P6 
BL 
Pre-Post 
Pre-FU 
 
1 (-3.56, 5.56) 
-6 (-10.56, -1.44)* 
-4 (-8.56, 0.56) 
 
1 (-2.42, 4.42) 
-3 (-6.42, 0.42) 
-3 (-6.42, 0.42) 
 
-3 (-7.08, 1.08) 
-5 (-9.08, -0.92)* 
-3 (-7.08, 1.08) 
P7 
BL 
Pre-Post 
Pre-FU 
 
-6 (-10.56, -1.44)* 
-2 (-6.56, 2.56) 
-2 (-6.56, 2.56) 
 
0 (-3.42, 3.42) 
0 (-3.42, 3.42) 
0 (-3.42, 3.42) 
 
-1 (-5.08, 3.08) 
-5 (-9.08, -0.92)* 
-4 (-8.08, 0.08) 
P8 
BL 
Pre-Post 
Pre-FU 
 
-3 (-9.49, 3.49) 
-4 (-10.49, 2.49) 
-11 (-17.49, -4.51)* 
 
0 (-3.42, 3.42) 
1 (-2.42, 4.42) 
0 (-3.42, 3.42) 
 
NA 
P9 
BL 
Pre-Post 
Pre-FU 
 
-4 (-8.56, 0.56) 
-16 (-20.56, -11.44)* 
-10 (-14.56, -5.44)* 
 
-1 (-4.42, 2.42) 
-5 (-8.42, -1.58)* 
-3 (-6.42, 0.42) 
 
1 (-3.08, 5.08) 
-10 (-14.08, -5.92)* 
-11 (-15.08, -6.92)* 
*Improvement significant at p<.05 
**Two confidence intervals were calculated for the BDI-II and GDS: one for participants 
(P3, P8) who met criteria for a current depressive disorder (BDI-II=6.49; GDS=5.33), 
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and the second for all other participants who did not meet diagnostic criteria for a current 
depressive disorder (BDI-II=4.56; GDS=4.08).   
NA=GDS was not administered to P8 due to her younger age. 
BL=last baseline score – first baseline score 
Pre-post=post-treatment score – last baseline score 
Pre-FU=6-week follow-up score – last baseline score 
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Table 11a.  Change Scores for Secondary Outcome Measures (Disorder-Specific 
Questionnaires). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Improvement at p<.05 
+: P8 follow-up completed at eight weeks post-treatment due to scheduling constraints. 
  
 
 
 
PSWQ 
95% CI = 
CS±10.23 
ASI 
95% CI = 
CS±9.45 
PDSS 
95% CI =  
CS±5.19 
P1 
Intake-Post 
Intake-FU 
 
-15 (-25.2, -4.8)* 
-18 (-28.2, -7.8)* 
 
NA 
 
NA 
P2 
Intake-Post 
Intake-FU 
 
NA 
 
-10 (-19.5, -0.6)* 
-16 (-25.5, -6.6)* 
 
0 (-5.2, 5.2) 
-4 (-9.2, 1.2) 
P3 
Intake-Post 
Intake-FU 
 
6 (-4.2, 16.2) 
6 (-4.2, 16.2) 
 
NA 
 
NA 
P4 
Intake-Post 
Intake-FU 
 
NA 
 
-19 (-28.5, -9.6)* 
-16 (-25.5, -6.6)* 
 
-12 (-17.2, -6.8)* 
-13 (-18.2, -7.8)* 
P5 
Intake-Post 
Intake-FU 
 
-1 (-11.2, 9.2) 
3 (-7.2, 13.2) 
 
-7 (-16.5, 2.5) 
-5 (-14.5, 4.5) 
 
-4 (-9.2, 1.2) 
-3 (-8.2, 2.2) 
P6 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
NA 
P7 
Intake-Post 
Intake-FU 
 
-15 (-25.2, -4.8)* 
-15 (-25.2, -4.8)* 
 
NA 
 
-8 (-13.2, -2.8)* 
-5 (-10.2, 0.2) 
P8+ 
Intake-Post 
Intake-FU 
 
0 (-10.2, 10.2) 
-2 (-12.2, 8.2) 
 
6 (-3.5, 15.5) 
-2 (-11.5, 7.5) 
 
-5 (-10.2, 0.2) 
-8 (-13.2, -2.8)* 
P9 
Intake-Post 
Intake-FU 
 
-4 (-14.2, 6.2) 
0 (-10.2, 10.2) 
 
NA 
 
NA 
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Table 11b.  Change Scores for Secondary Outcome Measures (Disorder-Specific 
Questionnaires and Quality of Life). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Improvement at p<.05 
+: P8 follow-up completed at eight weeks post-treatment due to scheduling constraints. 
  
 
 
 
SIAS 
95% CI = 
CS±12.03 
SPIN 
95% CI = 
CS±11.60 
PDQ-39 
95% CI = CS±17.49 
P1 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
-9.1 (-26.6, 8.4) 
-8.3 (-25.8, 9.2) 
P2 
Intake-Post 
Intake-FU 
 
NA 
 
-19 (-30.6, -7.4)* 
-18 (-29.6, -6.4)* 
 
-3.1 (-20.6, 14.4) 
3.4 (-14.1, 20.9) 
P3 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
-2.1 (-19.6, 15.4) 
1.7 (-15.8, 19.2) 
P4 
Intake-Post 
Intake-FU 
 
-4 (-16.0, 8.0) 
-7 (-19.0, 5.0) 
 
-5 (-16.6, 6.6) 
-9 (-20.6, 2.6) 
 
-18.0 (-35.5, -0.5)* 
-21.8 (-39.3, -4.3)* 
P5 
Intake-Post 
Intake-FU 
 
-9 (-21.0, 3.0) 
-17 (-29.0, -5.0)* 
 
NA 
 
-0.9 (-18.4, 16.6) 
-3.5 (-21.0, 14.0) 
P6 
Intake-Post 
Intake-FU 
 
-5 (-17.0, 7.0) 
-5 (-17.0, 7.0) 
 
-9 (-20.6, 2.6) 
-9 (-20.6, 2.6) 
 
10.6 (-6.9, 28.1) 
6.5 (-11.0, 24.0) 
P7 
Intake-Post 
Intake-FU 
 
-14 (-26.0, -2.0)* 
-8 (-20.0, 4.0) 
 
-14 (-25.6, -2.4)* 
-20 (-31.6, -8.4)* 
 
-5.9 (-23.4, 11.6) 
6.2 (-11.3, 23.7) 
P8+ 
Intake-Post 
Intake-FU 
 
6 (-6.0, 18.0) 
5 (-7.0, 17.0) 
 
-9 (-20.6, 2.6) 
-3 (-14.6, 8.6) 
 
-4.3 (-21.8, 13.2) 
3.8 (-13.7, 21.3) 
P9 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
-8.3 (-25.8, 9.2) 
-7.3 (-24.8, 10.2) 
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Table 12a.  Change Scores for Secondary Outcome Measures (Apathy, Fear of 
Falling, FOG). 
 AS 
95% CI = 
CS±7.74 
FES 
95% CI = 
CS±3.55 
FOG 
95% CI = 
CS±5.52 
P1 
Intake-Post 
Intake-FU 
 
NA 
 
-5 (-8.6, -1.5)* 
-5 (-8.6, -1.5)* 
 
NA 
P2 
Intake-Post  
Intake-FU 
 
-1 (-8.7, 6.7) 
-7 (-14.7, 0.7) 
 
NA 
 
NA 
P3 
Intake-Post 
Intake-FU 
 
9 (1.3, 16.7)^ 
9 (1.3, 16.7)^ 
 
NA 
 
-1 (-6.5, 4.5) 
0 (-5.5, 5.5) 
P4 
Intake-Post 
Intake-FU 
 
-9 (-16.7, -1.3)* 
-10 (-17.7, -2.3)* 
 
-25 (-28.6, -21.5)* 
-22 (-25.6, -18.5)* 
 
NA 
P5 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
NA 
P6 
Intake-Post 
Intake-FU 
 
3 (-4.7, 10.7) 
6 (-1.7, 13.7) 
 
NA 
 
NA 
P7 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
1 (-4.5, 6.5) 
-1 (-6.5, 4.5) 
P8+ 
Intake-Post 
Intake-FU 
 
-2 (-9.7, 5.7) 
-1 (-8.7, 6.7) 
 
NA 
 
3 (-2.5, 8.5) 
9 (3.5, 14.5)^ 
P9 
Intake-Post 
Intake-FU 
 
-7 (-14.7, 0.7) 
-9 (-16.7, -1.3)* 
 
NA 
 
NA 
*Improvement at p<.05. 
^Worsening at p<.05.    
+ P8 follow-up completed at eight weeks post-treatment due to scheduling constraints. 
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Table 12b.  Change Scores for Secondary Outcome Measures (Pain, Sleep, Motor 
Symptoms). 
 McGill-SF 
95% CI = CS±11.55 
PDSS-2 # 
95% CI = CS±12.82 
MDS-UPDRS  
Part III 
95% CI = CS±13.49 
P1 
Intake-Post 
Intake-FU 
 
NA 
 
11 (-1.8, 23.8) 
16 (3.2, 28.8)^ 
 
3 (-10.5, 16.5) 
0 (-13.5, 13.5) 
P2 
Intake-Post  
Intake-FU 
 
NA 
 
0 (-12.8, 12.8) 
4 (-8.8, 16.8) 
 
9 (-4.5, 22.5) 
17 (3.5, 30.5)^ 
P3 
Intake-Post 
Intake-FU 
 
NA 
 
NA 
 
1 (-12.5, 14.5) 
3 (-10.5, 16.5) 
P4 
Intake-Post 
Intake-FU 
 
NA 
 
-16 (-28.8, -3.2)* 
-17 (-29.8, -4.2)* 
 
3 (-10.5, 16.5) 
-6 (-19.5, 7.5) || 
P5 
Intake-Post 
Intake-FU 
 
NA 
 
-5 (-17.8, 7.8) 
-2 (-14.8, 10.8) 
 
-9 (-22.5, 4.5) 
-12 (-25.5, 1.5) 
P6 
Intake-Post 
Intake-FU 
 
NA 
 
2 (-10.8, 14.8) 
-1 (-13.8, 11.8) 
 
-1 (-14.5, 12.5) 
-9 (-22.5, 4.5) 
P7 
Intake-Post 
Intake-FU 
 
3 (-8.6, 14.6) 
-2 (-13.6, 9.6) < 
 
NA 
 
15 (1.5, 28.5)^ 
7 (-6.5, 20.5) 
P8+ 
Intake-Post 
Intake-FU 
 
9 (-2.6, 20.6) 
11 (-0.6, 22.6) 
 
5 (-7.8, 17.8) 
14 (1.2, 26.8)^ 
 
-14 (-27.5, -0.5)* 
-12 (-25.5, 1.5) 
P9 
Intake-Post 
Intake-FU 
 
NA 
 
-3 (-15.8, 9.8) 
0 (-12.8, 12.8) 
 
3 (-10.5, 16.5) 
2 (-11.5, 15.5) 
*Improvement at p<.05. 
^Worsening at p<.05. 
#P1: PDSS-2 intake questionnaire missing one item.      
|| P4, two items missing on follow-up UPDRS 
< P7 McGill-SF completed at approximately 8 weeks follow-up rather than 6 weeks.   
+ P8 follow-up completed at eight weeks post-treatment due to scheduling constraints. 
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Table 13.  Neuropsychological Outcomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Improvement >20% 
^Worsening >20%.     + P8 follow-up completed at eight weeks post-treatment due to scheduling constraints.	
 TMT-A TMT-B FAS Animals Digit 
Forward 
Digit 
Backward 
P1 
Intake-Post 
Intake-FU 
 
4.1% 
13.8% 
 
-28.9%* 
5.6% 
 
-2.4% 
26.2%* 
 
-25.9% ^ 
-37.0% ^ 
 
9.1% 
18.2% 
 
100% * 
33.3% * 
P2 
Intake-Post   
Intake-FU 
 
4.9% 
-15.5% 
 
7.3% 
21.8% ^ 
 
19.4% 
13.9% 
 
-11.5% 
-3.8% 
 
0% 
0% 
 
40.0%* 
20.0% 
P3 
Intake-Post 
Intake-FU 
 
-22.1%* 
-7.4% 
 
30.8% ^ 
8.3% 
 
-10.5% 
-3.5% 
 
9.4% 
0% 
 
40.0%* 
20.0% 
 
83.3%* 
0% 
P4 
Intake-Post 
Intake-FU 
 
-32.0%* 
-9.0% 
 
-9.4% 
-5.0% 
 
-6.5% 
-19.4% 
 
0% 
20.0% 
 
16.7% 
8.3% 
 
-25.0% ^ 
-12.5% 
P5 
Intake-Post 
Intake-FU 
 
-18.0% 
-25.5%* 
 
-4.2% 
32.5% ^ 
 
-14.8% 
-3.7% 
 
0% 
-21.7% ^ 
 
-7.1% 
7.1% 
 
-9.1% 
9.1% 
P6 
Intake-Post 
Intake-FU 
 
-15.9% 
-22.8%* 
 
44.0% ^ 
-8.3% 
 
3.5% 
36.8%* 
 
28.6%* 
19.0% 
 
0% 
-16.7% 
 
40.0%* 
0% 
P7 
Intake-Post 
Intake-FU 
 
-29.8%* 
-0.8% 
 
26.8% ^ 
32.3% ^ 
 
5.3% 
-5.3% 
 
13.3% 
0% 
 
0% 
-10.0% 
 
16.7% 
0% 
P8+ 
Intake-Post 
Intake-FU 
 
-2.8% 
-1.3% 
 
-21.2%* 
-22.1%* 
 
0% 
6.7% 
 
23.8%* 
28.6%* 
 
-8.3% 
-8.3% 
 
10.0% 
-30.0% ^ 
P9 
Intake-Post 
Intake-FU 
 
-36.3%* 
-16.4% 
 
-24.5%* 
8.9% 
 
39.5%* 
23.7%* 
 
21.1%* 
21.1%* 
 
7.7% 
-7.7% 
 
10.0% 
10.0% 
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Figure 2.  Participant Flow  
 
 
 
 
 
 
  
 
 
  Excluded (n=39) 
Due to scheduling/logistical conflicts 
(n=17), minimal anxiety (n=12), 
concurrent treatment (n=5), medication 
instability (n=3), and dementia (n=2) 
Excluded (n=2) 
1 with history of moderate TBI 
1 with minimal anxiety 
Randomized to two-, four-, or 
six-week baseline phase (n=11) 
Withdrawn before starting 
treatment due to symptom 
improvement during baseline (n=1) 
Started treatment phase 
(n=10) 
Dropped out after Session 2 due to time 
commitment and lack of interest (n=1) 
Completed 12-week treatment 
and all follow-up visits (n=9) 
Contacted potential 
participants (n=59) 
No response/unable to contact 
(n=7) 
Completed screening 
(n=52) 
Completed in-person 
intake (n=13) 
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Figure 3.  Weekly Self-Report Anxiety Scores:  P1, P2, P3 
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Figure 4.  Weekly Self-Report Depression Scores:  P1, P2, P3 
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Figure 5.  Weekly Self-Report Anxiety Scores:  P4, P5, P6 
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Figure 6.  Weekly Self-Report Depression Scores:  P4, P5, P6 
 
 
 
 
 
0	5	
10	15	
20	25	
30	
P4	
BDI	ODSIS	GDS	
0	2	4	
6	8	10	
12	14	16	
18	20	
P5	
0	5	
10	15	
20	25	
P6	
 	
 
88 
Figure 7.  Weekly Self-Report Anxiety Scores:  P7, P8, P9 
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Figure 8.  Weekly Self-Report Depression Scores: P7, P8, P9 
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2This chapter has been published as: Reynolds, G.O., Otto, M.W., Ellis, T.E., & Cronin-Golomb, A. 
(2016). The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease. 
Movement Disorders, 31(1): 23-38.  
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Appendix A.  Post-treatment Feedback Form. 
 
Please answer the questions below as honestly as possible to provide feedback for us 
about the intervention. 
 
1. Overall, how acceptable was the intervention to you?  Did you think the treatment 
approach and activities made sense and were reasonable?  (Circle answer). 
 
Not at all 
acceptable 
Slightly 
acceptable 
Moderately 
acceptable 
Very 
acceptable 
Extremely 
acceptable 
1 2 3 4 5 
 
 
2. Overall, how satisfied were you with the intervention?  (Circle answer). 
 
Not at all 
satisfied 
Slightly 
satisfied 
Moderately 
satisfied 
Very 
satisfied 
Extremely 
satisfied 
1 2 3 4 5 
 
 
3. In your own words, please tell us what you thought of the intervention overall. 
 
 
 
4. What elements of the intervention did you find most helpful? 
 
 
 
5. What elements of the intervention did you find least helpful? 
 
 
 
6. Are there any changes that you would recommend? 
 
 
 
7.  What are the most important things that you learned from this intervention? 
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CHAPTER 4:  STUDY THREE – THE THERAPEUTIC POTENTIAL OF 
EXERCISE TO IMPROVE MOOD, COGNITION, AND SLEEP IN 
PARKINS N’S DISEASE2 
 
Introduction 
Although traditionally conceptualized as a motor disorder, Parkinson’s disease 
(PD) is also associated with a variety of non-motor symptoms.  These symptoms – 
including disturbances of mood, cognition, and sleep – substantially reduce quality of 
life, often to a greater extent than the motor symptoms (Cronin-Golomb, 2013; Duncan et 
al., 2014; Hanna & Cronin-Golomb, 2012; McKinlay et al., 2008).  Also of note, 
traditional dopaminergic treatments for PD may exacerbate or contribute, at least in part, 
to mood, cognitive, and especially sleep symptoms in this population (Park & Stacy, 
2009).  In this article, we present the evidence supporting aerobic exercise and strength 
training as promising broad-spectrum interventions for these specific non-motor 
symptoms in PD, beyond the well-established benefits for core motor symptoms.  To 
date, most exercise programs in PD have focused on improving physical function, 
including gait, mobility, and balance, and on targeting disease-specific physical 
impairments, such as bradykinesia, rigidity, and strength (Corcos et al., 2013; Goodwin et 
al., 2008; Tomlinson et al., 2012).  In general, exercise, including aerobic and resistance 
training, improves physical function and motor symptoms in PD (Allen et al., 2010; 
Allen, Sherrington, Paul, & Canning, 2011; Canning et al., 2015; Earhart & Falvo, 2013; 
Gobbi et al., 2009; Goodwin et al., 2011; Grazina & Massano, 2013; Lamotte G., 2015;
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Li et al., 2012; Mehrholz et al., 2010; van der Kolk & King, 2013).  Given these benefits 
to core symptoms, exercise has a potential to be one of those rare adjunct interventions to 
treat principal non-motor symptoms of PD without worsening the primary motor 
disorder.   
In this manuscript, we review the efficacy of aerobic and strengthening exercise 
interventions in PD relative to more conventional treatments of mood, cognition, and 
sleep.  The following electronic databases were searched:  PubMed (1990 to July 6th 
2015), Google Scholar (1990 to July 6th 2015), and Cochrane Library (1990 to July 6th 
2015); citation tracking was also used to identify relevant references.  Specifically, we 
included studies if they met the following criteria:  1) at least one target population was 
adults with PD; 2) aerobic exercise and/or resistance exercise was used in at least one of 
the exercise conditions; 3) at least one outcome measure was included to examine mood 
(depression or anxiety), cognition, or sleep; 4) the paper was available in English as of 
July 6, 2015.  To inform these findings, we also discuss the relevant literature on aerobic 
and resistance exercise in healthy older adults, as well as neurologic populations.  
Although many forms of exercise may be beneficial, we limited our review to studies that 
included aerobic exercise and/or strengthening exercises, as the evidence in these areas is 
more developed in healthy older adults and in persons with PD from both a clinical and 
mechanistic perspective.  Also of note, additional non-motor symptoms manifest in PD, 
including fatigue and autonomic, gastrointestinal, and sensory symptoms (Chaudhuri et 
al., 2006), but the literature investigating the effects of exercise on these symptoms 
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remains very limited; accordingly, the present article focuses on the potential benefits of 
exercise interventions on mood, cognition and sleep only. 
 
Treatment of Mood Symptoms in PD 
Mood disturbance (here referring to depression and anxiety) develops in many 
individuals with PD, even in the early stages of the disease (Ishihara & Brayne, 2006), 
contributing to poorer quality of life (Duncan et al., 2014; Gallagher & Schrag, 2012; 
Hanna & Cronin-Golomb, 2012) and caregiver burden (Schrag et al., 2006).  Major 
depression is estimated to occur in 20-40% of individuals with PD (Lieberman, 2006; 
Veazey, Aki, Cook, Lai, & Kunik, 2005), and clinically significant anxiety in 
approximately 40% (Aarsland et al., 2009; Pontone et al., 2009; Walsh & Bennett, 2001); 
prevalence of psychiatric symptoms in PD reviewed in (Gallagher & Schrag, 2012)).  
Depression in PD is associated with poorer emotional well-being, communication, and 
activities of daily living (Holroyd, Currie, & Wooten, 2005; Oguru, Tachibana, Toda, 
Okuda, & Oka, 2010), as well as increased disability, falls, and caregiver distress, with 
some research indicating that depression may predict 10-year mortality (Bryant et al., 
2012; T. A. Hughes, Ross, Mindham, & Spokes, 2004; Weintraub, Moberg, Duda, Katz, 
& Stern, 2004).  Despite these high prevalence rates and associated distress and 
disability, clinical management of many non-motor symptoms, including depression and 
anxiety, remains inadequate (Seppi et al., 2011). 
Anxiety is common but less studied and treated in PD than depression (Chen & 
Marsh, 2014; N. N. Dissanayaka et al., 2014; Seppi et al., 2011; Weintraub & Burn, 
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2011).  In addition to generalized anxiety disorder, panic disorder, and simple and social 
phobias, individuals with PD also report recurrent situational anxiety related to their 
motor symptoms, including fear of falling or fear of crowded places due to freezing of 
gait (Aarsland et al., 2009; Pontone et al., 2009).  Anxiety is associated with reduced 
quality of life in PD (Carod-Artal et al., 2008; N. N. Dissanayaka et al., 2010; Havlikova 
et al., 2011), even after controlling for the effects of motor symptoms (Bonnet & 
Czernecki, 2013; McKinlay et al., 2008), and to a greater extent than depression (Hanna 
& Cronin-Golomb, 2012). 
The high prevalence, early manifestation, and negative impact of anxiety and 
depression in PD dictate the need to manage and improve these symptoms, which are 
under-treated and understudied (Frisina, Borod, Foldi, & Tenenbaum, 2008; Palanci et 
al., 2011; Pontone et al., 2013; Troeung et al., 2013; Weintraub, Moberg, Duda, Katz, & 
Stern, 2003).  To date, antidepressants have generally yielded non-significant and 
variable effects for both depression (Rocha, Murad, Stumpf, Hara, & Fuzikawa, 2013; 
Troeung et al., 2013) and anxiety (Troeung et al., 2013) in PD.  Some controlled studies 
suggest that certain selective serotonin reuptake inhibitors, dual reuptake inhibitors, and 
dopamine agonists may improve depression in PD, albeit with some risk of treatment-
related side effects (e.g. fatigue, dry mouth, orthostatic hypotension, dyskinesia) (Barone 
et al., 2010; M. Menza et al., 2009; Richard et al., 2012).  Benzodiazepines are not 
recommended for the treatment of anxiety in PD due to potential side effects, including 
autonomic, cognitive, sleep, and psychomotor impairments (B. S. Connolly & Fox, 2012; 
Gallagher & Schrag, 2012; Weintraub & Hoops, 2011).  There is emerging evidence for 
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psychosocial alternatives to pharmacologic treatment of mood, with limited but 
promising data from cognitive behavioral therapy (CBT) (Armento et al., 2012; 
Charidimou, Seamons, Selai, & Schrag, 2011; Dobkin, Menza, & Bienfait, 2008; 
Farabaugh et al., 2010; Heinrichs et al., 2001; Troeung et al., 2013, 2014; Veazey et al., 
2009; S. Yang et al., 2012). 
 
The Potential of Exercise Interventions for Mood 
Exercise interventions have demonstrated robust efficacy in the treatment of 
mood symptoms in the general population and in older adults, but few exercise trials in 
PD have included mood as an outcome measure.  A meta-analysis of 11 randomized 
controlled trials (RCTs) with adults with major depression reported a large combined 
effect size for exercise, usually aerobic or resistance training, relative to non-active 
control conditions (Stathopoulou et al., 2006).  More recent meta-analyses confirm a 
significant acute effect of exercise on depression relative to non-exercising control 
groups (Krogh, Nordentoft, Sterne, & Lawlor, 2011), with benefits generally following 
programs of at least moderate aerobic activity delivered several times a week, often in a 
group setting, with session durations of 20 to 45 minutes (Stathopoulou et al., 2006).  
Although promising, these meta-analyses are not without limitations, such as restricted 
power due to the small number of included trials, as well as the selection bias of 
individuals who volunteer to participate in exercise research (Krogh et al., 2011; 
Stathopoulou et al., 2006).  Despite this, the benefits of exercise are conferred across a 
wide range of settings and symptom severities.  For example, Mota-Pereira and 
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colleagues (Mota-Pereira et al., 2011) found that aerobic exercise (30-45 minute sessions, 
5 days/week) offered significant improvement or remission of depression in outpatients 
who had failed two previous trials of antidepressant medication (see also (Salehi et al., 
2014)).  Aerobic exercise also has efficacy in combination with antidepressants or CBT 
(Merom et al., 2008; Mura, Moro, Patten, & Carta, 2014).  Even in healthy adults without 
clinical depression, exercise interventions, including resistance exercise, have improved 
depressive symptoms (Conn, 2010b).  In sum, exercise has been shown to reduce 
depression in the general population, suggesting that it may also benefit those with PD 
and depression, either as a stand-alone or adjunctive intervention to improve mood.   
Besides its antidepressant effects, exercise is also anxiolytic (Asmundson et al., 
2013; Petruzzello, Landers, Hatfield, Kubitz, & Salazar, 1991).  Strong effects on self-
reported anxiety were documented in a meta-analysis of primarily non-clinical samples 
(B. M. Wipfli et al., 2008) with further evidence from clinical trials for panic disorder, 
generalized anxiety disorder, and social anxiety (Asmundson et al., 2013).  These clinical 
trials have focused largely on aerobic exercise (usually completed 2-5 times per week, for 
5-12 weeks), often in small samples, with unstandardized or unsupervised exercise 
sessions and/or lacking a non-exercising control group; nevertheless, the results are 
encouraging and suggest that aerobic exercise, in particular, may effectively treat anxiety 
disorders, either as a stand-alone intervention or as an adjunct treatment in combination 
with pharmacotherapy or CBT (Asmundson et al., 2013; Gaudlitz, Plag, Dimeo, & 
Strohle, 2015).  More controlled studies are needed to determine the optimal exercise 
dose and modality required to achieve lasting anxiolytic effects. 
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Exercise has also been shown to improve mood in healthy older adults (e.g., 
(Bridle, Spanjers, Patel, Atherton, & Lamb, 2012)).  For example, physical exercise, 
usually aerobic or resistance training completed 3 times per week for 20-60 minutes for 
6-19 weeks, yielded positive short-term outcomes for depressive symptoms (Blake, Mo, 
Malik, & Thomas, 2009; Brenes et al., 2007); and compared to a non-exercising control 
group, aerobic (but not resistance) exercise was associated with reduced depressive 
symptoms, regardless of baseline level of depression (Penninx et al., 2002).  Comparing 
an aerobic exercise program to pharmacological treatment, exercise (three 45-minute 
sessions/week) was equally effective at reducing depressive symptoms after 16 weeks of 
treatment, although the study did not control for the social interaction aspect of the 
exercise group (Blumenthal et al., 1999). 
There is promising evidence that exercise may improve depression among adults 
with neurologic disorders (Adamson, Ensari, & Motl, 2015), but there remains limited 
research on the effects of aerobic and resistance exercise on mood in PD specifically 
(Table 14).  In a large RCT with 231 adults with PD, six months of strengthening 
exercises (40-60 minutes, 3 times/week) yielded improved positive affect relative to a 
usual-care control group (Canning et al., 2015).  In a second controlled trial, individuals 
with PD were randomized to either an early- or late-start group exercise program 
(combined cardiovascular and strength training, completed for 60 minutes, 3 days/week, 
for 24-48 weeks) (Park et al., 2014).  Participants in the early-start group reported 
significantly fewer depressive symptoms after 48 weeks, relative to the delayed start 
group, although there was no control for the potential effects of weekly social interaction 
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on mood.  In a comparative trial of three types of exercise (high-intensity treadmill 
training, lower-intensity treadmill training, and stretching/resistance training), no changes 
in depression were observed for any group after 3 months of exercise (30-50 minutes, 3 
times per week), although participants reported only mild levels of depressive symptoms 
at baseline (Shulman et al., 2013). In a smaller study, aerobic exercise, completed twice 
per week for 12 weeks, improved mood, while maintaining functional ability, among 13 
adults with early PD relative to non-exercising PD participants (Bridgewater & Sharpe, 
1996).  In a sample of 11 early- to mid-stage participants with PD, 5 participants (mean 
age=64.0) completed a 4-week general exercise program (60-minute sessions of 
combined aerobic and resistance training, 4 times/week), and 6 participants (mean 
age=62.8) completed an exercise-based behavioral treatment focused on increasing 
amplitude of movement (Dashtipour et al., 2015).  Although there were no between group 
differences, the combined group showed improvement in depression and fatigue at all 
post-intervention assessments (weeks 4, 12, 24), suggesting benefits of both exercise 
approaches.  In an uncontrolled trial, 49 individuals with PD (mean age=65.5) reported 
reduced depressive symptoms after six months of aerobic walking (3 times/week for 45 
minutes per session), although depressive symptoms were very low among this sample 
(Uc et al., 2014).  In general, the PD exercise studies that have included mood outcomes 
have included participants with minimal depressive symptoms, limiting their 
generalizability.  Even so, these studies provide strong rationale for the targeted use of 
exercise to improve mood in PD.  
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Cognitive Impairment in PD 
Like mood symptoms, cognitive impairments are common and heterogeneous in 
PD (Dalrymple-Alford et al., 2011; Kehagia, Barker, et al., 2010; Litvan et al., 2011; 
Litvan et al., 2012; Mamikonyan et al., 2009), even in the early stages of the disease, with 
widespread implications for quality of life and functional abilities such as driving 
(Amick, Grace, & Ott, 2007; H. Devos et al., 2013; Duncan et al., 2014; Kurtis, 
Rodriguez-Blazquez, & Martinez-Martin, 2013; Schiehser et al., 2009; Svenningsson, 
Westman, Ballard, & Aarsland, 2012; Uc et al., 2009).  Cognitive disruptions can also co-
occur with other non-motor symptoms, tending to be worse in PD with depression, for 
example (Fernandez et al., 2009; Santangelo et al., 2009).  Up to 57% of individuals with 
PD experience some cognitive impairment within the first 3-5 years after diagnosis 
(Williams-Gray et al., 2007), including deficits in executive functioning, visuospatial 
function, and attention/working memory (Dirnberger & Jahanshahi, 2013; Muslimovic et 
al., 2005; Pfeiffer et al., 2014).  Measures of attention and executive function (“frontal” 
tests) are often the most sensitive to cognitive compromise (Miller et al., 2013).  
Executive dysfunction often emerges early in the disease course and is thought to be 
associated with dopaminergic dysfunction in fronto-striatal regions, whereas memory 
impairment and visuoconstructional difficulties, along with cognitive decline and 
dementia, may be driven by cortical Lewy body pathology and cholinergic deficiency 
(Kehagia, Barker, & Robbins, 2013).  With cognitive impairment beginning in the early 
stages of PD (Svenningsson et al., 2012), there is a corresponding need for early 
cognitive-enhancement strategies.  
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The Potential of Exercise Interventions for Cognitive Enhancement 
There is reliable evidence for significant benefits conferred upon cognition by 
exercise programs (Etnier, Nowell, Landers, & Sibley, 2006; Smith et al., 2010).  A 
meta-analysis of RCTs (29 studies, 2049 participants) has indicated that healthy older 
adults reliably achieve modest improvements in attention and processing speed, executive 
function, and memory following aerobic training (Smith et al., 2010).  The exercise trials 
ranged in duration from 6 weeks to 18 months, with modal length of 2.5 to 4 months, but 
with relatively minimal range of exercise intensity or frequency across trials (most often 
3 times per week at 70% peak oxygen uptake (VO2)).  Exercise typically comprised brisk 
walking and/or jogging relative to wait-list control or other comparison conditions 
(stretching and toning, health education, or relaxation). Greater benefits to attention and 
processing speed arose from trials that combined aerobic exercise with strength training, 
relative to aerobic only interventions. Likewise, aerobic training has been reported to 
improve cognition in healthy older adults, especially for executive-control processes (S. 
Colcombe & Kramer, 2003) – a finding particularly pertinent to the goal of improving 
executive dysfunction in PD (Dirnberger & Jahanshahi, 2013; Miller et al., 2013). There 
remains need for additional research to examine how aerobic exercise may affect various 
cognitive domains when maintained for extended periods of time (e.g. several years 
instead of months) (Smith et al., 2010). 
Exercise may also improve general cognitive functioning and balance in older-
adult neurological populations, including those with mild cognitive impairment, as well 
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as Alzheimer’s disease (AD) and other dementia-causing disorders (Forbes, Thiessen, 
Blake, Forbes, & Forbes, 2013; Hernandez, Coelho, Gobbi, & Stella, 2010).  This 
research is relevant to PD, given that cognitive impairment, including dementia, often 
emerges over the course of the disease (Apaydin, Ahlskog, Parisi, Boeve, & Dickson, 
2002; Compta et al., 2011; Meireles & Massano, 2012) and that an AD-like pattern of 
brain atrophy in PD may predict cognitive decline (Weintraub et al., 2012).  There is 
preliminary evidence that aerobic exercise may be associated with greater memory 
improvements among adults with mild cognitive impairment relative to cognitively intact 
adults (Smith et al., 2010).  In a large sample of adults (≥ 50 years) with subjective 
memory impairment, a six-month exercise program (at least three 50-minute sessions of 
moderate-intensity aerobic exercise per week) yielded modest improvements on brief 
cognitive tests of memory, language, and praxis (Alzheimer Disease Assessment Scale – 
ADAS-Cog) over an 18-month follow-up period; participants in the exercise group also 
improved on word list delayed recall (Lautenschlager et al., 2008).  It is important to note 
that the primary outcome measure in this study was a non-specific measure of overall 
cognitive function, rather than an index of a specific cognitive domain.  Relative to a 
non-active control group, elderly individuals with AD (mean age=78.3) demonstrated 
improved balance and executive functioning (Clock Drawing Test and Frontal 
Assessment Battery) following dual-task exercise that paired motor and cognitive tasks 
(60-minute sessions completed 3 times/week for 4 months) (Pedroso et al., 2012).  
Aerobic training has also been reported to improve visual learning, working memory, and 
processing speed in psychiatric populations, including depression (Oertel-Knochel et al., 
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2014).  In sum, exercise has demonstrated cognitive benefits in healthy older adults and 
in adults with conditions that may be observed in PD (e.g., depression and dementia), 
supporting the potential cognition-enhancing role of exercise for PD. 
There is initial evidence that these expectations will be realized in PD (Hindle, 
Petrelli, Clare, & Kalbe, 2013; Murray et al., 2014); see Table 15.  Aerobic exercise may 
particularly impact executive function in PD (Petzinger et al., 2013), consistent with the 
findings in healthy older adults (S. Colcombe & Kramer, 2003).  Twelve weeks of 
combined aerobic plus anabolic exercise, conducted twice weekly, resulted in selective 
improvement in frontal-based executive function (spatial working memory and verbal 
fluency, relative to spatial and pattern recognition memory) in 15 individuals with PD 
compared to 13 non-exercising PD control participants (all in mild to moderate disease 
stages and approximately 60 years old) (Cruise et al., 2011).  Likewise, in relatively large 
studies of a long duration, 6 months of moderate-intensity aerobic exercise, conducted 
three times per week for 45-60 minutes, led to improved executive functioning for 
individuals with mild to moderate PD (mean age of approximately 65 in both studies), 
though only one of these studies used a non-exercising PD control group (Tanaka et al., 
2009).  Across these studies, moderate-intensity aerobic exercise, conducted 2-3 times 
per week, produced promising effects on executive function in the mild to moderate 
stages of PD, consistent with studies in healthy older adults (S. Colcombe & Kramer, 
2003).  In small preliminary case studies, 8 weeks of aerobic exercise, completed 3 times 
per week for 20-40 minutes, yielded improvements in executive function, verbal fluency, 
and working memory for three individuals with PD – one with high cognitive 
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performance at baseline (age 66), and two with cognitive impairments (ages 61 and 72) 
(Nocera, Altmann, Sapienza, Okun, & Hass, 2010; Tabak, Aquije, & Fisher, 2013).  
Further research is warranted to examine the underlying mechanisms driving these 
selective improvements, which may relate to increased cerebral perfusion, release of 
growth factors, or angiogenesis following aerobic exercise, as suggested by Tabak and 
colleagues (Tabak et al., 2013).  Among healthy older adults, aerobic training, relative to 
non-aerobic, may even mitigate volume loss in prefrontal regions (S. J. Colcombe et al., 
2006), which are associated with a variety of executive control processes.  Of note, both 
prefrontal atrophy and executive dysfunction occur in PD, even in the early stages of the 
disease (Bruck, Kurki, Kaasinen, Vahlberg, & Rinne, 2004; Dirnberger & Jahanshahi, 
2013). 
At the same time, recent evidence suggests that resistance exercise may also 
benefit cognition in PD.  After 24 months of twice weekly progressive resistance exercise 
(60-90 minutes per session), adults with PD improved their performance on measures of 
working memory, inhibition, and attention (Digit Span, Stroop, Brief Test of Attention) 
(David et al., 2015).  The comparison group completed stretching, balance, and non-
progressive strengthening exercises (of the same duration and frequency) and improved 
on Digit Span and Stroop after 24 months (David et al., 2015).  There were no between-
group differences on any of the cognitive measures at 12 or 24 months, and the authors 
noted that their sample was relatively young, highly educated, and in mild-to moderate 
disease stages, thereby limiting the generalizability of their findings (David et al., 2015).  
Even so, these results provide clear rationale for future research to examine the targeted 
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use of resistance exercise to improve cognition in PD.  Taken together, emerging research 
suggests that aerobic and resistance exercise may improve cognition in PD; however, 
there remains a need for larger, well-controlled studies on the cognitive effects of 
exercise interventions among adults with PD. 
 
Sleep Disruption in PD 
 In the general population, the prevalence of insomnia symptoms ranges from 25% 
to 48% and insomnia diagnoses from 4.4% to 9.5% (Mallon, Broman, & Hetta, 2000; 
Morin, LeBlanc, Daley, Gregoire, & Merette, 2006; Ohayon, 2002; Ohayon, Carskadon, 
Guilleminault, & Vitiello, 2004).  Sleep disruptions are common among older adults 
(Crowley, 2011) and are particularly problematic and multifactorial in PD (Barber & 
Dashtipour, 2012; Diederich & McIntyre, 2012; Havlikova et al., 2011), with reference to 
this problem dating back to James Parkinson’s observations in his original essay 
(Parkinson, 2002).  Fragmented sleep has been reported (Claassen & Kutscher, 2011; 
Comella, 2007; Factor, McAlarney, Sanchez-Ramos, & Weiner, 1990; Pappert, Goetz, 
Niederman, Raman, & Leurgans, 1999; Karina Stavitsky & Cronin-Golomb, 2011; K. 
Stavitsky, Saurman, McNamara, & Cronin-Golomb, 2010), attributed in part to nighttime 
motor symptoms (Grinberg, Rueb, Alho, & Heinsen, 2010; Poewe, 2008), with reports of 
sleep benefits upon control of these symptoms (Trenkwalder, Kies, et al., 2011; Wood, 
2010).  Individuals with PD may present with REM sleep behavior disorder, excessive 
daytime sleepiness, sleep onset and sleep maintenance insomnia, as well as sleep 
disordered breathing, restless leg syndrome, and nocturia (Diederich & McIntyre, 2012; 
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M. Menza, Dobkin, Marin, & Bienfait, 2010).  Furthermore, sleep disturbances in PD 
are linked to mood and cognitive dysfunction (Borek, Kohn, & Friedman, 2006; Neikrug 
et al., 2013; K. Stavitsky, Neargarder, Bogdanova, McNamara, & Cronin-Golomb, 2012), 
likely related to neurodegenerative changes.  The underlying disease pathology in PD is 
now thought to begin in the brainstem (Braak et al., 2004), where damage to specific 
nuclei (e.g., locus ceruleus, pedunculopontine nucleus) and neurotransmitters (e.g., 
norepinephrine, serotonin, dopamine, GABA, acetylcholine) likely affects sleep-wake 
and REM sleep modulation in PD years prior to the manifestation of motor symptoms 
(Bohnen & Albin, 2011; Diederich & McIntyre, 2012; Grinberg et al., 2010; M. Menza et 
al., 2010).  Given the magnitude of the impact of sleep disruption on quality of life in PD 
(Duncan et al., 2014; Stocchi, Barbato, Nordera, Berardelli, & Ruggieri, 1998), there is 
need to address general, age-related, and disease-specific sleep disruptions in those with 
PD.  
 
The Potential of Exercise Interventions for Sleep Disruption 
 Meta-analytic review of 25 studies indicates that regular exercise programs help 
adults achieve moderate-to-large sleep quality benefits, as per the self-reported Pittsburgh 
Sleep Quality Index (PSQI; (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989)), which 
includes subscales of daytime sleepiness as well as sleep disturbance, duration, 
efficiency, latency, and medication use (Kredlow et al., 2015).  The moderate-to-large 
effects of regular exercise were observed for all PSQI subscales except sleep medication 
use.  Across aerobic, anaerobic, and mixed studies, regular exercise had small effects on 
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total sleep time and sleep efficiency and a small-to-moderate effect on sleep onset 
latency, predominantly assessed using objective measures (e.g. electroencephalogram or 
polysomnography) (Kredlow et al., 2015).  These benefits appear to be uniform across 
younger and older samples except for weaker effects on sleep-onset latency in older 
adults, consistent with its general worsening with age (Ohayon et al., 2004).  Even 
individual sessions of exercise, evaluated across 41 studies (predominantly aerobic 
training), conferred benefit on objective measures of sleep, though with small effect sizes 
that varied in reliability (Kredlow et al., 2015).  Moderate-intensity aerobic exercise (30- 
to 40-minute sessions, completed four times per week, for 16 weeks) yielded 
improvements in self-reported sleep quality (global PSQI score) among healthy older 
adults (ages 50-76) with sleep complaints, relative to wait-list control participants (King, 
Oman, Brassington, Bliwise, & Haskell, 1997). 
 There is some indication that the benefits of exercise for sleep extend to 
individuals with PD, including improved sleep, quality of life, and daily functioning 
(Nascimento et al., 2014; Rodrigues de Paula et al., 2006); see Table 16.  In an RCT 
(with stratified randomization), 17 PD participants in mild to moderate stages (mean 
age=67.8) who completed six months of multimodal exercise (three 60-minute sessions 
per week of muscular resistance, balance/motor coordination, and aerobic fitness) 
reported enhanced sleep and functional abilities on standardized questionnaires compared 
to 17 PD control participants who did not exercise (Nascimento et al., 2014).  The sleep 
questionnaire (Mini-Sleep Questionnaire) included items related to both insomnia and 
daytime sleepiness. Only the total score was used for data analysis, so it is not possible to 
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determine if exercise more strongly affected insomnia or daytime sleepiness.  Likewise, 
after 36 group sessions of combined aerobic conditioning and muscular strengthening (75 
minutes each, 3 times per week, for 3 months), twenty mild- to moderate-stage PD 
participants (mean age=61.5) reported significant improvements in quality of life, 
particularly within the domains of emotional reactions, social interactions, and physical 
ability, as well as reporting a trend toward improved sleep on a self-report questionnaire 
(Rodrigues de Paula et al., 2006).  A significant limitation of both PD studies was the 
lack of objective sleep measures.  Further research is needed to elucidate potential effects 
of exercise on daytime and nighttime sleep disturbances, including larger, well-controlled 
trials that include subjective and objective sleep outcome measures. 
 
Potential Mechanisms of Action of Exercise on Mood, Cognition, and Sleep 
Dopaminergic dysfunction in the hypothalamus and limbic regions may be 
associated with disturbances of mood, cognition, and sleep in PD (Chaudhuri, 2009; 
Chaudhuri & Odin, 2010; Chaudhuri & Schapira, 2009; Prediger et al., 2012).  It is 
plausible then that exercise may improve these non-motor symptoms at least partially via 
dopaminergic mechanisms.  More specifically, exercise may modulate dopaminergic and 
glutamatergic neurotransmission, and thereby attenuate basal ganglia hyperexcitability in 
PD (Fisher et al., 2008; Petzinger et al., 2010).  Among exercising rats (n=10) relative to 
sedentary counterparts (n=9), aerobic exercise (6 weeks of wheel running) has been 
associated with increased dopamine synthesis and reduced inhibition of dopamine 
neurons in the substantia nigra pars compacta (Foley & Fleshner, 2008).  Preliminary 
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evidence in humans suggests that aerobic exercise (three 60-minute treadmill 
sessions/week for 8 weeks) may lead to increased dopaminergic signaling (per imaging 
with positron emission tomography) and improved postural control in the early stages of 
PD (Fisher et al., 2013).  Although non-motor outcomes were not included in this pilot 
study, the reported improvements in postural control are potentially relevant for non-
motor symptoms given that common neural substrates may modulate balance control and 
anxiety (e.g., parabrachial nucleus network and associated connections to limbic regions) 
(Balaban, 2002; Balaban & Thayer, 2001; Prediger et al., 2012). 
Besides its dopaminergic effects, regular exercise also has a wide variety of 
effects on non-dopaminergic neurotransmitter systems, including serotonergic, 
noradrenergic, and GABA-ergic systems, which is relevant for depression, anxiety, and 
sleep (DeBoer, Powers, Utschig, Otto, & Smits, 2012; Melancon, Lorrain, & Dionne, 
2014).  In rats that swam (n=18) 5 days a week for 10 weeks (typically 30 minutes per 
day), exercise was associated with increased hippocampal levels of serotonin and 
norepinephrine (He et al., 2012) – two neurotransmitters that have been implicated in 
modulation of anxiety, depression, and sleep (Millan, 2003; Monti, 2011; Palazidou, 
2012; Prediger et al., 2012).  In regard to the potential for improved cognition (Erickson 
et al., 2011), animal work indicates that serotonin is necessary in order to achieve 
exercise-induced neurogenesis in the hippocampus (n=30 per group) (Klempin et al., 
2013).  In human research, aerobic exercise (three 30-minute cycling sessions per week, 
for 7 weeks) has been associated with reduced depression and reduced blood serotonin, 
relative to a stretching-control group (B. Wipfli, Landers, Nagoshi, & Ringenbach, 2011).  
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This effect is similar to effects of selective serotonin reuptake inhibitors, although the 
sample consisted of healthy undergraduate students who were not pre-screened for 
anxiety or depression, which limits its generalizability.  These findings suggest that 
aerobic exercise may increase levels of serotonin and norepinephrine in the brain, which 
may positively affect mood, cognition, and sleep.  For example, cognitive dysfunction 
and sleep disturbances (e.g., insomnia, vivid dreaming, and sleep-disordered breathing) in 
PD are generally unresponsive to dopamine therapy (Lee & Koh, 2015), suggesting that 
these symptoms may develop, at least in part, through non-dopaminergic mechanisms.  
Likewise, anxiety in PD is associated with dysfunction in a variety of neurotransmitter 
systems, including noradrenergic and serotonergic, which may precede dopaminergic 
depletion (Prediger et al., 2012).  Aerobic exercise, then, could act upon these non-
dopaminergic systems to improve non-motor symptoms, particularly in the early stages of 
PD. 
The mechanisms by which exercise may affect non-motor symptoms, especially 
cognition, in PD may be similar to structural and functional brain changes and 
proliferation of growth factors seen in exercising healthy adults.  Higher aerobic fitness in 
healthy older adults (mean age=66.6) has been associated with greater gray matter 
volume in dorsolateral prefrontal cortex and improved executive function (Stroop test of 
inhibition) and spatial working memory (Weinstein et al., 2012).  The association with 
prefrontal volume is relevant to PD as affected individuals may show prefrontal and 
hippocampal atrophy even in early stages of the disease (Bruck et al., 2004).  Imaging 
with positron emission tomography has also revealed that prefrontal dysfunction in PD 
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(hypometabolism) contributes to difficulties with set-shifting (Sawada et al., 2012).  
Following a one-year walking intervention (three 40-minute sessions per week), aerobic 
fitness in older adults was associated with white matter changes in frontal and temporal 
regions, as well as improved short-term memory relative to an active control group 
(flexibility, toning, and balance) (Voss, Heo, et al., 2013).  Also following one year of 
aerobic exercise, increased functional connectivity in the temporal lobe among healthy 
older adults (mean age=66.4) was associated with increased levels of growth factors, 
including brain-derived neurotrophic factor (BDNF), as well as insulin-like growth factor 
type 1, and vascular endothelial growth factor (Voss, Erickson, et al., 2013).  Consistent 
with these findings, regular aerobic exercise in healthy older adults is thought to promote 
neuroplasticity and facilitate learning and memory through the release of neurotrophins, 
including BDNF, glia-derived neurotrophin (GDNF), nerve growth factor (NGF), and 
galanin (S. Colcombe & Kramer, 2003; Hirsch & Farley, 2009).  In PD, aerobic exercise 
may increase the production of growth factors and promote gray and white matter 
changes, especially in prefrontal regions, both of which may contribute to improved 
cognitive function.  
 Animal and cellular studies further highlight the important effects of BDNF on 
neurogenesis, dendritic growth, and long-term potentiation (Altar, 1999; Gorski, Zeiler, 
Tamowski, & Jones, 2003; Huang et al., 1999; Lu, Pang, & Woo, 2005).  Meta-analytic 
review of 29 human studies (1111 participants) indicates that single sessions of exercise 
induce BDNF activity and that there is a significant increase in this activity with regular 
exercise (Szuhany et al., 2015).  These effects appear reliable enough that Szuhany and 
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colleagues (Szuhany et al., 2015) suggested that exercise can be considered as an 
intervention to induce BDNF for subsequent therapeutic benefit, although they note that 
future research is needed to examine the effects of exercise type (e.g., aerobic versus 
resistance training) on BDNF.  Rodent and human studies indicate that BDNF may 
mediate both the mood and cognitive effects of exercise (Erickson, Miller, & Roecklein, 
2012; Heyman et al., 2012; van Praag, Shubert, Zhao, & Gage, 2005; Vaynman, Ying, & 
Gomez-Pinilla, 2004), with a particular effect on executive function in older adults 
(Leckie et al., 2014), which is known to be compromised in PD (Dirnberger & 
Jahanshahi, 2013). 
These mechanisms may relate to potential cognitive benefits of exercise in PD, 
given the known executive dysfunction and reduced BDNF expression in this population.  
Postmortem human studies and rodent studies indicate significantly reduced expression 
of BDNF in the substantia nigra in PD (Howells et al., 2000; Mogi et al., 1999; Parain et 
al., 1999; Porritt, Batchelor, & Howells, 2005), and surviving dopaminergic neurons in 
the substantia nigra express reduced BDNF compared to control cases (Howells et al., 
2000).  In a 6-hydroxydopamine (6-OHDA) rat model of PD, exercise (4 weeks of 
treadmill running, 30 minutes/day, 5 days/week) has been found to increase levels of 
BDNF in the striatum (Tajiri et al., 2010).  In a recent human study of early-stage PD, 28 
days of intensive aerobic exercise increased BDNF levels, improved motor symptoms 
(balance and gait) (Frazzitta et al., 2014), and potentially slowed motor symptom 
progression after a two-year follow-up (Frazzitta et al., 2015).  Indeed, drawing largely 
from animal studies, Fumagalli and colleagues (Fumagalli, Racagni, & Riva, 2006) 
  112 
posited that BDNF may function as a neuroprotective molecule and also a 
neuromodulator in PD, such that it is associated with the loss of dopaminergic neurons 
when inhibited, and with improved cognition when expressed.  Exercise may improve 
hippocampal function via BDNF expression (Intlekofer & Cotman, 2013), and in non-PD 
rats (n=7 per group), BDNF expression has been associated with exercise-induced 
enhancement on learning and recall on the Morris water maze after one week of 
voluntary wheel running (Vaynman et al., 2004).  Though there are limitations related to 
translating results in animal models of PD to humans with PD (Potashkin, Blume, & 
Runkle, 2010), animal work as well as emerging human research suggest that aerobic	
exercise may lead to improvements in cognition that may be mediated, at least in part, by 
increased production of BDNF (Ahlskog, 2011b).  In sum, the potential effects of 
exercise-induced BDNF on cognition in PD are particularly promising.   
These findings suggest that exercise has potential neuroprotective and 
neurorestorative effects in PD, which may be associated with subsequent improvements 
in overall brain health, mood, and especially cognition (Petzinger et al., 2013), though the 
majority of this evidence in PD comes from animal studies and small pilot studies.  Other 
mechanisms may be active for the effects of exercise on sleep, and potentially include 
body temperature elevation (to promote slow wave sleep), increased cytokine levels, 
heart rate variability (and associated improvements in vagal modulation and 
parasympathetic control), as well as increased BDNF activity and associated changes in 
mood (Buman & King, 2010; Kredlow et al., 2015; Uchida et al., 2012).  As sleep 
disruption is a core symptom of depression, and aerobic exercise improves depression, it 
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is plausible that exercise may benefit sleep as a function of improved mood, or vice versa 
(Dunn, Trivedi, Kampert, Clark, & Chambliss, 2005; Uchida et al., 2012).  It may also be 
important to consider the potential effects of aerobic exercise on cholinergic function, as 
demonstrated in non-PD animal studies (Ang & Gomez-Pinilla, 2007).  It is unknown 
whether these positive effects translate to persons with PD, but it warrants examination, 
given the association between cholinergic dysfunction and disturbances of sleep, mood, 
and cognition in PD (Bohnen & Albin, 2011; Diederich & McIntyre, 2012).  Ultimately, 
sleep benefits from exercise may result from some of the same or alternative mechanisms 
as those that positively affect mood and cognition.  
It is also important to consider potential mechanisms specific to resistance 
exercise in PD.  Progressive resistance training in PD has yielded improvements in 
strength and motor symptoms, as well as cognition (David et al., 2015; Lamotte G., 
2015).  Future research should more closely examine the effects of resistance training on 
non-motor symptoms in PD, especially cognition, which may relate to reduced levels of 
homocysteine and/or increased levels of insulin-like growth factor I (David et al., 2012).  
At the same time, resistance training may facilitate motor improvements via increased 
neural drive and central neural changes, such as cross-education and reduced agonist-
antagonist coactivation (Falvo, Schilling, & Earhart, 2008).  These mechanisms may be 
relevant for PD given the reduced muscle activation observed in the disorder, which 
largely contributes to bradykinesia and muscle weakness (David et al., 2012).  Drawing 
from functional neuroimaging studies, resistance training may also promote functional 
neuroplasticity in the cortex and basal ganglia, although all of these potential mechanisms 
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require further study in PD (David et al., 2012).  For a review of potential mechanisms of 
resistance exercise in PD, please see (David et al., 2012).  
 
Exercise Dose and Adherence in PD 
Public health guidelines recommend a minimum of 150 minutes of moderate-
intensity aerobic exercise plus 2-3 sessions of strengthening exercises per week for adults 
aged 18-65 (Haskell et al., 2007), but it is unknown whether this recommendation is also 
appropriate for individuals with PD.  Optimal dosing of exercise in PD has not been 
determined. Current research efforts are beginning to examine this question, including an 
ongoing multi-site, randomized, controlled study designed to compare moderate-intensity 
to high-intensity aerobic training in PD (C. G. Moore et al., 2013).  Intensive 
rehabilitation strategies (three daily exercise sessions, 60 minutes each, 5 days per week, 
for 4 weeks) that include aerobic exercise (heart rate reserve ≤60%; maximum speed of 
treadmill scrolling=3.5 km/hour) revealed increased BDNF levels and improved motor 
symptoms in the early stages of PD, suggesting the benefits of higher intensity exercise 
(Frazzitta et al., 2014) as well as potential benefits in cognition via BDNF. Other exercise 
trials in PD, however, reveal equivalent benefits related to physical function for both low 
(50 minutes at 40%-50% of heart rate reserve) and high (30 minutes at 70%-80% of heart 
rate reserve) intensity of aerobic exercise conducted 3 times a week for 3 months 
(Shulman et al., 2013).  In studies examining the benefits of strength training, high-
intensity resistance programs have been shown to be safe and efficacious and associated 
with greater improvements in quality of life relative to active control groups (Corcos et 
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al., 2013; Dibble et al., 2006; Dibble, Hale, Marcus, Gerber, & LaStayo, 2009).  A 
progressive resistance training program (at least 5% increase in resistance as participants 
were able) was found to be more effective in improving motor symptoms than a 
strengthening program that was not progressive (no systematic increase in load), 
suggesting greater benefits of a high dosing (Corcos et al., 2013), although both programs 
produced improvements in cognition after 24 months (David et al., 2015).  The only other 
non-motor outcome included in these studies was quality of life, which may capture 
secondary effects on mood, but otherwise, the effects of exercise intensity on mood and 
sleep in PD remain largely unknown and warrant further study (Lamotte et al., 2015). 
Generally speaking, adherence to exercise programs among adults with PD is 
relatively high (often >80%) in the context of research where there is typically a great 
deal of emphasis on promoting adherence (Allen et al., 2012).  Likewise, across exercise 
trials in PD, retention rates are largely above 80%, with studies typically conducted in 
clinic and lasting 8 weeks on average, though some studies have reported similar 
retention rates for trials of a longer duration (up to two years) (Allen et al., 2012; Corcos 
et al., 2013; Shulman et al., 2013).  Persons with PD tolerate exercise programs quite well 
with relatively low dropout rates (~10-20%) and minimal adverse effects (Allen et al., 
2012; Canning et al., 2015; Corcos et al., 2013; Park et al., 2014; Schenkman et al., 2012; 
Shulman et al., 2013; Uc et al., 2014).  The majority of adverse events tend to consist of 
relatively mild musculoskeletal issues that resolve relatively quickly and do not require 
medical attention or restrict activities (Canning et al., 2015; Schenkman et al., 2012; Uc 
et al., 2014).  This minimal-risk profile compares favorably to medications for non-motor 
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symptoms in PD (Liu et al., 2013), and provides further support for the use of exercise to 
simultaneously improve multiple motor and non-motor symptoms.  At the same time, it 
should be noted that the largely supervised, in-clinic nature of current exercise studies in 
PD may limit generalizability of these findings to motivated research participants who 
have access to a highly structured research setting.  Further research is warranted to better 
examine the longevity of effects and to effectively tailor the content, dose, and delivery 
of exercise programs to individuals at various stages of PD.   
 
Treatment Stage and Exercise Intervention 
 Exercise has been shown to be beneficial to individuals with PD across Hoehn & 
Yahr stages I-IV, with most trials focusing on stages II and III (Ellis et al., 2008; 
Goodwin et al., 2008; Li et al., 2012; Monticone, Ambrosini, Laurini, Rocca, & Foti, 
2015; van Eijkeren et al., 2008).  At the same time, the potential neuroprotective and 
neurorestorative effects of exercise (Petzinger et al., 2013) underscore its importance 
early in the course of the disease (Ellis & Motl, 2013).  Non-motor symptoms of PD, 
including disturbances in sleep and mood, can emerge years before the motor symptoms 
(Claassen et al., 2010; Claassen & Kutscher, 2011; Jacob, Gatto, Thompson, Bordelon, & 
Ritz, 2010).  In particular, individuals in the early stages may present with depression or 
anxiety that may be more distressing or interfering than the motor symptoms (Bhidayasiri 
& Truong, 2012).  Accordingly, exercise programs are particularly well suited to early 
implementation in PD with the potential for diffuse non-motor benefits (e.g. mood, sleep, 
cognition) and few side effects or adverse events.  By implementing exercise 
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interventions to improve depression, for example, in the early stages of PD, we can hope 
to also affect associated comorbidities, such as anxiety, memory difficulties, and sleep 
disruption (N. N. Dissanayaka et al., 2011) and subsequently improve daily functioning 
and quality of life (e.g., (Lin et al., 2003)).  Of note, sufficient dopamine replenishment, 
most often with carbidopa/levodopa, may be necessary to facilitate adherence and 
motivation for regular exercise and to avoid the formation of sedentary habits among 
individuals with PD (Ahlskog, 2011a, 2011b).  The majority of exercise trials in PD have 
been conducted with participants on appropriate dosages of dopaminergic medication, 
and the combined effect of dopaminergic medication plus exercise in PD has yielded 
greater physical benefits relative to medication or exercise alone (Dibble, Foreman, 
Addison, Marcus, & LaStayo, 2015).  These findings highlight the importance of 
dopamine replenishment to enhance motor functioning and allow adults with PD to 
exercise at sufficient doses and intensities.  In sum, for as long as individuals with PD are 
able to safely engage in physical activity, exercise should be seriously considered as an 
intervention strategy with the potential for widespread benefits for both non-motor and 
motor symptoms.  
 
Conclusion 
 The conceptualization of PD has shifted from that of a pure motor disorder, with a 
burgeoning research effort in the domain of non-motor symptoms (Cronin-Golomb, 
2013; Weintraub & Burn, 2011).  There is as yet limited research on the management of 
mood, cognitive, and sleep symptoms in PD (Seppi et al., 2011), with these symptoms 
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often being comorbid (Aarsland, Taylor, & Weintraub, 2014).  As we expand our 
understanding of the etiology and manifestation of the non-motor symptoms, a shift in 
attention to identifying and prescribing effective treatment is warranted.  If these 
symptoms do share underlying pathologies, it is possible that a single treatment may yield 
multi-faceted symptom improvement. 
Aerobic and resistance exercise, in particular, offer especially promising 
treatment strategies for alleviating a spectrum of PD symptoms, including motor 
function, mood, cognition, and sleep.  It is important to emphasize that exercise programs 
have generally been well tolerated in PD with few adverse events (Ellis et al., 2013; Li et 
al., 2012; States, Spierer, & Salem, 2011; van Eijkeren et al., 2008), attenuating concerns 
about the ability of individuals with PD to successfully complete prescribed exercise due 
to motor limitations.  
 In conclusion, exercise presents a particularly feasible treatment approach in PD 
with minimal side effects and the potential to yield broad-spectrum benefits related to 
mood, cognition, and sleep, particularly if implemented in the early stages of the disease.  
The known benefits of exercise in healthy older adults may very well translate to this 
population, driven by potentially overlapping mechanisms.  As with the majority of PD 
studies, exercise research in PD has focused primarily on the motor symptoms and 
largely failed to consider its potential to improve non-motor symptoms.  Future studies 
should include a variety of non-motor outcome measures to systematically examine the 
effects of exercise on these symptoms.  With greater research and clinical attention 
devoted to the potential utility of exercise interventions in PD, we may meet the goal of 
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simultaneously treating motor and non-motor symptoms, and ultimately optimize quality 
of life for persons living with this disorder.  
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Table 14.  Exercise interventions for mood in PD. 
Authors Study 
Design 
Mean 
Age  
Intervention Sample 
Size 
Exercise 
Frequency/ 
Duration/ 
Setting 
Control 
Group 
Mood 
Outcome 
Measures 
Main 
Results 
Limitations 
Canning et 
al., 2015 
RCT 71.0 40-60 minutes of 
strengthening 
231 3X/wk 
for 6 months 
(in clinic + 
at home) 
Usual-care PANAS Improved 
affect in 
exercise 
group 
compared to 
usual care 
No attention 
control; Mood 
measures 
included as 
secondary 
outcomes 
Park et al., 
2014 
RCT 
(delayed-
start) 
59.9 60 minutes of 
combined aerobic 
and resistance  
31 3X/wk  
for 48 
weeks  
(in clinic) 
Delayed-
start at 24 
weeks 
BDI Greater 
reduction in 
depression in 
early-start 
group 
compared to 
late-start 
group at 48 
weeks 
Greater social 
interaction in 
early-start group 
relative to late-
start group  
Shulman et 
al., 2013 
RCT 65.8 3 exercise groups: 
1) 30 minutes of 
high-intensity 
treadmill exercise; 
2) 50 minutes of 
low-intensity 
treadmill exercise; 
3) stretching and 
resistance training 
67 3X/wk 
for 3 months 
(in clinic) 
Stretching 
and 
resistance 
exercise 
(comparative 
trial) 
BDI No change in 
depression 
within any 
group 
No non-
exercising 
comparison 
condition 
Bridgewater 
& Sharpe, 
1996 
Pilot RCT 67.3 
(EX); 
66.5 
(CON) 
20-30 minutes of 
aerobic exercise 
(+ warm-up 
calisthenics and 
cool-down 
stretching) 
26 2X/wk 
for 3 months 
(in clinic) 
Usual care 
+ 
attendance 
at 
“interest 
talks” 
once 
every 3 
wks 
LPDQ Improved 
mood in 
exercise 
group 
Small sample 
size; Less social 
interaction in 
control group 
	Dashtipour 
et al., 2015 
Prospective, 
double-
blinded 
randomized 
trial 
63.4 60 minutes of 
combined aerobic 
and resistance  
11 4X/wk 
for 4 weeks 
(in clinic) 
Exercise 
based 
behavioral 
treatment 
(LSVT 
BIG) 
BAI, 
BDI 
Reduced 
depression in 
combined 
group 
Small sample 
size; Combined 
data analysis 
across both 
groups 
Uc et al., 
201482 
Uncontrolle
d phase I/II 
trial 
65.5 45 minutes of 
aerobic walking 
49 3X/wk 
for 6 months 
(at home) 
None GDS Reduced 
depression 
across all 
completers 
Lack of a 
control group 
BAI=Beck Anxiety Inventory. BDI=Beck Depression Inventory. CON=control group. EX=exercise group. GDS=Geriatric Depression Scale; 
LPDQ=Levine-Pilowsky Depression Questionnaire. LSVT BIG=Lee Silverman Voice Therapy. PANAS=Positive affect subscale of the Positive 
and Negative Affect Schedule. PD=Parkinson’s disease.  RCT=randomized controlled trial. 
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Table 15.  Exercise interventions for cognition in PD. 
Authors Study 
Design 
Mean 
Age 
Intervention Sample 
Size 
Exercise 
Frequency/ 
Duration/ 
Setting 
Control 
Group 
Cognitive 
Outcome 
Measures 
Main 
Results 
Limitations 
Cruise et al., 
2011 
Controlled 
trial 
59.5 
(EX); 
60.6 
(CON) 
60 minutes of 
progressive 
aerobic and 
anabolic exercise 
28 2X/wk 
for 3 months 
(in clinic) 
Usual 
lifestyle 
COWAT, 
MMSE, 
PRM and 
SRM, SOC, 
SWM 
EX group 
improved on 
specific 
measures of 
executive 
function 
(SWM, 
COWAT) 
No attention 
control; No 
random 
allocation to 
groups 
Uc et al., 
2014 
Uncontrolled 
phase I/II 
trial 
65.5 45 minutes of 
aerobic walking   
49 3X/wk 
for 6 months 
(at home) 
None Complex 
Figure Copy 
and Recall, 
COWAT, 
Eriksen 
flanker task, 
JLO, 
MoCA, 
RAVLT, 
Stroop, 
TMT B-A, 
WCST  
Improved 
performance 
on flanker 
task after 
exercise 
program 
Lack of a 
control group 
Tanaka et 
al., 2009 
Quasi-
experimental 
design 
65.4 60 minutes of 
multimodal 
exercise 
(aerobics, 
flexibility, 
muscular 
resistance, motor 
coordination, 
balance) 
20 3X/wk 
for 6 months 
(in clinic) 
Usual 
lifestyle 
Symbol 
Search, 
WCST 
Improved 
executive 
function 
(WCST 
categories 
completed 
and 
perseverative 
errors) in the 
exercise 
group 
Small sample 
size; Non-
randomized 
control group; 
No attention 
control 
		
	
Tabak et al., 
2013 
Case series 61, 72 60 minutes of 
aerobic exercise 
2 3X/wk 
for 2 months 
(in clinic) 
None CTT, 
MoCA, 
PDCRS 
Both 
participants 
improved on 
all measures 
of executive 
function after 
exercise  
Case series 
design; 
Selection bias; 
No attention 
control  
Nocera et 
al., 2010 
Case study 66 20 minutes of 
aerobic exercise  
1 3X/week  
for 2 months 
(in clinic) 
None COWAT, 
Digit Span 
Forward and 
Backward, 
MMSE, 
Picture 
Description, 
Stroop 
Improved 
performance 
on Stroop, 
COWAT 
(especially 
animal 
fluency), 
Digit Span 
Backward, 
and Picture 
Description 
after exercise 
program 
Case study 
design; Limited 
generalizability 
David et al., 
2015 
RCT 59.0 
(EX); 
58.6 
(CON) 
60-90 minutes of 
progressive 
resistance 
exercise (PRET) 
51 2X/wk  
for 24 
months  
(in clinic) 
Stretching, 
balance, 
and non-
progressive 
strengtheni
ng (mFC) 
BTA, Digit 
Span, 
Stroop 
At 24 
months: 
PRET 
improved on 
BTA, Digit 
Span, and 
Stroop; and 
mFC 
improved on 
Digit Span 
and Stroop;  
No between-
group 
differences at 
12 or 24 
months 
No non-
exercising 
comparison 
condition; 
Limited 
generalizability 
(due to high 
education and 
younger age of 
participants) 
BTA=Brief Test of Attention. CON=control group. COWAT=Controlled Oral Word Association Test. CTT=Color Trails Test 1 and 2. 
EX=exercise group. JLO=Judgment of Line Orientation Test. mFC=modified Fitness Counts. MMSE=Mini-Mental Status Examination. 
MOCA=Montreal Cognitive Assessment. PD=Parkinson’s disease. PDCRS=Parkinson’s Disease Cognitive Rating Scale. PRET=Progressive 
Resistance Exercise Training. PRM and SRM=Pattern and Spatial Recognition Memory (computerized versions) from the Cambridge 
Neuropsychological Test Automated Battery. RAVLT=Rey Auditory Verbal Learning Test. SOC=Stockings of Cambridge. SWM=Spatial 
Working Memory. TMT=Trail Making Test. WCST=Wisconsin Card Sorting Test.	
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Table 16.  Exercise interventions for sleep in PD. 
Authors Study design Mean Age  Intervention Sample 
Size 
Exercise 
Frequency/ 
Duration/ 
Setting 
Control 
Group 
Sleep 
Outcome 
Measures 
Main Results Limitations 
Nascimento 
et al., 2014 
RCT with 
stratified 
randomization  
66.3 (PD, 
CON) 
67.8 (PD, 
EX) 
60 minutes of 
muscular 
resistance, 
balance/motor 
coordination, 
and aerobic 
fitness 
34  3X/week 
for 6 months 
(in clinic) 
Usual 
care 
MSQ Improvements 
in sleep 
disturbance 
(insomnia + 
daytime 
sleepiness) in 
exercise group 
No objective 
measures of 
sleep; No 
attention 
control 
Rodrigues de 
Paula et al., 
2006 
Uncontrolled 
trial 
61.5 75 minutes of 
combined 
aerobic 
conditioning and 
muscular 
strengthening 
20 3X/week 
for 3 months 
(in clinic) 
None NHP-S Trend for 
improved 
sleep after 
exercise 
program 
Lack of a 
control group; 
Small sample 
size; Non-
specific and 
subjective 
measure of 
sleep 
CON=control group. EX=exercise group. MSQ=Mini-Sleep Questionnaire (MSQ). NHP-S=Nottingham Health Profile (sleep domain). 
PD=Parkinson’s disease.	
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CHAPTER 5:  GENERAL DISCUSSION 
 
 In PD, anxiety is a prevalent non-motor symptom that compromises quality of 
life, even in early disease stages (Hanna & Cronin-Golomb, 2012); yet it remains 
understudied and undertreated, as studies of affective symptoms in PD have largely 
focused on depression (N. N. Dissanayaka et al., 2014; Seppi et al., 2011; S. Yang et al., 
2012).  To address these gaps in the literature, this set of three studies uniquely focused 
on anxiety in PD, including its relation to other non-motor symptoms, as well as potential 
treatment strategies to reduce anxiety in this population.  The specific aims included the 
following: (1) examine the relation between anxiety and cognition in PD; (2) evaluate the 
utility and feasibility of a cognitive-behavioral intervention for anxiety in PD; and (3) 
review the literature on aerobic and resistance exercise as treatments for dysfunctions of 
mood, cognition, and sleep in PD to provide a rationale for the targeted use of future 
exercise interventions to alleviate these symptoms.   
 In Study One, we hypothesized that self-reported anxiety would be associated 
with impaired cognitive performance as indexed by measures of attention and executive 
function in a sample of high-functioning adults with mild to moderate PD.  Executive 
dysfunction is commonly observed in PD, even in early disease stages, and is strongly 
associated with psychiatric symptoms, including depression, apathy, and hallucinations 
(Dirnberger & Jahanshahi, 2013), but few studies have investigated the relation between 
anxiety and cognition in PD (Poletti et al., 2012).  An earlier study from our lab found 
that anxiety correlated with disease duration, and in RPD only, with cognitive 
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performance on verbal tasks (phonemic fluency, clock reading errors, naming, and 
intrusion errors on a memory task) (Bogdanova & Cronin-Golomb, 2012).  Other than 
naming, these verbal tasks fall broadly within the domain of executive functioning, 
suggesting some relation between anxiety and executive deficits in PD.  More generally, 
attentional control theory posits that anxiety compromises cognitive efficiency, 
specifically via interference of bottom-up processing on tasks requiring inhibition and 
shifting (Derakshan & Eysenck, 2009; Eysenck et al., 2007).  Overall, though, there are 
few studies that have examined the relation between anxiety and cognition in PD despite 
the prevalence of these symptoms in early PD and their negative impact on quality of life 
(Hanna & Cronin-Golomb, 2012; Schrag, Jahanshahi, & Quinn, 2000).   
In Study One, we sought to investigate the association between self-reported 
anxiety and executive and attentional functions in a large sample of adults with mild to 
moderate PD.  We hypothesized that anxiety would negatively affect cognitive 
performance on tasks of executive functioning and attention/working memory in PD. 
Results from Study One showed that relatively minimal levels of anxiety among adults 
with mild to moderate PD were associated with a specific aspect of executive 
dysfunction, poorer set-shifting, even after removing the psychomotor component of the 
task.  There were no associations between anxiety and attention, working memory, or 
verbal fluency.  This finding is consistent with a recent work by Martens et al. (Martens 
et al., 2016), who reported that anxiety, as measured by the Hospital Anxiety and 
Depression Scale (HADS), correlated with freezing of gait and set-shifting (TMT B-A), 
but not with other aspects of cognition (attention, working memory, retention of 
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information) in a large sample of adults with PD (n=461).  In a second recently published 
paper, this research group reported that anxious PD participants (defined as >8 on the 
HADS-A) performed more poorly on tests of attention, working memory, and set-shifting 
than did non-anxious participants with PD, with no between-group differences on 
measures of verbal fluency, memory, or psychomotor speed (Ehgoetz Martens et al., 
2016).  It is important to note that in both of these studies, Martens and colleagues used a 
different measure of anxiety (HADS-A) than the measure used in our study (BAI) and 
still found an isolated association with set-shifting.  Our results are also consistent with 
their report of no association between anxiety and verbal fluency or psychomotor speed.  
In our sample, we did not find an association between anxiety and the Digit Span 
subtests, which is likely related to ceiling effects in our high-functioning PD group.  To 
illustrate, the means for Digit Span Forward (11.1) and Backward (7.5) in our sample 
aligned much more closely with the means of the non-anxious PD group in Martens’ 
study (Digit Forward=10.6, Backward=7.2 in non-anxious group vs. Digit Forward=8.8, 
Backward=5.7 in anxious group) (Ehgoetz Martens et al., 2016). 
Generally speaking, there remains concern about the use of current anxiety scales, 
including the BAI and HADS-A, in PD (Forjaz et al., 2013; Leentjens et al., 2008), 
suggesting a need for the development of PD-specific anxiety scales, such as the recently 
created Parkinson Anxiety Scale (PAS) (Leentjens et al., 2014).  Future research studies 
should incorporate this scale in combination with comprehensive neuropsychological 
assessment of attention, executive functioning, language, visuospatial skills, and memory 
to better characterize the relation between anxiety and all aspects of cognition in PD.  It 
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will also be critical to include PD participants with a wide range of anxiety severities 
across all stages of the disease, as well as those with and without diagnosed anxiety 
disorders according to DSM-5.  By including non-anxious PD participants as well as 
anxious non-PD participants for control groups, we can aim to better understand how 
anxiety may be contributing to cognitive dysfunction in PD above and beyond what 
would be expected by either the disease or anxiety in isolation.  Finally, longitudinal 
research may be helpful in clarifying how the relation between anxiety and cognition may 
change as the disease progresses. 
 
Anxiety and Cognition in Early PD:  Implications for Diagnosis and Treatment 
 The findings from Study One have important implications for the early diagnosis 
and management of non-motor symptoms in PD.  Although PD is now increasingly 
recognized as a multifaceted neuropsychiatric disorder (Cronin-Golomb, 2013; 
Weintraub & Burn, 2011) rather than a pure movement disorder, anxiety still remains 
terribly under-diagnosed and under-treated (N. Dissanayaka et al., 2015; Shulman et al., 
2002).  By improving screening procedures and considering the comorbidity of anxiety 
with other symptoms, non-motor and motor, we may be better able to identify targets for 
intervention, especially in early disease stages.   
To that end, additional screening for anxiety and cognitive dysfunction may be 
warranted by neurologists when possible, both qualitatively during the interview with the 
patient and also quantitatively via a brief self-report anxiety measure (e.g., PAS) and/or 
cognitive screen.  For a brief cognitive screen, the Montreal Cognitive Assessment 
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(MoCA) has been recommended for use in PD (Chou et al., 2010; Dalrymple-Alford et 
al., 2010).  The MoCA includes several items to assess executive functioning 
(Nasreddine et al., 2005), which could serve the dual purpose of identifying subtle 
executive dysfunction in early PD and alerting clinicians to the potential for elevated 
anxiety.  Given the association we observed in Study One between anxiety and poorer 
set-shifting in early PD, neurologists may also consider administering the TMT as a brief 
cognitive screen during regular office visits for individuals with complaints of anxiety 
and/or cognitive dysfunction.  Future research trials should also consider screening for 
potential comorbidities between anxiety and executive dysfunction, particularly if either 
of those outcomes is the primary variable of interest.   
With better identification of these non-motor symptoms in early disease stages, 
clinicians may be able to intervene and delay or alter disease progression.  Indeed, 
consistent with Study One, a recent study reported a specific association between anxiety, 
set-shifting, and freezing of gait in PD, and highlighted the possibility that treatment for 
anxiety could also reduce freezing (Martens et al., 2016).  In Study Two, we were limited 
in our exploration of this hypothesis, as the majority of participants did not report 
elevated freezing of gait and performed within normal limits on the measure of set-
shifting (compared to age-, education-, and in some cases, gender-matched normative 
samples; (Choi et al., 2014; Tombaugh, 2004; Tombaugh, Kozak, & Rees, 1999)).  
Future treatment studies on anxiety in PD could recruit individuals with elevated freezing 
of gait and/or reported cognitive dysfunction to better elucidate the potential of 
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interventions for anxiety to simultaneously improve comorbid motor and cognitive 
symptoms.   
 
Future Directions for Cognitive-Behavioral Therapy for Anxiety in PD 
With better recognition of anxiety in PD, we can also hope to intervene early in 
the disease course to reduce mood symptoms and improve quality of life.  To do so, there 
is urgent need for the development of evidence-based treatments for anxiety in PD, 
especially non-pharmacological options, such as cognitive-behavioral therapy (CBT).  
CBT may be especially well-suited for implementation in early PD when individuals 
experience fewer physical and cognitive limitations, allowing them to fully engage in 
treatment, complete out-of-session practice, and develop long-term skills to manage 
anxiety throughout the disease course. 
CBT has demonstrated strong efficacy as a treatment for anxiety disorders and 
stress in the general population, including preliminary evidence of efficacy in populations 
with medical conditions, such as cancer, HIV, and spinal cord injury (Hofmann et al., 
2012).  In PD, CBT has yielded positive effects on depression in a large RCT (Dobkin, 
Menza, Allen, Gara, et al., 2011), as well as promising preliminary effects on anxiety, 
mostly in smaller, uncontrolled pilot studies (N. N. W. Dissanayaka et al., 2016; Egan et 
al., 2015; Troeung et al., 2014).  The findings from Study Two build upon this literature 
by demonstrating the clear utility and feasibility of CBT for individuals with mild to 
moderate PD, who also met criteria for at least one DSM-5 anxiety disorder.  We aimed 
to critically evaluate the utility and feasibility of a transdiagnostic CBT protocol for 
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anxiety in PD, using a single-case, multiple-baseline, experimental design.  Twelve 
sessions of CBT were highly feasible with minimal dropout rates, and all participants 
reported high acceptability and satisfaction with treatment.  Seven of the nine participants 
reported a significant reduction in symptoms of anxiety and/or depression at either the 
post-treatment or 6-week follow-up assessment.  The intervention was delivered in-
person for five participants and via secure videoconferencing for the remaining four, and 
results did not differ by treatment modality.   
Future studies should aim to replicate these findings in larger samples and also 
continue to explore telehealth as a viable treatment strategy in this population.  Despite 
the promising literature on CBT in PD, anxiety continues to be terribly understudied and 
under-treated, and 83% of PD patients treated with medication reported minimal benefit 
on anxiety in a recent study (N. Dissanayaka et al., 2015).  Together, these findings point 
to the importance of considering the use of non-pharmacological strategies for anxiety 
treatment in PD, such as CBT.  To maximize treatment effectiveness, it will be 
imperative for future research to examine predictors of treatment response among those 
with PD, with the goal of best matching a specific treatment to the individual.  Study Two 
highlighted the importance of assessing for apathy among persons with PD, which 
frequently presents as a non-motor symptom that is often unique in presentation from 
depression (den Brok et al., 2015).  The one participant in our study who did not show 
any response to CBT (P3) reported significant levels of apathy at pre- and post-treatment, 
both on self-report questionnaires and in session.  He also missed sessions on occasion 
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and reported frequent amotivation and difficulty completing homework exercises out-of-
session, all of which likely contributed to his lack of treatment response.   
The only other participant who showed a relatively minimal response to treatment 
(P8) had a history of deep brain stimulation (DBS), and reported several adjustments to 
DBS settings/PD medications during the intervention, which often worsened her motor 
symptoms and subsequently contributed to increased depression, per her report in 
session.  Compared to all other participants, P8 was significantly younger and reported 
more frequent OFF time, greater motor fluctuations, and significantly higher anxiety 
across all study phases.  Even so, the intervention was feasible and acceptable for her 
with reported high satisfaction, and there were downward trends in her anxiety and 
depression during the second half of treatment, beginning in weeks 5-6, despite consistent 
DBS/PD-medication changes from weeks 1-10.  This suggests that the reductions in 
anxiety and depression were related at least in part to the effects of the intervention, 
despite the confound of medically-warranted DBS/dopaminergic medication adjustments. 
Based on these findings, future adaptations to the protocol may help to maximize 
treatment response.  First, it will be important consider adding supplemental modules or 
extra sessions on motivation for individual with high baseline apathy.  Recent research 
has also highlighted the potentially critical role of caregiver participation in optimizing 
treatment response and reducing caregiver burden (N. N. W. Dissanayaka et al., 2016; 
Kraepelien et al., 2015).  Caregiver involvement may be even more essential for 
individuals with comorbid apathy as an additional tool to facilitate out-of-session 
engagement and homework compliance.  Future studies may also wish to systematically 
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evaluate homework compliance, which could function as a predictor or mediator of 
treatment response.   
Study Two demonstrated preliminary efficacy of the CBT protocol for an 
individual with a history of DBS.  During treatment, it was crucial to monitor changes to 
DBS settings/dopaminergic dose on a weekly basis and inquire about the effects of these 
symptoms on mood and anxiety.  With this caveat in mind, future studies should expand 
inclusion criteria to include individuals with a history of DBS and consider adapting 
protocols as necessary for this subset of individuals (e.g., allowing for telehealth sessions 
for weeks when motor fluctuations are disabling, exploring how motor fluctuations 
change the experience of anxiety, and perhaps increasing the number of sessions 
depending on the severity of the anxiety).  GAD is more common among patients with 
motor fluctuations compared to those without fluctuations, but this anxiety is not 
consistently associated with motor state (e.g., ON vs. OFF periods, (Leentjens et al., 
2012)).  This finding underscores the need to better understand this relation between 
anxiety and motor states in PD, and also highlights the need for future studies to include 
individuals with motor fluctuations in order to develop effective treatments and identify 
any necessary adaptations to the CBT protocol.  Finally, as noted above, anxiety and 
subtle executive dysfunction may co-occur in early disease stages, as demonstrated in 
Study One.  For individuals with comorbid anxiety and cognitive symptoms, CBT 
protocols may require modification related to the presentation of information to 
compensate for any difficulty with multi-tasking or divided attention.  These 
modifications may include a session devoted to organization/planning, increased structure 
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and organization in session, repetition of information, provision of explicitly organized 
written materials/handouts, and systematic planning of homework exercises to maximize 
out-of-session practice. 
 
Dissemination and Potential of Telehealth Interventions in PD 
 Future interventions for anxiety in PD must also fully consider the potential of 
telehealth as a way to increase dissemination of evidence-based treatments to individuals 
who may be unable or unwilling to commit to weekly trips to a therapist’s office.  Indeed, 
several barriers to accessing mental healthcare have been reported in PD, including lack 
of local services, physical impairments, and lack of transportation (Dobkin et al., 2013).  
Dobkin and colleagues also found that many individuals with PD were interested in 
telehealth options for mental health treatment, though there have been few studies that 
have addressed the feasibility and utility of this approach. 
To date, telephone-delivered CBT has shown some promise for treatment of 
mood, primarily depression, in PD (Dobkin, Menza, Allen, Tiu, et al., 2011; Veazey et 
al., 2009).  In addition, a recent pilot study of internet-delivered CBT reported a 
significant reduction in depression, but not anxiety, among PD participants who endorsed 
elevated depression or anxiety on the Hospital Anxiety and Depression Scale (>7) 
(Kraepelien et al., 2015).  Although this study reported a relatively high dropout rate (3 
out of 9 participants), the authors described the CBT as self-guided with minimal 
therapist contact (<15 minutes per week), suggesting that the treatment approach was less 
standardized and structured than typical CBT. 
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Study Two first underscored the difficulty with recruitment that has been 
observed in previous studies in this population (Troeung et al., 2014; Veazey et al., 
2009).  In response to significant difficulty with recruitment, we modified the study to 
include the option of internet-delivered sessions, which allowed several new participants 
to engage in treatment who otherwise would not have enrolled in the study.  These 
telehealth participants comprised almost half of the sample (4/9), responded well to the 
intervention, and reported high satisfaction and acceptability of the treatment.  Despite 
the small sample size, these findings provide additional rationale to further investigate 
telehealth options for treatment of anxiety in PD.  Study Two demonstrated the utility and 
feasibility of internet-delivered CBT in this population, as all four telehealth participants 
completed the study and showed a positive response to treatment.  With larger, controlled 
trials focused on internet-delivered CBT, we can more systematically explore the efficacy 
of this treatment approach, increase recruitment and access to care, and provide urgently 
needed mental healthcare to a greater number of PD individuals, including those with 
more advanced physical limitations or those living in rural areas.  
 
Potential of Exercise Interventions for Anxiety in PD 
Despite the promising evidence of CBT for anxiety in PD, some individuals may 
not respond to CBT or may not have access to CBT therapists.  Hence, it is important to 
develop alternative non-pharmacological interventions.  In Study Three, we 
comprehensively reviewed the literature on aerobic and resistance exercise in healthy 
older adults and in PD and argued for the potential of exercise interventions to 
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simultaneously improve motor symptoms, as well as mood, cognition, and sleep in PD.  
Aerobic and resistance exercise interventions have previously demonstrated feasibility 
and efficacy in PD, yielding positive effects on physical fitness, gait, bradykinesia, and 
quality of life (Dibble et al., 2009; Goodwin et al., 2008; Shulman et al., 2013).  
However, as we discussed in Study Three, the potential of aerobic and resistance exercise 
to directly target non-motor symptoms, such as anxiety, has not yet been fully explored.  
Preliminary findings in PD suggest that aerobic and resistance exercise may improve 
mood in PD, although exercise research has largely focused on depression, with mood 
measures often included as secondary outcomes (Bridgewater & Sharpe, 1996; Canning 
et al., 2015; Cusso, Donald, & Khoo, 2016; Dashtipour et al., 2015; Park et al., 2014; Uc 
et al., 2014).  To illustrate the potential widespread effects of exercise on non-motor 
symptoms in PD, a recent controlled trial reported that 16 weeks of aerobic exercise 
(3x/week) improved aspects of executive functioning (relative to no change in stretch-
balance or no-contact control groups) and language (greater improvement in aerobic 
group than in the stretch-balance group) (Altmann et al., 2016).  They did not examine 
anxiety and reported no change in depression in the exercise groups, but noted an 
increase in depression in the control group only.  Strengths of their study include 
inclusion of outcome measures of both mood and cognition, but further exercise trials are 
needed that specifically target anxiety in PD. 
 In non-PD populations, exercise has been shown to yield positive effects on both 
depression and anxiety, among clinical and non-clinical samples, though with smaller 
effects on anxiety than on depression (Asmundson et al., 2013; Conn, 2010a, 2010b; 
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Stathopoulou et al., 2006; Wegner et al., 2014).  At the same time, a meta-analysis 
pointed to a lack of evidence for aerobic exercise as a superior stand-alone treatment for 
anxiety disorders relative to active control groups, including non-aerobic exercise, 
antidepressants, or CBT (Bartley, Hay, & Bloch, 2013).  These findings suggest that 
exercise, known to positively affect motor symptoms and physical health in PD 
(Goodwin et al., 2008), may be most helpful as an adjunctive treatment for mood in PD, 
to be added to either CBT or medication, as shown in non-PD populations.  For example, 
group CBT plus an adjunctive walking program improved depression, anxiety, and stress 
among adults with a range of anxiety disorders (Merom et al., 2008).  A more recent 
review of eight RCTs, including the study by Merom et al., highlighted the evidence for 
the use of aerobic and non-aerobic exercise as adjunctive treatments for anxiety 
disorders, in combination with either antidepressants, occupational therapy and lifestyle 
changes, or group CBT (Jayakody, Gunadasa, & Hosker, 2014).  Similar approaches of 
combined therapies should be explored in PD to maximize treatment response and tailor 
intervention programs to each individual. 
 To do so, we should consider individual presentations of motor and non-motor 
symptoms in PD, and encourage exercise interventions for their potential to positively 
affect not only anxiety, but also additional non-motor symptoms, including depression, 
reduced qualify of life, and fear of falling, all of which are frequently comorbid with 
anxiety in PD (Gallagher & Schrag, 2012; Hanna & Cronin-Golomb, 2012; Pontone et 
al., 2009).  Study Two showed that comorbid depressive symptoms were frequently 
present, but often at mild levels, among PD participants with anxiety disorders.  For these 
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participants, exercise may be an appropriate adjunctive treatment to reduce mild 
depressive symptoms in combination with CBT that more directly targets anxiety.  An 
adjunctive exercise intervention could also be helpful in improving quality of life among 
persons with PD.  Both CBT and exercise have yielded positive effects on quality of life 
in non-PD individuals with anxiety disorders, with specific effects on aspects of QoL 
related to physical function and mental health (Herring, Johnson, & O'Connor, 2016; 
Hofmann, Wu, & Boettcher, 2014).  These two domains seem particularly relevant areas 
of interest for anxious individuals with PD.  Lastly, preliminary findings in Study Two 
suggested that treatment of anxiety may reduce fear of falling in PD.  Exercise 
interventions could further explore this relation by examining the effects of resistance and 
balance training, for example, on fear of falling and anxiety.  For individuals with 
persistent fear of falling despite improved balance, CBT could be added to exercise 
training to directly target the psychological fear.  In PD, fear of falling has been shown to 
predict recurrent falls (Mak & Pang, 2009), and to affect quality of life to a greater extent 
than falls (Grimbergen, Schrag, Mazibrada, Borm, & Bloem, 2013), further emphasizing 
the need to address this symptom in intervention studies. 
Overall, these future avenues of research emphasize the need for treatment trials 
of CBT and exercise for anxiety and associated symptoms in PD, with the goal of 
establishing several evidence-based treatment options.  This approach will allow us to 
best match an individual to a specific treatment strategy and optimize treatment response.  
For example, individuals who respond best to behavioral strategies may benefit from 
exercise interventions for mood as a first treatment approach, whereas CBT may be most 
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helpful for individuals who present with inflexible cognitive schemas, to assist them in 
shifting thought patterns and facilitating subsequent engagement in behavioral treatment 
components (e.g., exposures).  To that end, it will be crucial for future PD intervention 
trials to examine predictors of treatment response. 
 
Conclusion 
 In sum, this set of studies critically adds to the PD literature in its primary focus 
on anxiety and evaluation of potential treatment options.  Studies One and Two included 
an investigation of its relation to cognition in early disease stages, and a utility and 
feasibility study to examine the potential of CBT for anxiety in PD, using a rigorous 
single-case, multiple-baseline experimental design.  In Study Three, we reviewed the 
literature on exercise interventions in PD and provided systematic rationale for the 
targeted use of exercise interventions to improve anxiety, as well as cognition and sleep, 
in this population.  Anxiety in PD continues to receive less attention in clinical and 
research settings even compared to other non-motor symptoms, despite its high 
prevalence, negative impact on quality of life, and comorbidity with other non-motor 
symptoms (Gallagher & Schrag, 2012; Hanna & Cronin-Golomb, 2012).  Our findings 
help to describe anxiety as it relates to cognition in mild to moderate PD, and also 
provide preliminary evidence for the use of CBT, delivered either in person or via secure 
videoconferencing, as a feasible treatment strategy to reduce anxiety and comorbid 
depressive symptoms in PD.  In addition, aerobic and resistance exercise interventions 
offer a promising alternative treatment strategy, known to benefit physical functioning in 
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PD (Goodwin et al., 2008), but with the potential to also improve mood, cognition, and 
sleep in this population, especially for individuals who fail to respond to CBT or who do 
not have access to CBT.   
With improved recognition of anxiety in PD, we can hope to intervene early in the 
disease course and improve daily functioning and quality of life.  We hope our work will 
provide the impetus for future research focused on anxiety in PD to better understand its 
unique clinical presentation, distinct from depression and apathy, and to develop tailored, 
evidence-based treatments for this symptom, such as CBT and exercise.  Future work 
should also aim to explore strategies for dissemination of such treatments with new 
technologies, in order to increase access to mental healthcare for individuals with PD and 
alleviate the negative effects of anxiety and associated non-motor symptoms across all 
stages of the disease.  
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